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Abstract 
 
Background:  Early on I identified that reticular basement membrane (Rbm) in 
current smokers with COPD was highly fragmented, with cracks termed “clefts” 
containing cells. This looked like the described hallmark of EMT (epithelial 
mesenchymal transition). I followed this preliminary observation with a 
comprehensive cross-sectional study in which I hypothesized that the airway 
epithelium is activated in smokers, and that this may promote EMT, but that this will 
be especially active in COPD. As a part of my thesis, I also investigated the 
expression and activity of the anti-inflammatory enzyme HDAC2 (histone 
deacetylase 2) which is reported to be reduced in COPD lungs and may account for 
associated pulmonary inflammation. I hypothesised that the current literature is 
correct in stating that HDAC2 is down-regulated in COPD airways and also that 
these reduced HDAC2 levels are normalised by aggressive inhaled corticosteroid 
(ICS) therapy and smoking cessation in patients with COPD.  
 
Methods and results: Endobronchial biopsies (ebb) from current smokers with 
COPD (COPD-CS) and ex-smokers with COPD (COPD-ES), smokers with normal 
lung function (NS) and never-smoking controls (NC) stained for markers of EMT, 
matrix metalloproteinase-9 (MMP-9), fibroblast protein (S100A4), epidermal growth 
factor receptor (EGFR), vimentin and cytokeratins. To confirm the extent of 
suppressed HDAC2 ebb were immuno-stained for HDAC2. In a double-blind, 
randomized, placebo-controlled study, I assessed the effects of ICS on Rbm 
fragmentation and HDAC2. Compared to NC, there was significant fragmentation of 
the Rbm in COPD-CS, COPD-ES and NS groups. COPD-CS, NS and COPD-ES 
demonstrated increases in staining for: basal epithelial S100A4, epithelial EGFR and 
MMP-9 and S100A4 for cells in Rbm ``clefts`` compared to NC. Dual staining 
revealed that vimentin (a mesenchymal marker) co-stained with cytokeratin (an 
epithelial marker). ICS normalised Rbm fragmentation. Compared to NC there was 
significant increase in HDAC2 positive cells in NS in the lamina propria (LP) but a 
decrease in COPD-CS. However, this latter abnormality was due to a reduction in 
total LP cells and not % cell HDAC2 staining. There were significantly more 
  
HDAC2 positive cells in COPD-ES compared to COPD-CS, but again due to an 
increase in total cell numbers. ICS made no difference to HDAC2 staining.   
 
Conclusions: This is the first description of likely EMT in smoking and COPD. ICS 
reversed Rbm fragmentation. HDAC2 expression was reduced in smokers but 
confounded by changes in cellularity. Quitting does seem to have a real effect on up-
regulating HDAC2, but it is not affected by ICS.  
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Chapter 1 
Introduction and Preliminary Data 
 
1.1 Background 
Chronic obstructive pulmonary disease (COPD) is characterized by progressive 
airflow limitation that is not fully reversible with bronchodilators and corticosteroids, 
and an associated inflammatory response of the airways to noxious particles and 
gases (Barnes, 2003). Tobacco smoking is considered as the main etiological factor 
in western countries, but why only a minority of smokers (about 20 %) develop 
COPD is not known (Barnes, 2003; Barnes, Shapiro, & Pauwels, 2003; M. Saetta, 
2006).  
 
Thus, in COPD, there may be both airway inflammation and damage and destruction 
of lung parenchyma (Barnes et al., 2003). COPD is pathologically and 
physiologically complex with a number of overlapping and interacting components. 
The airway component includes chronic obstructive bronchitis characterised 
pathologically by inflammation of central airways and obstructive bronchiolitis, 
which is an inflammatory state involving peripheral small airways (<2mm in 
diameter), characterized by obliterated lumen with accumulation of inflammatory 
mucous exudates (Barnes, 2003; Szilasi, Dolinay, Nemes, & Strausz, 2006).Chronic 
bronchitis is a clinical entity of “chronic productive cough for 3 months in at least 2 
consecutive years when there is no other reason for symptoms”(Mannino, 2003, 
2007; Viegi et al., 2007). This reflects mucous hypersecretion and is not necessarily 
associated with airflow limitation though it frequently is (Barnes, 2003). The 
parenchymal component involves the process of emphysema and is a destructive part 
of the disease defined as “enlargement of the distal airspaces, beyond the terminal 
bronchioles, caused by destruction of the alveolar walls” ("The definition of 
emphysema. Report of a National Heart, Lung, and Blood Institute, Division of Lung 
Diseases workshop; MacNee, 2005).  
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One of the features of chronic airway diseases, including the airway component in 
COPD, is airway remodelling (Nakano et al., 2002), although this aspect of COPD 
has not been studied to the same extent as asthma.  However, it is suggested that in 
COPD, remodelling may occur as a response to smoking-induced damage to the 
airways (Churg, Tai, Coulthard, Wang, & Wright, 2006; J. C. Hogg, Macklem, & 
Thurlbeck, 1968; Saetta et al., 2000), but the mechanism and structural changes are 
poorly described. A new explanation for remodelling in chronic airway disease is 
transition of airway epithelial cells to a mesenchymal phenotype with myofibroblast 
characteristics, through a process termed epithelial mesenchymal transition (EMT) 
(Peter K. Jeffery, 2004; Brigham C. Willis, duBois, & Borok, 2006). EMT was 
recently demonstrated in post transplant bronchiolitis obliterans syndrome (BOS) 
(Ward et al., 2005). BOS is characterised by neutrophilic airway inflammation, 
aberrant epithelial repair, airway remodelling and fixed airflow obstruction with 
some similarities to COPD, but develops over a much shorter time scale (Borthwick 
et al., 2009; Ward et al., 2005). It has been suggested that EMT could occur in COPD 
(Camara & Jarai, 2010), but there have been no studies undertaken specifically 
examining markers of EMT in human airway biopsy tissues from subjects with 
COPD.  
 
In this chapter I am going to review a preliminary study on which much of the rest of 
my work depended. Very early on, I identified that the central airway reticular 
basement membrane (Rbm) in current smokers with COPD was highly fragmented 
(Figure 1.1), with cracks or elongated spaces (termed “clefts”) in the Rbm with cells 
within them, this was very striking and quite different to what we see in bronchial 
biopsies from asthmatic patients where Rbm is very homogenously thick and hyaline 
in appearance (Saglani et al., 2006), and further in addition to that literature strongly 
supported the fact that this can be a hallmark of EMT (Acloque, Adams, Fishwick, 
Bronner-Fraser, & Nieto, 2009; R. Kalluri, 2009; Raghu Kalluri & Neilson, 2003; R. 
Kalluri & Weinberg, 2009; Zeisberg & Neilson, 2009).  These data are a 
fundamental platform for this thesis and explain that how this initial exciting 
observation led me to my hypothesis and research goals of the study.  
 
This finding of Rbm fragmentation and strong relevant supporting information from 
the literature suggesting that such fragmentation is a hallmark of EMT encouraged 
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me to test the hypothesis that the airway epithelium is activated in current smokers 
with COPD and that this may promote EMT.  After this original observation, my 
next phase was to design a pilot study in which I examined airway biopsies for 
expression of markers published on being associated with EMT including matrix 
metalloproteinase-9 (MMP-9), fibroblast specific protein 1, S100A4 and epidermal 
growth factor receptor (EGFR). MMP-9 can potentially digest type IV collagen 
(Ward et al., 2005) in the Rbm to potentially assist migration of cells from the 
epithelium through into the subepithelial lamina propria (Raghu Kalluri & Neilson, 
2003; J. M. Lee, Dedhar, Kalluri, & Thompson, 2006; Ward et al., 2005). S100A4 is 
a very early indicator of fibroblast differentiation towards a mesenchymal phenotype 
(Ward et al., 2005) and has been considered as a very reliable marker to characterise 
mesenchymal phenotype (R. Kalluri & Weinberg, 2009). EGFR expression (marker 
of epithelial activation) can be involved in mediating phenotypic transition of 
epithelial cells into myofibroblasts and stimulating their migration (de Boer et al., 
2006; Raghu Kalluri & Neilson, 2003). In this pilot study, I focussed on current 
smokers with COPD, essentially as a “test of concept”, I hypothesised that EMT 
would be most active in these individuals, and if nothing would be found, then there 
would be little point in carrying on to a large and more definitive study.  
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Figure 1.1: Bronchial biopsy specimen from (A) COPD current smoker, black 
arrows showing Rbm fragmentation with many “clefts” evident with cells in it, (B) 
non-smoker asthmatic showing thick homogenous Rbm with hyaline appearance. 
Stain: haematoxylin and eosin (H & E). Original magnification, x630 
5 
 
1.2 Materials and methods 
Most of the details of my materials and methods are given in chapter 3, but the 
following is a brief summary of how I carried out the preliminary pilot study. 
 
1.2.1 Subjects and study design  
The study was a cross-sectional analysis of airway remodelling in COPD and normal 
subjects, using biopsies obtained at fiberoptic bronchoscopy. Study was approved by 
the Alfred and Royal Hobart Hospital Ethic Committees. Subjects were recruited by 
advertisement. 10 COPD current smokers and 12 normal non-smokers were 
recruited. All subjects signed informed consent. Subjects with a history of other 
respiratory disorders were excluded.  
 
1.2.2 Details of biopsies and immunostaining 
Details regarding processing of biopsies and immunostaining are given in chapter 3 
and remained essentially unchanged throughout my thesis work. 
 
1.2.3 Biopsy analysis  
Image analysis was performed with a Leica DM 2500 microscope (Leica 
Microsystems, Germany), Spot insight 12 digital camera and Image Pro V5.1 (Media 
Cybernetics, USA) software, cellular plus other changes in the Rbm (Figure 1.1) 
were described in terms of the total length of basement membrane assessed. EGFR 
was measured as percentage of epithelium stained for EGFR. All slides were counted 
by an observer blinded to subject and diagnosis.  
 
1.2.4 Statistical analysis  
After counting of all specimens had been completed the data was analysed by group 
and only then unblinded.  As data were not normally distributed, results are presented 
as medians and ranges. Comparisons between COPD and normal controls were 
undertaken using the Mann Whitney U test. Associations between variables were 
assessed using Spearman's rank test. Statistical analyses were performed using SPSS 
15.0 for Windows, 2003, with a two-tailed p-value ≤ 0.05 being considered 
statistically significant. Details are given in Chapter 3. 
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1.3 Results of PILOT study 
Table1: Demographic and lung function data for subjects.    
 
                                         Non-smoking                        COPD               Significance 
                                            controls                          current smokers       (p Value) 
                                              n = 12                                  n = 10 
Male/female                              5/7                                     7/3 
Age (years)                         47(20-68)                        61(53-69)                 p = 0.02 
Smoking (pack years)               0                               46(32-79)                         
FEV1% predicted          114(86-140)                        74(66-96)                  p < 0.001 
                                                                                                                                                                                       
 
Data are expressed as medians and range(s) 
 
1.3.1 Fragmentation and presence of “clefts” within the Rbm  
A very remarkable finding was that the Rbm in COPD current smokers was indeed 
extensively fragmented. This included the presence of the linear elongated spaces or 
cracks already mentioned that we called “clefts” in the Rbm which we used these as 
the index to quantitate the degree of fragmentation. However, there were other 
changes including fragments hanging off the Rbm or similar pieces separated from it 
(Figure 1.1). Fragmentation was rarely present in normal controls. The length of the 
individual “clefts” was measured, summed and results expressed as percentage total 
clefts length/total Rbm length to give a measure of the degree of disruption. This was 
significantly higher in the COPD subjects compared to normal controls (14 % (0-39) 
versus 0 % (0-9) p<0.001) (Table 2).  
 
1.3.2 MMP 9 positive cells in the Rbm 
There were significantly more cells that stained positive in Rbm for MMP-9 in 
COPD subjects compared to controls, located predominantly within the “clefts” or 
adjacent and immediately below the Rbm (0.8 per mm (0-4.3) versus 0 per mm (0-
0.9), p=0.003) (Figure 1.2 & Table 2 ). There was minor MMP-9 staining of cells 
within the airway epithelium, but no significant difference between the COPD and 
normal subjects (p=0.7).    
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1.3.3 S100A4 positive cells in the Rbm  
Cells staining positively for S100A4 were found within the Rbm in COPD in the 
clefts, but not exclusively so, they were also found throughout the Rbm. The number 
of S100A4 positive cells within the Rbm was significantly higher in COPD subjects 
than in normal controls (44.1 per mm (28.1-92.6) versus 5.9 per mm (1.3-14.2) 
p<0.001) (Figure 1.2 & Table 2). It was evident that there were also cells staining for 
S100A4 within the basal layer of the airway epithelium just superficial to the Rbm in 
subjects with COPD, but this was much less apparent in normal controls (26 per mm 
(7-37) versus 5 per mm (1-15) p<0.001) (Figure1. 2 & Table 2).   
  
1.3.4 EGFR expression in the airway epithelium  
A greater proportion of the airway epithelium area stained significantly positive for 
EGFR in COPD subjects compared to normal controls (45 % (14 % -76 %) versus 6 
% (0.6 %-17 %), p<0.001) (Figure 1.2 & Table 2).  
 
Table 2 Summary of immunohistochemical data for different markers  
                               COPD                                Non-smoking                      
Significance 
                            Current smokers                      Controls                              (p Value) 
                                 n = 10                                   n = 12                                                        
Clefts *                  14(0-0.39)                          0 (0-0.09)                             p < 0.001 
MMP-9 +ve           0.8(0-4.3)                           0 (0-0.9)                               p = 0.003 
cells ** 
Rbm S100A4     44.1(28.1-92.6)                  5.9 (1.3-14.2)                           p < 0.001 
+ve cells***  
Basal S100A4       26(7-37)                             5(1-15)                                  p < 0.001 
+ve cells† 
EGFR % stain   45.2 (14.4-76.1)                 6.2 (0.6-17.7)                            p < 0.001 
area 
 
Data expressed as median and (range) (26 (7-37) versus 5 (1-15) p<0.001) per mm 
 
* Values for clefts represent ratio of length of clefts to total length of BM  
** Values for MMP-9 positive cells represent as number of cells counted in clefts per 
mm of BM  
*** Values for S100A4 positive cells represent number of cells counted in Rbm per 
mm of Rbm  
† Values for basal S100A4 positive cells represent number of cells counted in basal 
epithelium per mm of Rbm 
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Figure 1.2: Immunohistochemical staining of bronchial biopsy sections from COPD-
CS, compared to NC: (A) MMP-9, black arrows showing clefts containing cells 
positive for MMP-9, (B) S100A4, black arrows showing clefts, cells positive for 
S100A4 in the Rbm and basal cell S100A4 expression (C) intense brown staining for 
EGFR in the epithelium. Original magnification, x630 
9 
 
1.4 Preliminary discussion 
This is the first description of marked Rbm pathological changes with extensive 
fragmentation in current smokers with established COPD. This included the presence 
of linear “clefts” or longitudinal spaces or cracks, which we decided pragmatically to 
use for quantifying the degree of fragmentation, but there were also commonly 
fragments of Rbm “hanging off” and similar pieces seemingly separated from it, 
albeit in the largely two-dimensional sections. “Clefts” within the disrupted Rbm 
contained cells expressing the proteolytic enzyme MMP-9 and the fibroblast marker 
S100A4. More superficial to the Rbm, the airway epithelium stained strongly for 
cells expressing the receptor for epidermal growth factor (EGFR). There was also 
marked staining with S100A4 in cells within the basal layers of the airway 
epithelium, situated in close proximity to the Rbm, in COPD subjects.  
 
Rbm fragmentation has been suggested as the “hallmark” of EMT in the literature. 
Indeed, especially when associated with S100A4 positive cells such fragmentation is 
considered as one of the major in vivo criteria for identifying tissue undergoing 
EMT. From a general prospective EMT basically involves epithelial cells 
disaggregating, changing shape, becoming motile and digesting their way through 
basement membrane collagen into the subepithelial layer, while at the same time they 
also develop a fibroblast phenotype (Raghu Kalluri & Neilson, 2003). The process 
involves loss of epithelial markers such as tight junctions, apical-basal polarity and 
specific markers such as cytokeratins and E-cadherins, and this is replaced with gain 
of migratory potential, irregular cell shape and expression of mesenchymal markers 
cell markers such as matrix metalloproteinases, vimentin and S100A4 (Raghu Kalluri 
& Neilson, 2003; J. M. Lee et al., 2006; Ward et al., 2005; Brigham C. Willis et al., 
2006). EMT has only recently been recognised in the human lung in idiopathic 
pulmonary fibrosis (Brigham C. Willis et al., 2006) and in the airway in BOS (Ward 
et al., 2005), but it is well described in lung embryogenesis (J. M. Lee et al., 2006), 
metastatic malignant disease (Bjornland et al., 1999) and as part of the repair process 
in renal disease following tissue injury (Yanez-Mo et al., 2003).  
 
EMT has been described in metastatic malignant disease especially when associated 
with S100A4 expression. Nuclear expression of S100A4 strongly correlates with 
10 
 
both active EMT and metastatic disease in the oncology literature (Flatmark et al., 
2003; Ward et al., 2005). In particular, in the context of lung diseases, increased 
expression of both S100A4 and MMP-9 are observed in human non-small cell lung 
cancer and are significantly correlated with clinical and biological behaviour of this 
cancer cells (Chen, Wang, Zhang, Chen, & Sun, 2008). Further, EGFR is also over-
expressed in many types of cancers, including non–small cell lung cancer. It has now 
been shown that sensitivity to EGFR inhibition using the “biologic” monoclonal 
antibody erlotinib is directly linked to the degree of EMT in this lung cancer. It is 
clear from these data that EGFR over-expression is an important aspect of the lung 
cell cancer phenotype (Dasari, Gallup, Lemjabbar, Maltseva, & McNamara, 2006) 
and that active EMT is potentially important in the pathogenesis of lung cancer and 
its prognosis.  
 
The link between EMT and lung cancer needs to be placed in the context of the well-
described association between COPD and lung cancer.Although, a proportion of this 
may be related to a common exposure to tobacco smoke.,it has become clear that for 
any level of tobacco exposure, patients with COPD have a substantially greater risk  
for lung cancer than smokers without COPD (Parimon et al., 2007). Thus, my finding 
of active EMT in smokers, which is especially active in COPD current smokers, may 
well advance understanding of why lung cancer is so common and aggressive in 
smokers. In this context it is an aggressive and invasive tumour which is fatal in over 
80% of cases. 
 
One of the features of chronic inflammatory airway diseases, including COPD, is 
airway remodelling. There are several known features of airway remodelling in 
COPD including; metaplasia of the epithelium, loss of epithelial cilia, an increase in 
goblet cell size and number (Saetta et al., 2000) and hypertrophy of submucosal 
mucus glands. These were first described 40-50 years ago by Professor Lynne Reid 
in London.  In contrast to asthma, there is much less information in COPD on 
changes to the basement membrane and extracellular matrix.  There aren’t any 
studies reporting potential presence of EMT in COPD; this is the first suggestion that 
EMT may be active in COPD. However, there is evidence of EMT in patients after 
lung transplantation and it is suggested that there may be a potential link between 
EMT and airway remodelling leading to development of BOS (Borthwick et al., 
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2009). So as a simile to the EMT suggested in BOS (Borthwick et al., 2009; Ward et 
al., 2005) it is possible that in COPD, the epithelium gets damaged and/or activated 
by cigarette smoke constituents, which may lead to airway remodelling, a part of 
which is related to active EMT.  
 
Our finding of Rbm fragmentation in COPD current smokers is novel. However, in 
retrospect we have now looked for and noted Rbm fragmentation in micrographs 
published by other investigators, (de Boer et al., 2006) but this has not previously 
been commented on to our knowledge. Within the “clefts” in the Rbm, we observed 
cells expressing MMP-9 and S100A4 and we suggest that these cells have originated 
from the surface airway epithelial layer. It is also possible that the cells we identified 
in clefts may have migrated from the lamina propria, but against this explanation was 
the presence of S100A4 staining cells in the basal layer of the epithelium in COPD, 
and the accompanying marked increase in expression of EGFR in the epithelium. 
However, in chapter 5, I went on to show that these cells were not infiltrating 
inflammatory cells. 
 
In summary, this preliminary “pilot”, test of concept, study demonstrated that the 
Rbm in subjects with COPD who are current smokers is highly fragmented and that 
this appears to be associated with cells expressing the proteolytic enzyme MMP-9. 
Epithelial expression of EGFR suggested that epithelial cells may be priming 
themselves for migration, and increased expression of the fibroblast marker S100A4 
suggests phenotypic transition. These preliminary data suggested that EMT could be 
active in COPD pathology, and needed following up in a more definitive set of 
studies, asking the following questions: 
 
1) At this stage it was very hard to say whether these observations represented 
underlying pathology of COPD per se or whether they simply reflected the general 
effects of cigarette smoking. To address this issue, we needed to stain biopsy sections 
from normal lung function smokers without physiological evidence of COPD for the 
chosen markers of EMT to help us define whether this is a smoking effect or it is 
related to COPD, or indeed both i.e. additive.  
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2) Another key question which needed to be answered was whether these changes are 
plastic over time, especially with quitting smoking? In the first instance I chose to 
have a COPD ex-smoker group to help us to understand whether smoking cessation 
has any potential for decreasing EMT or not.  
 
3) Is Rbm fragmentation normalised with ICS therapy? 
 
4) I addressed the need to confirm the epithelial origin of the cells we identified in 
the Rbm (positive for S100A4 and MMP-9). To do this I needed to double-stain 
biopsies for an epithelial marker such as cytokeratins and with a mesenchymal 
marker such as S100A4 and/or vimentin. This would be additional evidence to my 
finding of basal epithelium cells positive for S100A4.  
 
5) The last question which needed to address, was the possibility that these cells I 
identified in the Rbm could be infiltrating inflammatory or structural cells, such as 
neutrophils, macrophages, fibroblasts, dendritic cells, CD4+ or CD8+ T cells or B-
cells, for which I needed to stain biopsy sections for their specific markers.  
 
So in summary, after the pilot study, I needed a comprehensive cross-sectional 
analysis of these new features of airway pathology and putative markers of EMT in 
currently smoking physiologically normal subjects, as well as in reformed smokers, 
especially those with and without COPD to confirm and extend these prelimnary but 
novel and exciting findings into a longitudinal analysis to investigate reversibility of 
Rbm changes with ICS therapy.  
 
As a part of my thesis, but not directly related to my preliminary study which I have 
outlined in this chapter, I also decided early on to study the status of histone 
deacetylase-2 (HDAC2) in COPD. It is not well understood why COPD responds 
relatively poorly to some therapies compared to asthma, especially the relative 
resistance to the anti-inflammatory effects of corticosteroids. The molecular 
mechanism behind “corticosteroids resistance” in COPD, although perhaps 
exaggerated by Peter Barnes and others,  is now being revealed and anti-
inflammatory effects of steroids are now better understood (Barnes, 2006b; Barnes & 
Stockley, 2005). These workers have suggested that corticosteroid resistance in 
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COPD is due to a decrease in the key nuclear enzyme HDAC-2 (Barnes, 2006c; Ito 
et al., 2001), but the reason behind HDAC-2 reduction in COPD is not clear, 
although it is suggested that increased oxidative and nitrative stress in the airways 
due to cigarette smoking might lead to inactivation or destruction of the enzyme 
(Barnes, Adcock, & Ito, 2005). In addition, the expression of anti-inflammatory 
HDAC2 may be reduced in COPD due to increased oxidative stress secondary to 
airway inflammation and this may induce (relative) resistance to inhaled 
corticosteroid therapy, but there is little confirmatory data on this, especially outside 
of the Peter Barnes group in London, which is highly committed to this theory. 
Furthermore, I hypothesized that reduced HDAC2 levels could be normalised by 
aggressive ICS therapy and smoking cessation in patients with COPD.  
To test these questions and address these issues, I designed a comprehensive cross-
sectional and longitudinal study (for longitudinal analysis I used bronchial biopsies 
from the study previously designed (D. W. Reid et al., 2008) by our group): 
 
 Firstly, I looked at the extent of HDAC2 suppression by immunostaining airway 
biopsy sections from COPD current smokers and also from normal lung function 
smokers to understand whether HDAC changes are solely related to COPD or 
smoking or both.  
Secondly I wished to investigate the potential of smoking cessation to raise HDAC2 
levels, so I included   COPD ex-smokers.  
Finally, to see if HDAC2 levels are normalised by aggressive ICS therapy, I used 
material from the study in which COPD subjects entered a double blind randomised 
controlled trial comparing fluticasone propionate (0.5 mg/twice daily) with placebo 
for 6 months (D. W. Reid et al., 2008); I assessed the bronchial biopsies which had 
been obtained before and after treatment for effects of ICS on HDAC2. This is the 
same study in which I investigated ICS effects on Rbm fragmentation. 
In summary, my thesis involves a comprehensive cross-sectional analysis into the 
potential for active EMT in COPD, whether it is specific to COPD and/or smoking or 
both, and a longitudinal analysis to see if ICS therapy has any potential for reducing 
Rbm fragmentation. The second part of my thesis involves a cross-sectional and 
longitudinal analysis questioning the status of HDAC2 in COPD and asking whether 
smoking cessation and/or ICS therapy have any potential to raise HDAC2 levels in 
COPD.  
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Chapter 2 
 
 
General Introduction 
 
 
2.1 Definition of COPD 
“COPD is a disease state characterized by airflow limitation that is not fully 
reversible, usually progressive and associated with an abnormal inflammatory 
response of the lung airways in response to noxious particles and gases” (Barnes, 
2003).  
 
The term “chronic obstructive pulmonary disease” (COPD) now widely used was 
first used in the literature in 1964 (Mitchell & Filley, 1964). Later on in the 1970s 
and 1980s, sub-diagnosis such as emphysema, chronic bronchitis, chronic obstructive 
bronchitis and chronic bronchitis with emphysema were used and shortly 
recommendations and international guidelines became available on how to use these 
terms to define the disease, today called COPD (Larsson, 2007; Mitchell & Filley, 
1964). Tobacco smoking is considered as the main etiological factor in this 
condition, at least in western countries. Why only a minority of smokers develop 
COPD is not known.  
 
A number of different specific definitions exist for COPD in the literature but they 
are of course more or less similar. The American Thoracic Society (ATS) define 
COPD as “a disease state characterized by the presence of airflow limitation due to 
chronic bronchitis or emphysema; the airflow obstruction is generally progressive, 
may be accompanied by airway hyper-reactivity, and may be partially reversible” 
("Standards for the diagnosis and care of patients with chronic obstructive pulmonary 
disease. American Thoracic Society," 1995).  This, therefore, allows some overlap 
with asthma.  
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The European Respiratory Society (ERS) on the other hand defines COPD as 
“reduced maximum expiratory flow and slow forced emptying of the lungs, which is 
slowly progressive and mostly irreversible to present medical treatment” (Siafakas et 
al., 1995).  
 
The Global Initiative for Chronic Obstructive Pulmonary Lung Disease (GOLD) 
report classified COPD as “a disease state characterized by airflow limitation that is 
not fully reversible. The airflow limitation is usually both progressive and associated 
with an abnormal inflammatory response of the lungs to noxious particles or gases” 
(GOLD, 2007; Gomez & Rodriguez-Roisin, 2002; Pauwels, Buist, Ma, Jenkins, & 
Hurd, 2001). GOLD definition is the most widely recognised definition of COPD 
worldwide and is somewhat different in that it introduces an underlying pathological 
process. The GOLD criteria also further categorized COPD into four different stages 
on the basis of the physiological and clinical severity of disease as given below: 
 
“GOLD Stage I is considered as mild COPD, characterized by mild airflow 
limitation (FEV1/FVC < 0.70; FEV1 ≥ 80 % predicted). Symptoms of chronic cough 
and sputum production may be present, but not always. At this stage, the individual 
is usually unaware that his or her lung function is abnormal” (taken from 
www.goldcopd.com).  
 
“GOLD Stage II is considered as moderate COPD, characterized by worsening of 
airflow limitation (FEV1/FVC < 0.70; 50% ≤ FEV1 < 80 % predicted), with 
shortness of breath typically developing on exertion and cough and sputum 
production sometimes also present. This is the stage at which patients typically seek 
medical attention because of chronic respiratory symptoms or an exacerbation of 
their disease” (taken from www.goldcopd.com).    
 
“GOLD Stage III is severe COPD, characterized by further worsening of airflow 
limitation (FEV1/FVC < 0.70; 30% ≤  FEV1 < 50 % predicted), greater shortness of 
breath, reduced exercise capacity, fatigue, and repeated exacerbations that almost 
always have an impact on patient’s quality of life” (taken from www.goldcopd.com).  
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“GOLD Stage IV is very severe COPD, characterized by severe airflow limitation 
(FEV1/FVC < 0.70; FEV1 < 30 % predicted or FEV1 < 50 % predicted plus the 
presence of chronic respiratory failure). Thus, patients may have Stage IV: Very 
severe COPD even if the FEV1 is > 30 % predicted where secondary complications 
are present. At this stage, quality of life is very appreciably impaired and 
exacerbations may be life threatening” (taken from www.goldcopd.com). Prognosis at 
this stage is also poor. 
 
As included in ATS definition, COPD includes two distinct entities, chronic 
obstructive bronchitis characterized pathologically by airway inflammation and 
airway damage, and emphysema which consists of enlargement of peripheral 
airspaces and destruction of lung parenchyma, leading to loss of lung elasticity which 
then causes dynamic closure of small airways in expiration. “Chronic bronchitis” is a 
clinical entity defined symptomatic features of “chronic productive cough for 3 
months in each of 2 consecutive years provided other causes of cough have been 
ruled out” (Mannino, 2003, 2007; Viegi et al., 2007). This reflects mucous 
hypersecretion and is not necessarily associated with airflow limitation though it 
frequently is (Barnes, 2003). There is no exact clinical definition of “emphysema” 
apart from the anatomical definition, but “clinically patient’s experiences progressive 
dyspnea and variable cough” (Mannino, 2003, 2007). However, it is reflected 
physiologically in decline in gas-absorption function of the lungs as reflected in 
measurement of the CO-transfer factor (diffusion capacity). 
 
2.1.1 Social and economic burden  
COPD is one of the leading causes of disability and death worldwide and is the 
fourth most common cause of death in the United States, Australia and Europe. In 
Australia nearly 12 % of the entire adult population is affected by the disease and due 
to inadequate diagnosis in its early stages related to its slowly progressive and 
insidious nature its prevalence is probably much higher (D. W. Reid et al., 2003). It 
is estimated that over one million individuals in the UK, 6% of men and 4% of 
women, suffer from COPD with around about 30,000 deaths annually and is 
anticipated that it will rank fifth by 2020 in burden of disease worldwide, according 
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to a study published by the World Bank/World Health Organization (Barnes, 1998b; 
Rabe et al., 2007; Thorley & Tetley, 2007).  
 
COPD has very major social and economic consequences (Johnson, Campbell, 
Bowers, & Nichol, 2007). Thone and colleagues (Thone, Schurmann, Kuhl, & Rief) 
in a very interesting study reported spouses’ quality of life during the course of the 
disease. They showed that spouses also had poor quality of life and with increased 
psychological suffering. It has also been observed that patients with COPD feel 
disgrace and distancing from people around them and also from their physicians 
(Johnson et al., 2007). A study reported by Earnest and colleagues described patients 
feeling personal shame and embarrassment when they are carrying oxygen cylinders 
with them in public (Earnest, 2002).   
 
The European Lung White Book in 2001 evaluated exhaustively the annual cost 
associated with COPD in Europe; they found that COPD costs €38.7 billion per 
annum (A$ 54.4 billion) including €4.7 billion (A$ 6.6 billion) for ambulatory care, 
€2.7 billion for drugs (A$ 3.7 billion), €2.9 billion (A$ 4.08 billion) for inpatient care 
and €28.4 (A$ 39.9 billion) for lost work days very year. The estimated cost for 
individual European countries annually ranged from €109-€541 million (A$153-
A$761 million), and individual patient costs were estimated around from €151-
€3,912 annually (A$ 212-A$5504) (Chapman et al., 2006; Loddenkemper R, 2003). 
The economic burden associated with COPD is probably underestimated as well, 
because the economic value of the care provided by family members of patients with 
COPD is not usually reported. A patient with very severe COPD needs long term 
home care which has serious negative effects not only on their own professional life 
but also on the life of engaged relatives and carers (Viegi et al., 2007).  
 
2.1.2 Risk factors associated with COPD 
Direct exposure to tobacco smoke is considered as the main risk factor associated 
with progression of COPD in western countries. The cigarette smoke which is 
inhaled while puffing is approximately 45% of the total while the remaining 55% is 
released into the surrounding environment (Yoshida & Tuder, 2007). Environmental 
tobacco exposure or “passive smoking” (Pinkerton & Joad, 2006; Sethi & Rochester, 
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2000; Yoshida & Tuder, 2007) is a growing centre of attention, given that such 
lifetime exposure could be associated with  COPD (Eisner et al., 2005). The 
increasing burden of indoor pollution due to biomass fuel smoke (Fullerton, Bruce, 
& Gordon, 2008), outdoor air pollution, viral infections and occupational exposure to 
noxious gases and dust may also cause COPD (Blanc et al., 2009; Driscoll et al., 
2005). Biomass fuel refers to burned animal or plant material; charcoal, wood, and 
even cow dung and crop residues, which provide more than one-half of domestic 
energy in most of the developing world and nearly 95 % in low income countries 
(Fullerton et al., 2008). There is evidence in the literature now, and more data is 
accumulating, explaining the potential link between an increased risk of respiratory 
tract infections, inflammatory lung / airway diseases and increased levels of indoor 
air pollution especially due to increase in biomass fuel consumption in rural areas 
(Fullerton et al., 2008; Jaakkola & Jaakkola, 2006). Understanding the effects of 
burning biomass fuels on health is important for any physician practising in the 
developing world, but unfortunately not well represented in the literature and it is 
quite surprising how little published research there is to date on its health 
consequences (Jaakkola & Jaakkola, 2006). There are few studies reporting 
associations between biomass fuel combustion and physiological and structural 
pathological changes in the respiratory system and little hard data are available on 
relationships between biomass fuel consumption and COPD. However, a Chinese 
study reported that biomass fuels are the probable primary risk factor for COPD in 
rural South China; they found that the use of biomass fuel was higher in rural areas, 
with a strong association between COPD and exposure to biomass fuel used for 
cooking. They also reported higher concentrations of carbon monoxide, particulate 
matter, sulphur dioxide and nitrogen dioxide in the kitchen during biomass fuel 
combustion compared to LPG combustion (Liu et al., 2007).  
 
In another study in Spain, Orozco and colleagues reported a strong association 
between wood or charcoal smoke exposure and COPD, suggesting that this is also a 
problem in less developed European countries (Orozco-Levi et al., 2006). In a 
systematic review and meta-analysis, Kurmi et al reported that even with enormous 
heterogeneity across different studies, exposure to biomass fuel is consistently 
associated with COPD and chronic bronchitis (Kurmi, Semple, Simkhada, Smith, & 
Ayres).  
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Despite the recognition of these environmental factors, the major cause of COPD 
worldwide/non-westernised countries is still a matter of debate (M. Roth, 2008). 
However, Salvi and Peter Barnes suggested in a recent review in the Lancet that 
about 3 billion people, which is nearly half of the total world population, are exposed 
to smoke from biomass fuel compared with 1.01 billion people who smoke tobacco, 
which suggests that exposure to biomass smoke, might be the biggest risk factor for 
COPD globally compared to tobacco smoke (Salvi & Barnes, 2009). However in 
westernised countries tobacco smoking is considered as the main etiological factor 
associated with COPD, but why only a minority of smokers develop COPD while 
others not, leads to a possibility that there may be a genetic susceptibility associated 
with COPD development interacting with environmental factors. Deficiency of 
protease inhibitor, alpha-1 antitrypsin is the only confirmed genetic risk factor 
associated with emphysema (Babusyte, Sitkauskiene, & Sakalauskas, 2006; 
Silverman, 2001), but this is a relative rare cause. Further discussion of the genetics 
of COPD is beyond the scope of this thesis although it is an area of much active 
research.  
 
2.1.3 Tobacco smoke, components and airway epithelium 
Cigarette smoke is a very diverse mixture of more than 4,700 different chemical 
compounds with a high concentration of free radicals and different oxidants and 
consists of a gas and a particulate phase or tar phase (MacNee, 2000). Free radicals 
are part of both gas and particulate phase in tobacco smoke.  The gas phase of the 
cigarette smoke contains roughly 1015 radicals per puff mainly from alkyl and 
peroxyl categories. Nitric oxide is another main component of cigarette smoke, 
present at concentration of 500 to 1000 ppm, which has the capacity to react with 
superoxide anion to form peroxynitrites and can also react with peroxyl radicals to 
form alkyl peroxynitrites (MacNee, 2000; Pryor & Stone, 1993). Both peroxynitrite 
species are highly chemically reactive. The particulate phase, on the other hand, has 
more stable radicals like semiquinone radicals, hydrogen peroxide and hydroxyl 
radicals (Pryor & Stone, 1993), which add substantially to the oxidant burden. 
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The airway epithelium is one of the first tissue targets of cigarette smoke, which 
leads to the activation of a number of biological and cellular pathways characterising 
the development of COPD (Figure 2.1 and 2.2) (K. F. Chung & Adcock, 2008). 
Chronic exposure to reactive oxygen species (ROS) can cause lipid peroxidation in 
airway epithelium leading to disruption of cellular membranes and inactivation of 
membrane-bound receptors and enzymes (Rahman, 2003, 2005; Rahman, Marwick, 
& Kirkham, 2004). Cigarette smoke induces epithelial changes related to 
development of chronic bronchitis in large airways which may or may not be 
associated with COPD, depending on the degree and/or outcomes of epithelial 
inflammation (J. C. Hogg, 2006). It can lead to mucus hypersecretion which is a 
feature of both large and small airways in COPD. Mucus secreting pathways are 
associated with EGFR over-expression in the airway epithelium in response to 
cigarette smoke-generated reactive oxygen species (Figure 2.3). Over expression of 
EGFR is also considered as one of the earliest abnormalities found in smokers at 
high risk of developing lung cancer (K. F. Chung & Adcock, 2008; Mutch, 2002). In 
small airways, cigarette smoke induces goblet cell metaplasia (Saetta et al., 2000) 
and increased connective tissue in the airway wall (James C. Hogg et al., 2004).  
 
Figure 2.1: Showing link between aetiology of COPD and clinical outcomes (K. F. 
Chung & Adcock, 2008) 
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Figure 2.2: Outlining different inflammatory and cellular interactions linking 
chronic cigarette smoke exposure to chronic inflammation in COPD (K. F. Chung & 
Adcock, 2008).  
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Figure 2.3: Mechanism of cigarette smoke induced mucin secretion in COPD 
(Thorley & Tetley, 2007).  
 
Increased oxidative stress due to cigarette smoke inhalation also initiates the process 
of airway remodelling which is defined as alterations in structural components of the 
airways leading to (gross) thickening of the airway wall causing airway obstruction 
(P. K. Jeffery, 2001b). Increased oxidative stress also disturbs the protease-
antiprotease balance of the lung, activates macrophages and neutrophils (both of 
which can secrete various proteolytic enzymes) and also CD8+ T cells which release 
perforin (cytolytic protein) and granzymes (sreine proteases). In addition oxidative 
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stress decreases VEGF signalling and alveolar repair and increased apoptosis of cells 
is also observed. All these pathways are associated with development of emphysema 
(Figure 2.4) with increased proteolytic load leading to elastic fibre damage (Kasahara 
et al., 2001; Morissette, Parent, & Milot, 2007; Sharafkhaneh, Hanania, & Kim, 
2008).  
 
 
 
 
 
Figure 2.4: Mechanism of cigarette smoke induced airway remodelling and 
emphysema (Sharafkhaneh et al., 2008).  
 
Numerous studies have reported changes in gene expression in epithelial cells in 
smokers and non-smokers (Carolan et al., 2006; Chari et al., 2007; N. R. Hackett et 
al., 2003; Harvey et al., 2007; K. M. Lee et al., 2007). Epithelial cells from small 
airways demonstrated an increase in the activation of pro-apoptotic gene pirin, and in 
anti-oxidant genes including glutathione peroxidase, and ubiquitin carboxyl-terminal 
hydrolase (UCH) L1, which is a member of ubiquitin proteasome pathways, but in 
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contrast the expression of IL-4 receptor, CX3C chemokine ligand (CX3CL) 1 and the 
extracellular matrix protein spondin 2 were inhibited (Harvey et al., 2007).  
 
Genes up-regulated during current smoking and then down-regulated with smoking 
cessation included those for trefoil factor 3, calcium-binding tyrosine-(Y)-
phosphorylation-regulated protein, CXCL6, CX3CL1 and S100 calcium-binding 
protein A9 (S100A9). Partial reversibility with quitting was shown for genes 
transcribing for mucin (MUC) 5 subtypes A and C (also called as MUC5AC), but an 
irreversible gene was that for glycogen synthase kinase 3β. The authors suggested 
that irreversible changes may account for the persistent lung cancer risk despite 
smoking cessation (Chari et al., 2007). 
 
2.2 Pathology of COPD 
The pathological changes in lungs associated with COPD essentially involve two 
anatomical compartments; the airway component of the disease, and that involving 
the parenchyma. They frequently coexist, but with some people having 
predominantly the airway component of the disease and some the parenchymal. The 
airway component includes inflammation of the central airways and small 
(peripheral) airways, and the parenchymal component of the disease involves the 
destructive process of emphysema.  
 
2.3 Airway component 
 
2.3.1 Central airways  
Tobacco smoking is a critical factor in the pathological changes and inflammatory 
response associated with central airways in COPD. Inflammation may present as 
“chronic bronchitis”, a clinical-epidemiological entity defined by cough and sputum 
production which reflects mucous hypersecretion in response to tobacco smoke, 
noxious gases and dust which may not be associated with airflow limitation (Barnes, 
2003; J. C. Hogg, 2004). Pathologically, in COPD when associated with airflow 
limitation, chronic bronchitis involves mucus gland hypertrophy and mucus 
hypersecretion, squamous metaplasia, loss of epithelial cilia, goblet cell hyperplasia 
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and hypertrophy, and infiltration of  airway wall with inflammatory cells (Figure 2.5) 
(Caramori et al., 2004 32; Saetta et al., 2000 143).  
 
 
 
 
 
Figure 2.5:   Pathologic changes of the central airways in COPD. (A) Central 
bronchus from the lung of a physiologically normal current smoker, which shows 
that only small amounts of bronchial smooth muscle are present and the glands are 
small, compared to a subject (B) with chronic bronchitis with thick bronchial smooth 
muscle and enlarged bronchial glands. (C) The enlarged bronchial glands at a higher 
magnification. It also indicates a chronic inflammation involving leukocytes (see 
arrows) and mononuclear cells, including plasma cells (see arrows) (Macnee, 
2007).  
 
 
26 
 
Inflammation observed in airways/lungs from patients with COPD is multifaceted 
and not well understood. In chronic bronchitis inflammation is mainly associated 
with the epithelium of the larger airways and extends to mucus glands, and involves 
infiltration of neutrophils and macrophages with increased number of CD8+ T-
lymphocytes in the bronchial glands (Mullen, Wright, Wiggs, Pare, & Hogg, 1985; 
Saetta et al., 1997).  
Mucus gland hypertrophy was first described in 1954 by Reid (L. M. Reid, 1954), 
she observed that bronchial glands were enlarged in chronic bronchitis and used the 
ratio of mucosal gland to the thickness of bronchial wall for the diagnosis of chronic 
bronchitis, known as Reid’s index (Caramori et al., 2004; L. Reid, 1960; L. M. Reid, 
1954). Mucus hypersecretion associated with chronic bronchitis is still a matter of 
debate as to whether it is related to airway flow limitation or not (Maestrelli, Saetta, 
Mapp, & Fabbri, 2001).  
 
It has been suggested that up-regulation/activation of the epidermal growth factor 
receptor (EGFR) on epithelial cells may be associated with abnormal epithelial cell 
growth and proliferation leading to goblet cell hyperplasia and hence to mucus 
hypersecretion in COPD (de Boer et al., 2006; Innes et al., 2006). Cigarette smoke is 
considered the main etiological factor associated with COPD and in humans chronic 
exposure to tobacco smoke may activate EGFR signalling pathway leading to mucus 
hypersecretion(Yoshida & Tuder, 2007).  
 
2.3.2 Small airways (obstructive bronchiolitis) 
COPD is widely accepted as a pan airway disease, but most attention has been given 
to the small airways (<2mm in diameter) where most of the obstruction occurs, 
characterized by an obliterated lumen with accumulation of inflammatory mucous 
exudates (Figure 2.6) (Szilasi et al., 2006). 
 
Macklem and colleagues in 1967 introduced the idea of peripheral or small airway 
disease (J. C. Hogg, 2006; Macklem & Mead, 1967). Soon after, Hogg and 
colleagues suggested that small airways represent the “quiet zone” where disease can 
progress for a long time without being clinically diagnosed (James C. Hogg et al., 
2004; J. C. Hogg et al., 1968; M. Saetta, 2006). The key pathological changes related 
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to progression of COPD in small airways involve inflammatory cell infiltration 
(James C. Hogg et al., 2004; Saetta et al., 1998), goblet cell metaplasia (Saetta et al., 
2000) and increased connective tissue in the airway wall (James C. Hogg et al., 
2004).  
 
 
 
 
Figure 2.6: Small airway obstruction 
(A) Normal small airway. (B) Small airway containing plug of mucus (C) Acutely 
inflamed airway with thickened wall in which the lumen is partly filled with an 
inflammatory exudates of mucus and cells (D) Airway surrounded by connective 
tissue and B cell follicles (J. C. Hogg, 2004).  
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Severe obstruction is associated with presence of B cells, CD4 and CD8 lymphocytes 
organized into follicles (James C. Hogg et al., 2004). The increase in the lymphocyte 
population is also associated with bronchial associated lymphatic tissue (BALT) 
which is hardly seen in normal-lung function non-smokers but frequently seen in 
smokers (J. C. Hogg, 2004). The existence of lymphocyte and BALT in COPD 
suggests that the adaptive immune system is involved and might be associated with 
microbial colonisation and infections of the lower respiratory tract in COPD (J. C. 
Hogg, 2004; J. C. Hogg & Timens, 2008).  
 
Alveolar attachments to small airways, which provide support during expiration 
preventing the airways from collapsing, are though to be damaged as the 
inflammation progresses. It is still not well understood whether small airway 
obstruction in COPD is because of bronchiolitis or due to obliteration of surrounding 
parenchyma and the loss of alveolar attachments, but probably both contribute to 
small airway obstruction (Szilasi et al., 2006).  
 
2.4 Lung parenchyma component  
The parenchymal component of the disease involves the process of emphysema 
which is further divided into two major types; centrilobular or centriacinar and 
panlobular or panacinar emphysema. 
 
2.4.1 Emphysema  
Emphysema in COPD has been defined as the enlargement of the distal airspaces, 
beyond the terminal bronchioles, caused by destruction of the alveolar walls (Figure 
2.7) ("The definition of emphysema. Report of a National Heart, Lung, and Blood 
Institute, Division of Lung Diseases workshop," 1985; MacNee, 2005).  
 
Laennec was the first to explain the lesions produced by emphysema characterized 
by dilation and destruction of the lung parenchyma (J. C. Hogg, 2004; Kligfield, 
1981; Laennec, 1834.) leading to a decrease in maximal expiratory airflow by 
reducing the elastic recoil force available to drive air out of the lungs (J. C. Hogg, 
2004; Macnee, 2007).  
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The two major types of emphysema referred to above (Figure 2.8) are differentiated 
according to the region of lung acinus being destroyed. Centrilobular or centriacinar 
emphysema results from destruction and dilation of respiratory bronchioles in the 
central portions of the acinus. This type of emphysema is usually related to tobacco 
smoke and is especially severe in the upper lobes of the lung. Panlobular or 
panacinar emphysema on the other hand involves a more even destruction and 
dilation over the entire acinus and is usually associated with the lower lobes of the 
lungs, for example in α1 anti-trypsin deficiency. α1 anti-trypsin acts as anti-elastase 
to protect the lungs from destruction (J. C. Hogg, 2004; W. D. Kim et al., 1991; M. 
Saetta, 2006), its genetic absence or low levels may lead to lung destruction at young 
age and can also lead to liver disease in children (P. Lee, Gildea, & Stoller, 2002).  
 
 A diverse variety of processes seems to be involved in the pathogenesis of 
emphysema related to tobacco smoking, but the most widely accepted hypotheses 
relate protease-antiprotease or oxidant/anti-oxidants imbalance. The hypothesis states 
that the destruction of alveolar walls results from protease activity leading to 
obliteration of extracellular matrix tissue (ECM), but the various proteases involved 
and their specific targets is still a matter of debate (Abboud & Vimalanathan, 2008; 
J. C. Hogg, 2004; J. C. Hogg & Senior, 2002).   
 
Even though the protease-antiprotease hypothesis has predominated it still doesn’t 
completely explain the pathogenesis of emphysema because if that was the case then 
all inflammatory lung diseases should be associated to emphysema (Walters, Reid, 
Soltani, & Ward, 2008). However, there is growing evidence for the vascular 
hypothesis which states that reduced vascularity might be the primary defect leading 
to development of emphysema. In 1959 Liebow reported a scarcity of vessels in the 
lungs of people with emphysema (Liebow, 1959) and later it was reported that 
inhibition of VEGF receptors can cause emphysema in rats (Kasahara et al., 2000). 
The same investigators later demonstrated that the process involved a progressive 
loss of capillary endothelial cells and epithelial cells due to apoptosis secondary to a 
decrease in vascular endothelial growth factor (VEGF) and VEGF receptor 2, the 
active VEGFR (Kasahara et al., 2001). Thus, VEGF might be playing a key role in 
COPD pathogenesis but unfortunately very little data is available on vascular 
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changes in human COPD, compared for example to work in asthma (Walters et al., 
2008).  
 
 
                                                                                                                                 
 
Figure 2.7:  Pathology of emphysema.  
Scanning electron micrographs of (A) a normal alveoli and (B) early emphysema 
with holes in alveolar walls. (C) Histologic section of a normal airway with 
surrounding alveolar attachments. (D) Enlargement of distal airspaces and reduced 
alveolar attachments in collapsed airway in emphysema (Macnee, 2007). 
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Figure 2.8: Photomicrograph showing the microscopic appearance of the different 
types of emphysema. 
(A) Normal lung; (B) Centriacinar emphysema showing an area of destruction and 
end enlargement of airspaces around a bronchiole in the central portion of the acinus 
surrounded by areas of grossly normal lung parenchyma; and (C) panacinar 
emphysema demonstrating homogenous enlargement of all air spaces beyond the 
terminal bronchiole (M. Saetta, 2006).  
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2.5 Airway inflammation in COPD 
Inflammation observed in the respiratory tracts (airways and lungs) from patients 
with COPD is multifaceted and not well understood; even though it involves the 
activation of both innate and adaptive immune responses. Thus, the inflammatory 
response observed in COPD is very diverse tautologous and recruitment of various 
inflammatory cells and mediators contribute significantly to the lung injury in 
patients with COPD, and appears to serve as a self-perpetuating stimulus for further 
enhancement of the immune response. The progression of disease involves an active 
migration of “leukocytes” (mainly neutrophils and macrophages) associated with 
production of inflammatory mediators and potentially destructive pro-inflammatory 
cytokines, proteases and various growth factors, which lead to structural changes in 
the airways termed as “airway remodelling” (explained in detail latter on) (V. Kim, 
Rogers, & Criner, 2008; Rumora et al., 2008). Chronic inflammation in COPD in 
response to chronic cigarette smoke and then other exposures, (Figure 2.2) is mainly 
characterised by accumulation of neutrophils, macrophages, B-cells lymphoid 
aggregates and CD8+ T-cells, especially in small airways and inflammation becomes 
worse with disease severity (Sutherland & Martin, 2003).   
 
COPD is predominantly a neutrophilic disease at least in the airway and airspace 
lumen. Neutrophils are usually found in bronchial epithelium, glands and also in 
airway smooth muscle bundles but mainly in the airway lumen of both small and 
large airways, as reported in sputum and BAL (bronchoalveolar lavage) (K. F. Chung 
& Adcock, 2008). Saetta et al assessed number of neutrophils, eosinophils, mast 
cells, macrophages, CD4+ and CD8+ T-lymphocytes, and the ratio of CD4+ to CD8+ 
cells in the bronchial glands, epithelium, and lamina propria by 
immunohistochemistry. They found that smokers with symptoms of chronic 
bronchitis had an increased number of neutrophils and macrophages and a decreased 
CD4+/CD8+ ratio in the bronchial glands when compared to smokers without 
symptoms, and smokers with chronic bronchitis also had increased number of 
epithelial neutrophils, whereas the numbers of macrophages and CD4+ and CD8+ T-
lympohcytes in the epithelium and lamina propria were similar in the two groups of 
smokers (Saetta et al., 1997). In another study it was shown that current smokers 
with COPD had increased number of neutrophils and CD8+ T cells in the airway 
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smooth muscle of peripheral airways compared with non-smokers, and they also 
reported that smokers with normal lung function also had a neutrophilic infiltration 
in the airway smooth muscle, but to a lesser extent compared to current smokers with 
COPD (Baraldo et al., 2004). When all the groups were analysed as one group 
neutrophilic infiltration in the smooth muscle of peripheral airways inversely related 
to FEV1% predicted (forced expiratory volume in one second) (Baraldo et al., 2004). 
Stanescu et al reported increased levels of neutrophils in sputum of smokers and 
showed that airways obstruction, chronic expectoration, and rapid decline of FEV1 in 
smokers are associated with increased levels of sputum neutrophils (Stanescu et al., 
1996). 
 
Different studies have variably reported increased levels of eosinophils in the airway 
wall and BAL and also in induced sputum, but the role of eosinophils in COPD are 
not very clear. It is suggested that eosinophilia may represent a different sub-group 
of COPD (K. F. Chung & Adcock, 2008). Interestingly, a few studies have reported 
that an increase in BAL and sputum eosinophils in COPD patients is related to good 
clinical response to steroid therapy (Chanez et al., 1997; Fujimoto, Kubo, 
Yamamoto, Yamaguchi, & Matsuzawa, 1999; Pizzichini et al., 1998), but this was 
not replicated by our group who could also not relate eosinophils to bronchodilator 
responsiveness in COPD (D. W. Reid et al., 2008).  
 
The situation of mast cells in COPD is not very clear either, with some studies 
reporting an increase in airway mast cells while others not. Pesci et al investigated 
BAL and bronchial biopsies with immunohistochemical techniques for mast cells in 
current smokers and ex-smokers with chronic bronchitis, and found that subjects with 
“chronic bronchitis” (both current and ex-smokers with cough and sputum) had 
higher numbers of mast cells both in the epithelium and in the bronchial glands 
compared to normals, whereas the numbers of mast cells in BAL and in the lamina 
propria were similar in the two groups. In current smokers with bronchitis an increase 
in mast cell numbers was observed in the epithelium and lamina propria, and in BAL 
compared to ex- smoker bronchitis (Pesci et al., 1994). In another study, it was 
reported in small airway samples from COPD patients (both current smokers and ex-
smokers) that numbers of epithelial mast cells and macrophages increased in the 
airway wall of smokers with airflow limitation, suggesting a potential role for mast 
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cells in development of COPD (Grashoff et al., 1997). On the other hand, Saetta et al 
reported no change in mast cell numbers in the bronchial mucosa of subjects with 
chronic bronchitis (Saetta et al., 1993). The same group later reported normal mast 
cell numbers in current smokers with COPD and also in normal lung function 
smokers (Di Stefano et al., 1998). In a similar study, Shaughnessy et al reported no 
change in sub-epithelial mast cells in subjects with chronic bronchitis 
(O'Shaughnessy, Ansari, Barnes, & Jeffery, 1997).  
 
More consistently, CD8+ T cells are reported increased in COPD airways and also in 
the lung parenchyma (Peter J. Barnes, 2008). Shaughnessy et al  reported that the 
number of CD8+ T cells increase in the sub-epithelial zone (lamina propria) of 
bronchial biopsies from patients with chronic bronchitis and inversely correlated to 
FEV1(O'Shaughnessy et al., 1997). Baraldo et al reported increased numbers of 
CD8+ T cells localised within the smooth muscle of peripheral airways of COPD 
patients (Baraldo et al., 2004). Chrysofakis et al also reported increased levels of 
CD8+ T cells in sputum of smokers with and without COPD compared to non-
smokers, and interestingly they also reported that they are highly active and 
expressed high levels of lytic substances such as perforin which may lead to 
parenchymal damage in COPD lung (Chrysofakis et al., 2004). Saetta et al also 
reported increased CD8+ T cells in peripheral airway wall of smokers who develop 
COPD, suggesting potential role in COPD pathogenesis (Saetta et al., 1998).   
 
Gosman et al reported increased number of B-cells in the sup-epithelial region of 
bronchial biopsies from COPD patients (Gosman et al., 2006). Severe airway 
obstruction is associated with presence of B cells, organized into follicles in small 
airways (James C. Hogg et al., 2004). As also described earlier, increase in the 
lymphocyte population is also associated with bronchial-associated lymphatic tissue 
(BALT) which is hardly seen in physiologically normal non-smokers but frequently 
seen in smokers (J. C. Hogg, 2004). The existence of lymphocytes and BALT in 
COPD suggests that the adaptive immune system is involved and might be associated 
with microbial colonisation and infections of the lower respiratory tract in COPD (J. 
C. Hogg, 2004; J. C. Hogg & Timens, 2008). Dendritic cells along with B-cells have 
also been reported to play a role in adaptive immunity in COPD (K. F. Chung & 
Adcock, 2008). Van der et al reported lymphoid follicles consisting of B cells and 
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follicular dendritic cells with adjacent T cells both in the parenchyma and in 
bronchial walls of patients with emphysema (van der Strate et al., 2006). Demedts et 
al reported increased numbers of dendritic cells in the epithelium of small airways of 
patients with COPD compared with never-smokers and smokers without COPD 
(Demedts et al., 2007). Additional evidence for recruitment of dendritic cells by 
tobacco smoke exposure comes from studies done in mice in which chronic cigarette 
exposure led to an increase in CD11c+ dendritic cells (D'Hulst A et al., 2005). 
 
It is suggested that COPD may also have an auto-immune component as it is a 
chronic inflammatory disease, albeit with a much better recognised aetiology than 
other such illness e.g. rheumatoid arthritis (RA). But like RA, once initiated, the 
inflammatory response COPD seems to be self-perpetuating even after smoking 
cessation (Agusti, MacNee, Donaldson, & Cosio, 2003). In a very interesting study, 
Lee et al showed that emphysema is an autoimmune disease, which could be 
characterised by circulating anti-elastin antibodies and Th1-type immune responses, 
which correlated with disease severity (Peter J. Barnes, 2008; S. H. Lee et al., 2007). 
Feghal et al reported increased levels of IgG auto-antibodies with increased avidity 
for pulmonary epithelium, and the potential to mediate cytotoxicity in patients with 
COPD (by using immuno-fluorescence and immuno-precipitation and immuno-
histochemistry techniques), suggesting that auto-reactive adaptive immune responses 
may be important in the etiology of COPD (Feghali-Bostwick et al., 2008). The jury 
is still out on whether these observations are centrally important, or whether they just 
represent an epi-phenomenon related to release of airway antigens by tissue 
proteolytic damage. 
 
 Macrophage numbers are increased in COPD, to a greater extent compared to 
asthma (Peter J. Barnes, 2008). Saetta et al observed increased numbers of CD68+ 
macrophages in the sub-epithelial lamina propria of patients with chronic bronchitis 
(Saetta et al., 1993). In another study clusters of macrophages were observed in small 
airways associated with peri-bronchial fibrosis seen in smokers and ex-smokers and 
it was suggested that they may be related to small airway fibrosis and/or 
development of centrilobular emphysema (Fraig, Shreesha, Savici, & Katzenstein, 
2002). Finlay et al showed that macrophages from BAL of patients with emphysema 
express higher levels of mRNA for MMP-1 and MMP-9 (matrix metalloproteinases), 
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and they demonstrated that alveolar macrophages from the emphysematous lung 
produced large amounts of matrix-degrading enzymes which may play an important 
role in development of COPD (Finlay et al., 1997). Others have also suggested that 
alveolar macrophages could be orchestrators of COPD (Barnes, 2004).  
 
2.6 Airway remodelling in COPD 
Airway inflammation is the response of a fully vascularised tissue to injury and the 
rationale behind the inflammatory response is to protect the host and to restore 
normal tissue functioning. It is widely assumed that accelerated decline in lung 
function in COPD is a consequence of acute inflammation leading to parenchymal 
and airway wall remodelling respectively. However, whether remodelling is part of 
the inflammatory process, or whether it is a separate and parallel entity is still a 
matter of debate and there is no convincing evidence either way available in the 
literature (P. K. Jeffery, 2001b). In reality there are very few data available on airway 
remodelling in COPD, even in comparison to asthma where many questions remain 
to be answered.  
 
During lung development, the lung undergoes extensive “modelling” and then 
“remodelling “changes and this whole process is very tightly regulated by different 
signalling pathways, growth factors and various cytokines. It may be possible that 
the perception of remodelling in airway disease is a reactivation of these 
embryological mechanisms as most of the cytokines and growth factors thought to be 
detrimental in COPD and other respiratory disorders are expressed normally during 
lung morphogenesis (P. K. Jeffery, 2001b; Warburton et al., 2001).  
 
Currently airway remodelling is defined as an alteration in size, mass, or number of 
tissue structural components leading to gross thickening of the airway wall occurring 
in response to oxidant or other injury and/or inflammation (P. K. Jeffery, 2001b). In 
COPD, remodelling may occur as a response to smoking-induced damage to the 
airways, but the mechanisms of damage and initiation, and even the structural 
changes themselves are poorly described compared to work published in asthma 
(Churg et al., 2006; Saetta et al., 2000). Structural changes mainly described in 
COPD are: small airway wall thickness(James C. Hogg et al., 2004), metaplasia of 
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the epithelium, loss of epithelial cilia, increase in goblet cell size and number, 
submucosal gland and smooth muscle hypertrophy (Figure 2.9 & 2.10) (Bergeron & 
Boulet, 2006; Saetta et al., 2000).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.9: Airway structural changes in COPD.  
(A) Epithelial metaplasia (white arrow) and submucosal gland hyperplasia (black 
arrow). (B)  Increase in smooth-muscle mass (black arrow) (Bergeron & Boulet, 
2006). 
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Figure 2.10: Examples of airway remodelling in COPD. (A) Represents mucous 
metaplasia (MM) of the epithelium and smooth muscle hypertrophy (SM). (B) 
Represents peribronchial fibrosis (black arrow). (C) Shows squamous metaplasia. 
(D) shows an inflammatory infiltrate of lymphocytes in the adventitia of a bronchiole 
(V. Kim et al., 2008). 
 
2.6.1 Epithelium  
Respiratory epithelium is described as pseudostratified “columnar”, consisting of 
eight different types of epithelial cells classified into three main categories: basal, 
ciliated and secretory. It is a highly active part of the airways and acts as a chemical, 
physical, and immunological barrier. It is also the site of first contact for cigarette 
smoke and plays an important role in protecting the lung (Davies, 2009; Knight & 
Holgate, 2003; Thorley & Tetley, 2007).  
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Epithelial shedding is not widely reported in COPD; however denuded epithelium 
has been reported in young smokers in small airways associated with increased 
inflammatory cell infiltration (M. G. Cosio, Hale, & Niewoehner, 1980). Thick 
epithelium, loss of cilia, goblet cell hyperplasia and squamous metaplasia 
(transformation of a columnar epithelium into a squamous epithelium) are also 
frequently observed and reported in COPD (Figure 2.9 & 2.10) (P. K. Jeffery, 2001b; 
V. Kim et al., 2008).  
 
Chronic exposure to cigarette smoke activates various oxidative pathways leading to 
the secretion of a diverse variety of cytokines and chemokines and various epithelial 
derived growth factors including; granulocyte- macrophage colony stimulating factor 
(GM-CSF), which is secreted by a wide variety of cells in the airways including 
epithelium, airway smooth muscle, fibroblasts, T lymphocytes, mast cells, 
eosinophils and macrophages(Saha et al., 2009) These can lead to alterations in the 
reticular basement membrane (Rbm) by activating fibroblasts/myofibroblasts, sub-
mucosal glands, smooth muscle and the vascular bed (P. K. Jeffery, 2001b). 
However, few studies have shown potential for GM-CSF in COPD, and no direct 
evidence is available (Saha et al., 2009).  
 
EGFR expression and function has been studied broadly in asthma and reported in 
several studies, but fewer data are available in COPD. Cigarette smoke has the 
potential to activate signaling associated with EGFR which can further lead to mucus 
hypersecretion (Shao, Nakanaga, & Nadel, 2004). EGFR can induce abnormal 
epithelial cell growth, differentiation, migration and proliferation leading to goblet 
cell hyperplasia and hence to mucus hypersecretion in COPD (de Boer et al., 2006; 
Innes et al., 2006).  
 
Transforming growth factor-β1 (TGF-β1) expression has been observed in the 
epithelium in bronchial biopsies from COPD patients (Kokturk, Tatlicioglu, Memis, 
Akyurek, & Akyol, 2003) and is also considered as one of the major growth factors 
driving the process of airway remodelling generally in inflammatory airway disease.  
Some studies have reported that interactions between TGF-β and its second 
messenger, Smad signalling pathway play an important role in airway remodelling 
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by regulating extracellular matrix (ECM) turnover (Figure 2.11) (Postma & Timens, 
2006). Springer and colleagues demonstrated that Smad signalling is altered in 
COPD due to a decrease in TGF-β inhibitory Smad-6 and Smad-7 observed in 
epithelium in bronchial biopsies from COPD patients compared to normal controls. 
This may suggest that inhibitory pathways are distorted in COPD leading to lack of 
control of fibrotic changes (Springer, Scholz, Peiser, Groneberg, & Fischer, 2004).  
 
 
 
Figure 2.11: Main components of the Smad pathway (Gosman et al., 2006).  
 
Increased vascular endothelial growth factor (VEGF) expression in the epithelium 
has also been reported in COPD compared to normal non-smokers, which may 
suggest a role for VEGF in epithelial repair in response to cigarette smoke exposure 
(Kranenburg, de Boer, Alagappan, Sterk, & Sharma, 2005). The exact role of VEGF 
in epithelium is not clear but a significant body of literature suggests a decrease in 
VEGF in lung parenchyma may be associated with emphysema (Liebow, 1959).  
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Cigarette smoke increases the oxidative stress in the lungs which also leads to 
increased proteolytic load in the lungs of smokers through infiltrating neutrophils and 
macrophages, but there is very convincing evidence available now that the 
epithelium itself has the capacity to secrete a variety of proteases, mainly matrix-
metalloproteinases (MMPs). MMPs are the largest family of proteases with more 
than 25 members identified so far. They have the capacity to degrade all the 
components of the ECM, (Thorley & Tetley, 2007) playing a key role in matrix 
turnover, remodelling and angiogenesis (Kian Fan Chung, 2005).  
 
Immunohistochemical studies (Baraldo et al., 2007; Thorley & Tetley, 2007) and 
sputum profiles (Mercer et al., 2005) in COPD have shown that MMP-2 and MMP-9 
levels are elevated during disease progression. On the other hand it  was also shown 
that epithelial anti-proteases like SERPIN2 (serine protease inhibitor) which codes 
for a thrombin and urokinase inhibitor(Demeo et al., 2006), tissue inhibitors of 
metalloproteinases TIMPs (Mercer et al., 2005) and secretory leukocyte protease 
inhibitors (SLPI) (Thorley & Tetley, 2007) are elevated during chronic inflammation 
in COPD. This suggests activation of defensive mechanism of the epithelium against 
the enhanced proteolytic activity induced by smoking.  It is the balance of this 
“combat” between competing proteolytic forces that may decide the fate of the 
airway and lung in smokers.    
 
2.6.2 Reticular basement membrane (Rbm)  
The human airway epithelium is attached to a true basement membrane, which 
further consists of a lamina rara and a lamina densa. The reticular basement 
membrane, also known as lamina reticularis, is located just below the true basement 
membrane extending superficially (Postma & Timens, 2006; Saglani et al., 2006), 
and separates the epithelium from the underlying lamina propria mesenchymal 
structure.  
 
Immunohistochemical studies have confirmed that true basement membrane is 
comprised mainly of type IV collagen (Montes, 1996) and is attached strongly to the 
underlying Rbm by collagen VII strands (Liesker et al., 2009). In asthmatics Rbm is 
homogenous and hyaline in appearance(Peter K. Jeffery, 2004) (Figure 2.12) and 
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comprises mainly collagen I, III, V, fibronectin, tenascin (Postma & Timens, 2006) 
and laminin (Liesker et al., 2009) and is thickened(P. K. Jeffery, 2001b). Thickening 
of the Rbm in asthma has a strong positive correlation with the number of 
subepithelial fibroblasts and myofibroblasts (Brewster et al., 1990). Rbm develops in 
normal healthy individuals during childhood, but thickening may develop early in 
individuals with asthma perhaps even before symptoms start (P. K. Jeffery, 2001b).  
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Figure 2.12:  The airway mucosa as it appears by light microscopy (LM) of 
bronchial biopsies from (A) an atopic asthmatic showing loss of surface epithelium 
and early thickening and hyaline appearance of the reticular basement membrane 
Rbm and (B) a heavy smoker with COPD demonstrating epithelial squamous 
metaplasia and a thinner Rbm of normal thickness. Stained with haematoxylin-eosin 
(H&E) (P. K. Jeffery, 2001b).  
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In COPD, data on Rbm are rare and very ambiguous; there is no clear evidence on 
Rbm thickness, composition or appearance (Figure 2.12), although some studies have 
reported that tenascin is increased in COPD Rbm and there is also a trend towards 
stronger type IV collagen staining. Less collagen I and laminin is also reported in 
COPD Rbm compared to asthma (Kranenburg et al., 2006; Liesker et al., 2009). Rbm 
thickness in COPD is still a matter of debate, with some studies showing increased 
thickness while others report no difference (Liesker et al., 2009), but it appears that 
composition of reticular basement membrane is different in COPD subjects 
compared to asthmatics (Liesker et al., 2009; Postma & Timens, 2006).  
 
Interstitial collagen (forming scar tissue), which  lies deeper than the Rbm and 
reported as airway wall fibrosis, is usually considered as the feature of smokers who 
are more likely to develop COPD (especially in small airways), but no such evidence 
of fibrosis is available in large airways(Bosken, Wiggs, Pare, & Hogg, 1990; Peter 
K. Jeffery, 2004).  
 
2.6.3 Extracellular matrix  
Increase in airway wall tissue has been observed due to increase in volume of 
epithelium, lamina propria, muscle and adventitial compartments of small airways 
and may lead to fixed airflow limitation in COPD (James C. Hogg et al., 2004). In 
asthma matrix deposition is mainly observed in the subepithelium Rbm area but in 
COPD the whole airway wall seems to be affected. However,  there are actually very 
few studies reporting matrix changes and their exact role in COPD, this needs further 
investigations (Kian Fan Chung, 2005), which we aim to do. 
 
Van Straaten et al reported immunohistochemical studies in lung tissues from 
patients with mild and severe emphysema, and from patients with lung fibrosis. They 
looked at collagens, laminin, fibronectin, proteoglycans and beta1-integrins and 
reported that majority of the patients with severe emphysema showed a decrease in 
staining for the interstitial proteoglycans decorin and biglycan in the peribronchiolar 
area, compared to controls and patients with fibrosis. Very few patients with mild 
emphysema showed this pattern of reduced staining. In comparison, decorin and 
biglycan were strongly positive in the perivascular area of all of the sections from 
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patients with emphysema. There was no change to collagen type I, III and IV and 
also no abnormality was observed in laminin or fibronectin expression in the three 
pathological groups. They also suggested that specific loss of interstitial 
proteoglycans may be essential for elastic recoil loss and following bronchiolar 
obstruction, as seen in patients with smoking-related emphysema (van Straaten et al., 
1999).   
 
Somewhat contradictory to these findings, Kranenburg et al(Kranenburg et al., 2006) 
in another immunohistochemical study observed that COPD has increased expression 
of collagen type I, III and IV, fibronectin and laminin and also increased expression 
of matrix proteins in the Rbm, lamina propria and adventitia of the bronchial walls 
and vessels. At the site of damaged bronchial epithelium in the surface epithelial 
basement membrane, enhanced matrix protein deposition was observed. They also 
observed that collagens I and III were dominant in COPD patients in the reticular 
layer near the lamina propria, when compared to normal controls, and there was also 
increased expression of fibronectin and laminin observed in bronchial vessels. FEV1 
correlated inversely with the collagen in the Rbm region, fibronectin in bronchial 
vessels and laminin in the airway smooth muscle layer. These findings may indicate 
a pathogenic role for matrix proteins in airway remodelling in COPD, but these 
studies are limited by the fact that tissue was obtained from COPD patients who had 
undergone surgery for lung cancer. There is no direct evidence from airway biopsies 
in otherwise healthy non-cancer COPD patients (Kranenburg et al., 2006).    
 
2.6.4 Vascularity  
The literature on vascular remodelling and angiogenesis in chronic airway disease is 
scant, although there are studies reported in asthma (Feltis et al., 2006; McDonald, 
2001). Vascular remodelling involves structural changes, usually enlargement of 
arterioles, capillaries or venules without the formation of new vessels whereas 
angiogenesis is the growth of new blood vessels from the existing ones (Feltis et al., 
2006; McDonald, 2001).  
 
Dunnill et al in 1960 (Dunnill, 1960) were the first to describe enlargement of the 
capillary bed in the airway wall of patients who died of chronic asthma. Increased 
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vascularity was later reported in mild asthmatics as well, but perhaps especially in 
severe corticosteroid dependent asthmatics (Peter K. Jeffery, 2004). Bronchial 
mucosal blood vessel dilation, congestion and wall edema are reported as hallmarks 
of chronic asthma and may account for substantial swelling and stiffening of the 
airway wall (Peter K. Jeffery, 2004). In another study, Khor, et al suggested that 
airway vascular leakage is a major pathophysiologic feature of early asthma 
deterioration, occurring before recrudescence of cellular inflammation (Khor et al., 
2009). 
 
Several angiogenic growth factor cytokines have been recognized including members 
of the fibroblast growth factor (FGF) family, vascular endothelial growth factor 
VEGF, TGF-α and TGF-β, angiogenin, platelet derived growth factor, tumor 
necrosis factor-α (TNF-α), GM-CSF, hepatocyte growth factor (HGF), and various 
interleukins and chemokines such as IL-8. Angiopoietin 1 and 2 are also involved 
(Postma & Timens, 2006; Puxeddu, Ribatti, Crivellato, & Levi-Schaffer, 2005), 
perhaps more in a vessel stabilisation/maturation role.  Among all the different 
angiogenic factors, VEGF has been recognised as the key growth factor involved in 
regulation of angiogenesis (Figure 2.13) and is highly expressed during chronic 
inflammation (Postma & Timens, 2006).   
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Figure 2.13: Schematic representation of the main regulatory roles of vascular 
endothelial growth factor (VEGF). ECM = extracellular matrix; TGF = transforming 
growth factor; MMP = matrix metalloproteinase; TIMP = tissue inhibitor of 
metalloproteinase (Gosman et al., 2006).   
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Imbalance between VEGF and endostatin (a potent anti-angiogenic factor) levels has 
been observed in the sputum of patients with asthma, this suggests that this disparity 
may trigger proangiogenic factors leading to abnormal new blood vessel formation in 
asthma (Asai et al., 2002). Hoshino and colleagues reported that VEGF expression 
increases in the airway mucosa of patients with asthma compared to normal controls 
(Hoshino, Nakamura, & Hamid, 2001). A very interesting study reported higher 
levels of VEGF in bronchoalveolar lavage fluid and in bronchial biopsies in subjects 
with asthma which were related to number of vessels (Feltis et al., 2006). Angiogenic 
sprouts (i.e., early-forming vascular structures) were also observed and their number 
increased in subjects with asthma (Feltis et al., 2006).    
 
Yet again, data on COPD are much more limited. Vascular abnormalities have been 
reported in COPD, and associated with disease progression (Postma & Timens, 
2006). Kranenburg and colleagues reported enhanced expression of VEGF in the 
bronchial, bronchiolar and alveolar epithelium and macrophages. They also observed 
VEGF expression in airway smooth muscle and vascular smooth muscle cells in both 
the bronchiolar and alveolar compartments (Kranenburg et al., 2005). They 
suggested that VEGF and its receptors VEGFR1 (decoy) and VEGFR2 (active) may 
be involved in epithelial and endothelial cell repair and maintenance in response to 
injury caused by cigarette smoking and may be associated  with airway remodelling 
in COPD(Kranenburg et al., 2005; Siafakas, Antoniou, & Tzortzaki, 2007).  
 
In a very interesting study, Calabrese and colleagues (Calabrese et al., 2006) 
evaluated the contribution of vasculraity in airway remodelling in smokers with 
normal lung function and smokers with COPD. They performed an 
immunohistochemical analysis involving vessels positive for integrin αvβ3. High 
αvβ3 expression was observed in bronchial vessels which was associated with higher 
cellular expression of VEGF, suggesting that these two molecules might be playing 
an important interacting role in angiogenesis. Enhanced bronchial vascularity was 
also observed as both number of vessels and vascular area of lamina propria in 
smokers with normal lung function and smokers with COPD compared to normal 
healthy controls. These data from normal lung function smokers may suggest that 
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vascular changes might be independent of the airway obstruction and severity of the 
disease (Calabrese et al., 2006).  
 
Inflammation, which is one of the hallmarks of COPD, also has the potential to 
promote angiogenesis in numerous ways (Figure 2.14) (Siafakas et al., 2007). 
Airway inflammation in COPD mainly involves infiltration of neutrophils, 
macrophages and CD8+ T cells in the lumen, bronchial and bronchiolar airway wall 
and lung parenchyma (P. K. Jeffery, 2001a; Siafakas et al., 2007). These 
inflammatory cells in the lungs can release various mediators such as TNF-α which 
can promote angiogenesis. Hypoxia can also occur in COPD either globally or 
focally in inflamed tissue, which may also induce angiogenesis (Siafakas et al., 
2007).  
 
 
Figure 2.14: Schematic representation of an angiogenetic process in COPD 
(Siafakas et al., 2007).  
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Hypoxia has also been considered a key factor involved in pulmonary vascular 
remodelling leading to pulmonary hypertension in COPD (Nilsson, Shibuya, & 
Wennstrom, 2004; Wright et al., 1983). However, vascular remodelling of 
pulmonary arteries is not only the characteristic of severe COPD but has also been 
reported in patients with mild COPD without arterial hypoxemia and also in smokers 
with normal lung function (Barbera et al., 1994). It is reported that VEGF could play 
a major role in remodelling of pulmonary arteries in smokers and COPD (Peinado et 
al., 1999; Siafakas et al., 2007).  
 
2.6.5 Airway smooth muscle 
Bronchial smooth muscle mass (Figure 2.10) and its contribution to airway wall 
remodelling has been predominantly studied in small airways compared to large 
airways in COPD (P. K. Jeffery, 2001b). Whether airway smooth muscle mass is a 
prominent cause of airflow limitation, is still a matter of debate, with no convincing 
evidence available (V. Kim et al., 2008).   
 
However, an increase in airway smooth muscle in small airways was inversely 
correlated with lung function in one study (Kian Fan Chung, 2005). In another it was 
reported that muscle mass was increased by 50% in patients with severe COPD in 
small airways (James C. Hogg et al., 2004). There is little information available on 
airway smooth muscle cells, but they may be functionally altered in proximal 
airways in COPD. Unfortunately there is no information available on function of the 
airway smooth muscle in small airways. It is not clear whether any increase in 
muscle mass in COPD is due to an increase in number of muscle cells, or increase in 
airway smooth muscle size, or a combination of both. In asthma, airway smooth 
muscle predominantly increases in large airways whereas in COPD this seems to 
occur mainly in small airways (Kian Fan Chung, 2005).   
 
Abnormalities associated with smooth muscle mass in large airways have not been 
reported in COPD, although internal airway wall thickness has been associated with 
reduced FEV1/FVC ratio (Kian Fan Chung, 2005; Peter K. Jeffery, 2004). Even 
biopsy studies from large airways reported no increase in smooth muscle area and 
size; moreover, smooth muscle protein isoforms were not increased, but there was a 
51 
 
slight increase in myosin light chain kinase but with no increase in phosphorylated 
myosin light chain. Thus, more data are required on airway smooth muscle 
remodelling in large airways in COPD (Kian Fan Chung, 2005).  
 
2.6.6 Goblet cells, submucosal glands and mucus   
Goblet cells are mucus-producing cells which are dispersed widely in the airways, 
reproductive tract and alimentary canal. In the airway their major function is to 
hydrate, lubricate and to clear the particulate matter and pathogens from the lumen 
by secreting mucus, which forms a slimy film covering mainly the luminal surface of 
epithelial cells. Goblets cells are the major secretory cells of the airways and the 
major source of luminal mucus (Davis & Dickey, 2008; Yoshida & Tuder, 2007).  
 
Goblet cell hyperplasia has been associated with both asthma and chronic bronchitis 
in large airways (P. K. Jeffery, 2001b). Their number is usually less in small airways, 
but an increase in peripheral airways (diameter < 1 mm) in COPD subjects has been 
associated  with an influx of neutrophils into the airways promoting the concept that 
neutrophils might be playing a role in goblet cell degranulation through release of 
secretagogues neutrophils elastase and cathepsin G (Sommerhoff, Nadel, Basbaum, 
& Caughey, 1990). In another study done by M. Saetta, et al there was an increase in 
the number of goblet cells and inflammatory cells in the epithelium of peripheral 
airways of smokers with chronic bronchitis and airflow limitation (Saetta et al., 
2000).  
 
Submucosal gland hypertrophy was described by Reid in 1954 (L. M. Reid, 1954). 
Mucus gland hypertrophy is observed in both asthma and COPD. In COPD 
submucosal gland hypertrophy is mainly seen in large airways (P. K. Jeffery, 2001b). 
Glands are composed of serous and mucus secretory units or acini. In asthma normal 
proportions of mucus and serous units are retained, whereas in chronic bronchitis this 
balance is disturbed and there is a disproportionate increase in mucous units and 
decrease in serous units (Glynn & Michaels, 1960). Serous units in the submucosal 
glands secrete a wide range of antibacterial substances such as the secretory 
component of secretory IgA, lysozyme and lactoferin. Loss of these substances 
during airway remodelling may create a potential for chronic bacterial colonisation in 
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the airways (P. K. Jeffery, 2001b), but interestingly, mucus production and gland 
hypertrophy are poorly related to each other, whereas inflammation has been shown 
to be closely associated with mucus hypersecretion (Barbera et al., 1994). 
                                                                                                                                                     
There are very few studies in the literature reporting the composition of mucus in 
COPD and the various types of mucins involved (Kian Fan Chung, 2005) and data 
regarding mucus hypersecretion are contradictory. Innes and colleagues reported that 
epithelial mucin stores are elevated in the large airways of habitual smokers with 
airflow limitation, with predominant increase in MUC5AC gene expression (gene 
which encodes for mucin-5AC protein in humans, also commonly known as 
MUC5AC in literature). They reported significant decrease in MUC5B gene 
expression (gene which encodes for mucin-5B protein in humans, also commonly 
known as MUC5B in literature) while other authors found no change (Innes et al., 
2006). In peripheral airways Caramori and colleagues found increased expression of 
MUC5B in the bronchiolar lumen and increases in MUC5AC expression in the 
bronchiolar epithelium of patients with COPD (Figure 2.15) (Caramori et al., 2004).   
 
How mucus secretion is controlled is not well understood. However, limited studies 
have reported that cellular signaling initiated by epidermal growth factor receptor 
(EGFR) may be playing a key role in mucus production and regulation (Yoshida & 
Tuder, 2007). Cigarette smoke is considered as the main etiological factor associated 
with COPD and in humans chronic exposure to tobacco smoke may activate EGFR 
signalling pathways leading to mucus hypersecretion(Yoshida & Tuder, 2007). 
EGFR can be activated in two different ways ie, involving a ligand-dependent or a 
ligand-independent mechanism (Figure 2.16) (Burgel & Nadel, 2004). In ligand-
dependent EGFR tyrosine phosphorylation, EGFR ligands bind to their receptor and 
activate it, but on the other hand in a ligand independent mechanism EGFR tyrosine 
phosphorylation can occur directly in response to increase in oxidative stress due to 
cigarette smoke and inflammation (Burgel & Nadel, 2004).  
 
In COPD there are few studies reporting EGFR expression. Immunohistochemical 
analysis done by De Boer et al revealed that EGFR expression is increased in 
biopsies from COPD patients (de Boer et al., 2006). EGFR family has four different 
types of receptors termed ErbB1, ErbB2, ErbB3 and ErbB4 and EGFR itself is also 
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known as ErbB1. Donnell and colleagues reported enhanced expression of EGFR, 
ErbB3 and MUC5AC in the airways of long term current smokers; they also 
observed that this increase was not associated with neutrophilic inflammation and 
suggested that ErbB3, may be playing an important role in mucus hypersecretion 
(O'Donnell et al., 2004).  
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Figure 2.15: Representative photomicrographs of (A) bronchiolar epithelium 
immunostained for MUC5AC (brown) and (B) bronchiolar lumen immunostained for 
MUC5B (brown) from smokers with chronic obstructive pulmonary disease (COPD) 
(Caramori et al., 2004).  
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Figure 2.16: Ligand dependent and ligand independent EGFR activation leading to 
mucin synthesis (Burgel & Nadel, 2004).  
 
2.6.7 Airway remodelling and lung function consequences  
Small airways have been reported as the major site of obstruction in COPD in 
various studies (James C. Hogg et al., 2004; J. C. Hogg et al., 1968). Airway 
remodelling and chronic inflammation in these airways has been associated with 
airflow limitation (Bosken et al., 1990; M. Cosio et al., 1978; James C. Hogg et al., 
2004). In addition, a strong association has been observed between disease 
progression and increased structural abnormalities in components of the airways 
including epithelium, lamina propria, airway smooth muscle and adventitia in COPD 
(James C. Hogg et al., 2004). Furthermore, chronic inflammation in peripheral 
airways has been associated with abnormal connective tissue deposition in the airway 
wall and with emphysema (M. Cosio et al., 1978). With increasing abnormalities in 
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the peripheral airways, lung function declined progressively and small airway 
function tests helped to differentiate patients with minimal but progressive 
pathologic and physiological changes from patients with normal airways (M. Cosio 
et al., 1978).  
 
Emphysema in COPD may also be play an important role in airflow limitation, 
depending on the type of the emphysema involved (Kian Fan Chung, 2005). 
Centrilobular or centriacinar emphysema results in destruction and dilation of 
respiratory bronchioles in the central portions of the acinus, is usually related to 
tobacco smoke and is primarily severe in the upper lobes of the lung and associated 
with small airway obstruction. Panlobular or panacinar emphysema on the other hand 
involves a more uniform destruction and dilation over the entire acinus and is usually 
associated with the lower lobes of the lungs (for example in α1 anti-trypsin 
deficiency) (J. C. Hogg, 2004; W. D. Kim et al., 1991; M. Saetta, 2006) and its major 
impact is on lung diffusing capacity.  
Panacinar emphysema is also related to loss of lung elasticity and higher compliance, 
whereas centrilobular emphysema is associated with chronic airway inflammation 
and airway hyper-responsiveness (Kian Fan Chung, 2005). Hale K. A. et al reported 
that severe pathological changes, including emphysema, correlated with the degree of 
airflow limitation as measured by FEV1 (Hale, Ewing, Gosnell, & Niewoehner, 
1984). However in emphysema the loss of elastic recoil is the cause of airflow 
limitation rather than changes in airway wall remodelling directly on the airway 
lumen (J. C. Hogg et al., 1968). Where diffusing capacity is reduced in addition to 
airflow limitation, symptoms are appreciably greater (Burgess et al., 2008). 
Recent detailed data on airway remodelling in COPD is very sparse, and how these 
changes lead to decline in lung function are not well understood. It is likely that in 
COPD the epithelium may get damaged by cigarette smoke and airway wall 
remodelling may occur in response to this, but the mechanisms and detailed 
structural changes are poorly described. In other COPD-like airway disease, 
especially bronchiolitis obliterans syndrome (BOS, a manifestation of chronic 
rejection post lung transplant), a new component of remodelling is emerging in 
which alveolar epithelial cells undergo a transition to a mesenchymal phenotype with 
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myofibroblast characteristics and then migrate through the Rbm to the sub-epithelial 
lamina propria, a process termed “epithelial-mesenchymal transition” (EMT) 
(Borthwick et al., 2009; Ward et al., 2005)}. There are no reported studies on EMT 
in COPD, but a significant body of literature shows evidence of EMT in BOS 
(Borthwick et al., 2009; Ward et al., 2005) and also in idiopathic pulmonary fibrosis 
(IPF) (Brigham C. Willis et al., 2006).  Hackett et al, recently reported that alveolar 
epithelial cells from asthmatics can undergo a transition to a mesenchymal phenotype 
when stimulated with TGF-β1, but when the actual airway biopsy sections from 
asthmatics were stained for markers of EMT they were negative and in addition the 
thickened homogenous Rbm in asthma shows none of the characteristic 
fragmentation, characteristic of EMT (T. L. Hackett et al., 2009).   
 
2.7 Epithelial - mesenchymal transition (EMT) 
 From a general perspective, epithelial mesenchymal transition is a biological process 
in which epithelial cells undergo extensive molecular reprogramming allowing 
epithelial cells to undergo numerous biochemical changes and acquire a 
mesenchymal phenotype. This is accompanied by progressive loss of epithelial 
markers, gain in migratory potential and invasiveness, and enhanced capacity to 
produce extracellular matrix components (Figure 2.17) (Raghu Kalluri & Neilson, 
2003; R. Kalluri & Weinberg, 2009). The digestion of underlying basement 
membrane facilitates the process of EMT and the fragmented anatomical changes in 
the Rbm have been reported as a marker of completion of the process of EMT (R. 
Kalluri & Weinberg, 2009). This, of course is what first attracted my attention to 
EMT being a possibility in COPD.  
Elizabeth Hay from Harvard University was the first to describe the process of 
“epithelial mesenchymal transformation” in 1982 and then in 1995 as an important 
process involved in embryogenesis and organ development (Guarino, Tosoni, & 
Nebuloni, 2009; Hay, 1982, 1995). In the intervening time, the term “transformation” 
has been replaced with the term “transition”, indicating potential induction and 
reversibility of the process, even a two-way process (Raghu Kalluri & Neilson, 
2003). The reverse process has been termed as mesenchymal-epithelial transition 
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(MET), but there are very few studies reporting MET in the literature and most are 
concerned with embryogenic kidney formation (R. Kalluri & Weinberg, 2009).  
 
 
Figure 2.17: Epithelial mesenchymal transition, with progressive loss of epithelial 
markers and gain of mesenchymal markers (R. Kalluri & Weinberg, 2009).   
The literature on these different terms is somewhat conflicting; they are often used 
inappropriately. Thus, the terms “epithelial mesenchymal transformation, interaction 
and transition are often confused and inappropriately used with the term epithelial 
mesenchymal transdifferentiation” (Raghu Kalluri & Neilson, 2003). 
“Transformation” is typically associated with the oncogenic conversion of the 
epithelium and is not usually plastic over time, whereas “transdifferentiation” is 
associated with differentiated cells changing into other differentiated cells. Also, 
epithelial mesenchymal “interaction” involves paracrine cross-talk between epithelial 
cells and stromal fibroblasts and is totally separate from the concept of epithelial 
mesenchymal “transition” (Raghu Kalluri & Neilson, 2003). Epithelial mesenchymal 
transition is considered as a type of transdifferentiation, but the term epithelial 
mesenchymal transition is preferred over transdifferentiation as the latter is 
associated with differentiated cells changing into other differentiated cells. This issue 
is still a matter of debate with no clear explanation available (Raghu Kalluri & 
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Neilson, 2003).  For my work in COPD, I have maintained use of the term epithelial 
mesenchymal “transition” or EMT.  
Recently, Raghu Kalluri et al (R. Kalluri, 2009; R. Kalluri & Weinberg, 2009; 
Zeisberg & Neilson, 2009) also from Harvard, suggested that EMT could be divided 
into three different types (Figure 2.18) based on the biological conditions in which 
they occur and associated consequences: 
 
 
Figure 2.18: Different types of EMT. (A) Type 1 EMT (B) Type 2 EMT (C) and 
Type 3 EMT, (R. Kalluri & Weinberg, 2009). 
• Type 1 EMT occurs during implantation, embryogenesis and organ 
development, this type of EMT is not associated with organ fibrosis and 
metastasis, and however type 1 EMT has the potential for MET to form 
secondary epithelia.  
60 
 
• Type 2 EMT is implicated in wound healing, organ fibrosis and tissue 
regeneration. It occurs in response to injury and contributes to the repair 
process by generating fibroblasts and other cells to repair the tissue. This type 
of EMT is usually associated with inflammation and may stop once the 
inflammation ceases, but if the inflammation is long lasting due to repeated 
injury, type 2 EMT could well lead to organ damage and may have very 
severe consequences. Type 2 EMT could potentially be picked up using very 
reliable mesenchymal markers available like fibroblast-specific protein (also 
called S100A4), collagen I, along with vimentin, desmin, E-cadherins and 
cytokeratins.  
• The last type of EMT, type 3 is associated with cancer progression and 
metastasis. Cells produced by this type of EMT may invade through and into 
the circulation and produce metastases. A significant body of literature 
explains the signalling pathways involved with type 1 and type 2 EMT, but 
we don’t know much about type 3 signalling pathways which are mainly 
involved with cancer progression.  
 
2.7.1 Mechanism of EMT  
EMT can be considered as a marker of profound epithelial plasticity engaged by 
disaggregating and reshaping epithelium for movement (B. C. Willis & Borok, 
2007). The epithelium is basically a sheet of cells, in the airways one cell deep, with 
epithelial cells joined to each other in a uniform way. Tight junctions and adheren 
junctions between epithelial cells hold the epithelial cells strongly together as a 
single layer and restrict the movement of individual cells away from the epithelium. 
The epithelial cells are polarized, from which we understand that in epithelium apical 
and basal surfaces are likely to be visually different and may carry different 
functions.  Mesenchymal cells compared to epithelial cells are lacking uniform 
composition and strong adhesion properties; they are of a more elongated and 
irregular shape allowing the cells to gain migratory potential for movement (J. M. 
Lee et al., 2006).   
During transition the epithelium loses cell polarity, tight junctions like zonula 
occludins, adheren junctions like E-cadherins and desmosomes, cytokeratin filaments 
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(Cytokeratins are keratin containing intermediate filaments found in epithelial cells 
and are vital for regular tissue function and structure) and reorganize their actin 
fibres, emission of filopodia and lamellopodia and then finally go through a 
transition into an elongated and irregular morphology associated with gain of 
mesenchymal markers (e.g.: S100A4 and vimentin) simultaneously (Savagner, 2001; 
B. C. Willis & Borok, 2007).  
The process of EMT can simply be induced by a combination of different cytokines 
and growth factors associated with dismantling of the basement membrane by 
proteolytic activity (Raghu Kalluri & Neilson, 2003). The cells undergoing transition 
have the capacity to secrete proteolytic enzymes from the metalloproteinase family, 
which can start the proteolytic digestion of the underlying basement membrane 
assisting migration of the cells (J. Yang & Liu, 2001). A diverse variety of growth 
factors are involved in the process, mainly TGF-β, EGF, insulin growth factor-II 
(IGF-II), hepatocyte growth factor (HGF) and also fibroblast growth factor-II (FGF-
II) (Figure 2.19); they have the capacity to induce EMT by binding to different 
receptors on epithelium cells (Raghu Kalluri & Neilson, 2003).  
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Figure 2.19: Schematic representation of different signalling pathways involved in 
EMT (Raghu Kalluri & Neilson, 2003). 
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TGF-β has been considered a prototypical driver of EMT; Fan et al (Fan et al., 1999) 
reported that TGF-β can induce the differentiation of tubular epithelial cells into α-
SMA positive myofibroblasts. It was also reported that TGF-β and FGF-II 
expression is central to MMP-2 and MMP-9 expression; these porteolytic enzymes 
have the capacity to digest the basement membrane/Rbm to facilitate the migration 
of cells (Raghu Kalluri & Neilson, 2003; Ward et al., 2005). TGF-β can act mainly in 
two ways, through Smad-3 dependent pathway or other Smad independent pathway 
(B. C. Willis & Borok, 2007). Depending on the type of tissue all three isoforms of 
TGF-β could be involved during transition (Raghu Kalluri & Neilson, 2003). Other 
studies have also shown that TGF-β expression is up-regulated in lungs of patients 
with idiopathic pulmonary fibrosis (IPF) and can enhance EMT (B. C. Willis & 
Borok, 2007). On the other hand, a study reported by Zeisberg et al revealed that 
bone morphogenic protein (BMP)-7 which is a member of the TGF-β superfamily 
has the ability to reverse TGF-β-induced EMT by restoring E-cadherin levels to 
normal through the Smad pathway, mainly through Smad 5, but Smad 1 and Smad 8 
can also transduce BMP-7 actions (Zeisberg et al., 2003).  
Citterio et al reported that EGFR expression increases in the epithelium during the 
process of EMT and interaction between TGF-β and EGFR might play a key role in 
EMT by assisting in migration and matrix turnover (Citterio & Gaillard, 1994). 
Furthermore, Lo et al reported that EGF/EGFR signalling pathways can lead to EMT 
via STAT3-mediated (signal transducer and activator of transcription 3) up-
regulation of TWIST gene expression (Lo et al., 2007). IGF-II signalling pathways 
relocate the β-catenins (which belong to the family of cell adhesion molecules and is 
a subunit of the cadherin complex) from cells surface leading to the nuclear 
internalization resulting in intracellular degradation of the E-cadherin complex which 
further facilitates migration of cells as the epithelium becomes loose (Morali et al., 
2001).   
Janda et al (Janda et al., 2002) made an effort to differentiate true EMT from an 
epithelial phenocopy termed “reversible scatter”. Reversible scatter is similar to 
EMT but not true EMT, but more like a brief episode of EMT. For example Hackett 
et al, (T. L. Hackett et al., 2009), recently reported that alveolar epithelial cells from 
asthmatics can undergo a transition to a mesenchymal phenotype when stimulated 
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with TGF-β1, but when the actual airway biopsy sections from asthmatics were 
stained for markers of EMT they were negative. Thus, this is not true EMT, but 
probably reversible scatter as a result of TGF-β1 stimulation for a short period of 
time, and occurs only temporarily following cytokine stimulation with cells assuming 
spindle like cell morphology, loss of epithelial markers and gain of mesenchymal 
markers for a brief period of time. However, as the stimulus is removed the 
epithelium returns to its original shape and the whole process ceases. They also 
reported that true EMT is mainly induced by TGF-β and Ras signalling pathways, 
whereas EGF, HGF and FGF favour scattering only, and are not able to produce 
classical EMT.   
 
2.8 Signalling pathways in EMT 
The epithelial signalling which drives the process of EMT is very complicated 
(Figure 2.19). Further, these signalling pathways are linked to each other with broad 
cellular consequences (Raghu Kalluri & Neilson, 2003). Brigitte Boyer et al 
suggested that when EMT is not activated by an oncogenic stimulus, then it is 
primarily induced by specific growth factors or extracellular matrix components 
binding to their associated cellular receptors leading to a strategic intrinsic kinase 
activation which sets the process off (Boyer, Valles, & Edme, 2000). The major 
signalling pathways involved in EMT are: TGF-β signalling pathways, the Wnt/β-
catenin signalling pathway, the Ras pathway and the Notch signalling pathway. All 
these pathways are extensively inter-related (Boyer et al., 2000; Guarino et al., 2009; 
Raghu Kalluri & Neilson, 2003).   
 
2.8.1 TGF-β signalling pathway 
I have already introduced transforming growth factor beta (TGF-β). It is a 
multifunctional protein playing a range of different roles through regulating tissue 
morphogenesis and differentiation by modulating cell proliferation, differentiation, 
cell adhesion, apoptosis, migration of cells, vasculogenesis and angiogenesis and is 
also involved in extracellular matrix turnover(Dennler, Goumans, & ten Dijke, 
2002). TGF-β is a member of a large superfamily of structurally related proteins 
consisting of more than 30 members in mammals, including three types of TGF-β, 
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four activins and over more than twenty bone morphogenetic proteins (BMPs) 
(Dennler et al., 2002). TGF-β has been implicated as a master switch in the induction 
of fibrosis in various organs including the lungs (B. C. Willis & Borok, 2007).  
Signal transduction associated with TGF-β involves two different pathways in EMT, 
Smad-dependent signaling pathway and smad-independent signaling pathway 
(Dennler et al., 2002; B. C. Willis & Borok, 2007).  
Smad-dependent pathway: Most members of the TGF-β superfamily signal through 
cell-surface receptors of the serine/threonine kinase category. A family of proteins 
known as Smads are involved in transducing the ligand-induced signals from the cell 
surface to the nucleus of the cell (Flanders, 2004). Thus, Smads are mainly signalling 
proteins that have the capacity to modulate the activity of TGF-β ligands. The name 
Smads was derived from a contraction of the names of TGF-β like ligand signalling 
intermediates first recognized in Drosophila (Mad) and Caenorhabditis elegans 
(Sma) (Flanders, 2004).  Eight different types of Smads have been reported, further 
grouped into three subfamilies. The first five include receptor-regulated Smads 
(Smad 1, Smad 2, Smad 3, Smad 5 and Smad 8/9), termed as R-Smads; one common 
mediator Smad (Smad 4), named Co-Smads; and two inhibitory Smads (Smad 6 and 
Smad7), termed I-Smads (Flanders, 2004; Wikipedia).  
The Smad-dependent pathways in the process of EMT in response to TGF-β are 
mainly mediated by Smad 3. In this pathway, TGF-β-generated signals are mediated 
by type I and type II serine-threonine kinase receptors and this process is initiated by 
binding of extracellular TGF-β ligands to the type II receptor on the cell surface. 
This binding further leads to the recruitment of type I receptors to form a heteromeric 
complex; at this stage the type I receptor is phosphorylated by the type II receptor, 
resulting in its activation. The type I receptor later phosphorylates Smad 2 and Smad 
3 at serine residues inducing association with Smad 4 (Co-Smad) and forming a 
heteromeric complex leading to the translocation of this complex to the nucleus. In 
the nucleus this complex can act as a transcription factor and can also interact with 
other transcription factors leading to the activation or regulation of TGF-β responsive 
genes, which may include, Snail, connective tissue growth factor (CTGF), α-SMA 
(α-smooth muscle actin), collagen 1A2 and also plasminogen activator inhibitor-1 
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(PAI-1). Smad proteins also have the potential to combine with the lymphoid 
enhancer factor-1 (LEF-1) which is also an important transcription factor involved in 
EMT. LEF has binding sites for both Smads and β-catenin, formation of this 
complex there after leads to the activation of various other transcription factors 
which further lead to transcription of genes associated with the EMT proteome. TGF-
β-activated Smad proteins can also activate the integrin-linked kinase (ILK) or 
integrin signalling leading to the suppression of E-cadherin by expression of the β-
catenin/LEF complex,  and this process may enhance the expression of fibronectin 
and proteolytic enzymes from the matrix metalloproteinase family (Guarino et al., 
2009; Raghu Kalluri & Neilson, 2003; Postma & Timens, 2006; B. C. Willis & 
Borok, 2007).   
Smad-independent pathway:  The Smad-independent pathway is not as well studied 
compared with the Smad dependent pathway in EMT although a significant body of 
in-vitro evidence is available for the role of a Smad independent pathway in EMT. It 
is hard to differentiate these pathways clearly as there is potential for significant 
cross-talk between Smad proteins and non-Smad proteins during EMT. The Smad-
independent pathway mainly includes RhoA, Ras MAPK (mitogen-activated protein 
(MAP) kinases), PI3 kinase (Phosphatidylinositol 3-kinases), Notch and Wnt/β-
catenin signalling pathways. Although the Smad-dependent pathway is considered as 
the main pathway, depending on the type of tissue it may not be sufficient to induce 
full blown EMT without activation of other supplementary pathways (Zavadil & 
Bottinger, 2005). Major Smad-independent pathways are discussed separately below.  
 
2.8.2 The Wnt/β-catenin signalling pathway 
The Wnt signalling pathway is activated when Wnt proteins bind to specific cell 
surface receptors. “The name Wnt was coined as a combination of Wg (wingless 
gene, originally identified in Drosophila melanogaster) and Int (Int gene was 
originally identified as vertebrate genes near several integration sites of mouse 
mammary tumor virus)” (Wikipedia). The Wnt signalling pathway describes a 
network of Wnt proteins, which form a family of highly conserved secreted signaling 
molecules that regulate cell-to-cell interactions during embryogenesis and cancer. 
Wnt-mediated signalling (Figure 2.19) can inhibit phosphorylation of β-catenin by 
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glycogen synthase kinase 3β (GSK-3β), hence stabilizing cytoplasmic levels of β-
catenin, this leads to the translocation of β-catenin to the E-cadherin complex or into 
the nucleus where it combines with the lymphoid enhancer factor-1 (LEF-1) and 
other transcription factors leading to the activation of a diverse variety of EMT-
associated genes, including those encoding for fibroblast specific protein-1 (FSP-1 or 
S100A4), vimentin, fibronectin, MMPs and also members from the Snail family. On 
the other hand, in the absence of Wnt-associated signals most of the β-catenin is 
bound to the E-cadherin complex, while the unbound β-catenin undergoes 
phosphorylation by GSK-3β which further allows it to form a complex with APC 
suppressor protein and Axin (Adenomatosis polyposis coli or APC is a protein 
encoded by the APC gene in humans; it is suggested that APC protein plays a 
important role in cell migration by targeting β-catenin for proteasomal degradation) 
(Nathke, 1999).  
 
p53 activates an APC-dependent pathway and both of these lead to the direct loss of 
β-catenin through proteasomal degradation. In this whole process free levels of β-
catenin are regulated by E-cadherin complexes or by APC/β-catenin/Axin 
complexes, the latter shuttle β-catenin between its degradation through proteasomal 
pathways and adheren junctions in EMT.  β-catenin plays a dual role in the EMT 
process: it has the potential for cell-cell adhesion when bound to the cadherin 
complex, and on the other hand can also act as a transcription factor when present in 
the nucleus. The cell adhesion due to β-catenin depends on binding of β-catenin to 
the α-catenin and further binding of the α-catenin to the cadherin. Furthermore, in 
addition to Wnt glycoproteins, IGF-II, Ras and integrin-linked kinase (ILK) all lead 
to β-catenin accumulation in the cytoplasm and also increased Snail, possibly by 
GSK-3β or by inhibition of other kinases to facilitate EMT (Guarino et al., 2009; 
Raghu Kalluri & Neilson, 2003; Nathke, 1999; Postma & Timens, 2006; B. C. Willis 
& Borok, 2007; Zavadil & Bottinger, 2005).  
 
2.8.3 The Ras signalling pathway  
Ras is a superfamily of small GTPases or G-proteins. All the signalling pathways 
involved with EMT can activate small GTPases through ligand-inducible receptor 
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kinase activation. These small GTPases are involved with changes in cell shape and 
gain of migratory potential. Transition of epithelium to mesenchymal phenotype 
depends considerably on different molecular switches under the control of small 
GTPases from the Ras superfamily. Small GTPases are activated by guanine 
nucleotide exchange factors and deactivated by GTPase activating proteins. There 
are more than a hundred proteins in the Ras superfamily but the 3 best studied small 
GTPases are, Rho, Rac and Cdc42, and they can activate or inhibit each other during 
the process of EMT.  
Rho signal transduction pathways are linked to the actin cytoskeleton and are also 
helpful in rearranging the actin stress fibres and can stimulate actin-myosin 
contraction in the cell body. Furthermore, they also participate in regulation of cell 
polarity, gene transcription, cell cycle, vesicular transport pathways and are also 
involved with various enzymatic activities. Rac on the other hand has the capability 
to induce actin-rich surface extensions called lamellopodia. Cdc42 supports the 
development of actin-rich finger-like protrusions called filopodia and modulates 
cellular asymmetry. The small GTPase family is able to control or regulate different 
cellular properties including contraction, migration, proliferation, and phagocytosis. 
These cellular activities of small GTPases can potentially activate MAP kinases, 
altering gene transcription and are vital to change in cell phenotype during the 
process of EMT. (Bar-Sagi & Hall, 2000; Etienne-Manneville & Hall, 2002; Guarino 
et al., 2009; Raghu Kalluri & Neilson, 2003; Savagner, 2001).  
2.8.4 The Notch signalling pathway 
The Notch pathway plays an important role in EMT and functional interactions 
between Notch signalling and EGF, FGF, TGF-β and Smads have been suggested 
(Dasari, Gallup, Lemjabbar, Maltseva, & McNamara, 2006; Zavadil, Cermak, Soto-
Nieves, & Bottinger, 2004). It is a highly preserved cell signalling system present in 
most multicelllular organisms and is a family of four different types of receptors, 
Notch1-4. Different ligand proteins can bind to the extracellular domain of the Notch 
receptor and can induce proteolytic cleavage and release of the intracellular domain, 
which then enters the nucleus of the cell to alter the gene expression. The first mutant 
of Notch was identified in Drosophila melanogaster (Artavanis-Tsakonas, Rand, & 
Lake, 1999). Zavadil et al demonstrated that when keratinocytes were induced to 
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EMT by TGF-β, Notch signalling pathway activation occurred downstream of TGF-
β, controlled by early up-regulation of the Notch ligand, Jagged1 and also the Notch 
target genes TLE3 (transducin-like enhancer) and HES1 (hairy enhancer of split) 
(Zavadil et al., 2001).  
In 2004, the same group described the expression of the HES1-related(Dasari et al., 
2006)transcriptional repressor family which included HEY1, HEY2, HES1 and 
HES5 and the Notch ligand jagged1 being induced by TGF-β at the start of EMT in a 
panel of epithelial cells from kidney tubules, mammary glands and epidermis 
(Zavadil et al., 2004). They also reported that TGF-β-induced EMT could be 
inhibited by suppressing the expression of the Notch ligand Jagged1 and HEY1 and 
also by chemical inactivation of Notch (Zavadil et al., 2004).  
2.9 Transcriptional control of EMT  
Signalling pathways implicated in the process of EMT end up as a final common 
path in the nucleus of the cell where they regulate the transcription of EMT-related 
genes. In EMT a wide array of different proteins are gained, maintained or 
attenuated, which requires the coordinated expression of numerous set of genes. 
Therefore, it becomes quite critical to understand and identify the different molecular 
targets of these signalling pathways leading to EMT (Boyer et al., 2000). A range of 
different transcriptional factors are involved in regulating EMT; among these several 
transcription factors can act as master switches in regulating the whole process of 
EMT (Zavadil & Bottinger, 2005), with a degree of synergy and/or redundancy 
between them.  
 
2.9.1 The Snail family 
The Snail family of transcription factors has been implicated in EMT; it includes 
Snail or Snail1 and Slug or Snail2 zinc finger proteins, and recently Snail3 has also 
been found. The Snail family induces EMT mainly by repressing transcription by 
recognizing E-box elements (they are “enhancer” elements and play a regulatory role 
in control of gene transcription) in their associated target promoters. It is reported 
that Snail can repress transcription of the E-cadherin gene through several E-boxes 
located in the E-cadherin promoter in cultured cells and also during embryonic 
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development and tumour progression (Barrallo-Gimeno & Nieto, 2005; Xu, 
Lamouille, & Derynck, 2009; Zavadil & Bottinger, 2005). Snails themselves are 
regulated by a variety of signalling pathways and at numerous levels. For example, it 
is reported that selective phosphorylation by GSK3 leads to the inhibition of Snails 
by ubiquitination or degradation. On the other hand Wnt signalling pathway can 
inhibit GSK3 resulting in Snail activation and loss of E-cadherins.   
Various growth factors or signalling molecules involved in EMT can also regulate 
Snails. For example, TGF-β has the potential to activate both Snail and Slug directly 
through a Smad3-dependent pathway (Zavadil & Bottinger, 2005). TGF-β1 can 
induce Snail1 expression in mesothelial cells, epithelial cells and hepatocytes and 
also during palate development (Xu et al., 2009). TGF-β2 and BMP-4, on the other 
hand, can induce expression of Snail2 or Slug (Zavadil & Bottinger, 2005). EGF has 
also been reported in several studies as an inducer of Snail and EMT. The EGF 
pathway promotes caveolin-dependent endocytosis which leads to loss in E-cadherin 
function and successive Snail and EMT activation (Lu, Ghosh, Wang, & Hunter, 
2003). In addition, EGF can also activate STAT3 (“signal transducer and activator of 
transcription 3”, it is a transcription factor encoded by STAT3 gene in humans), 
which has the potential to enhance Snail function (Barrallo-Gimeno & Nieto, 2005).  
Another Zinc-finger protein from the Snail family widely reported in EMT is Slug or 
Snail2, which can play an important role in regulating EMT (Savagner, 2001). Slug 
can be quickly induced in epithelial cells undergoing EMT by FGF and HGF and 
effectively regulates disassembly of desmosomes (Savagner, 2001; Zavadil & 
Bottinger, 2005). During EMT it is suggested that Slug appears to be activated 
through Ras/MAPK pathway and does not seem to be participating in E-cadherin 
suppression but rather contributes more to the maintenance of the mesenchymal 
phenotype (Boyer et al., 2000; Savagner, 2001).  But interestingly it is also suggested 
that dissociation of E-cadherin junctions can lead to autoregulatory induction of Slug 
with successive suppression of E-cadherin transcription, although its exact role is 
still a matter of debate (Zavadil & Bottinger, 2005).   
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2.9.2 Role of Transcriptional repressors (DeltaEF1, SIP1 and Fos) 
Delta-crystalline enhancer factor-binding factor 1 (DeltaEF1) (also known as ZFH1 
and ZEB1), and Smad-interacting protein-1 (SIP1) (also known as ZFH2) are two 
closely related zinc finger transcriptional repressors. DeltaEF1 is a very close 
homologue of SIP1 and both have the capability to regulate E-cadherin expression 
during carcinogenesis associated EMT (Type 3 EMT) (Eger et al., 2005; Zavadil & 
Bottinger, 2005). SIP1 expression can be induced in response to TGF-β and has the 
potential to regulate the activity of Smad proteins. Comijn et al have shown that 
ectopic expression of SIP1 in MDCK cells (Madin-Darby canine kidney cell line) 
leads to the destruction of adheren junctions, especially E-cadherin, favouring 
invasion in malignant epithelial tumours (Comijn et al., 2001; Zavadil & Bottinger, 
2005).  
Eger and colleagues (Eger et al., 2005) strongly suggested that DeltaEF1 has the 
potential to directly inhibit E-cadherin transcription, being associated with the E-
cadherin promoter at the chromatin level. They also suggested that although E-
cadherin suppression is considered as a hallmark of EMT, it is still not itself 
sufficient to induce the expression of N-cadherin and vimentin, EMT-related 
mesenchymal markers. Thus DeltaEF1 may play an important role in regulating 
epithelial plasticity by controlling other proteins, but cannot induce EMT fully on its 
own.  
Reichmann and colleagues showed that Fos transcription factor expression in 
mammary epithelial cells can lead to the process of EMT, by modulating epithelial 
phenotype and increasing invasiveness (Reichmann et al., 1992). Zavadil and 
colleagues reported that in human keratinocytes, TGF-β stimulates the ERK-
dependent induction of c-Fos, which occurs very rapidly but for only a short period 
of time at the inception of sustained EMT (Zavadil et al., 2001), when it may have a 
very strategic role.  
2.9.3 Id, Twist and E2A 
Id proteins (Id1, Id2, Id3, and Id4) are recognized as inhibitors of differentiation, 
playing a vital role during carcinogenesis (Kowanetz, Valcourt, Bergstrom, Heldin, 
& Moustakas, 2004).  Kowanetz et al did a microarray analysis of epithelial cells and 
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reported that TGF-β1 suppresses Id2 and Id3 for a long period of time, whereases 
BMP7 induced these factors. In addition, Id2 also inhibited the destruction of 
adheren and tight junctions in TGF-β-induced EMT (Zavadil & Bottinger, 2005). 
This suggests that TGF-β may favour EMT by suppressing these inhibitors of 
differentiation and BMP-7, but still the exact physiological role of these pathways is 
poorly understood (Kowanetz et al., 2004; Zavadil & Bottinger, 2005). Id proteins 
associate constitutively with the basic helix-loop-helix (bHLH) transcriptional 
regulator E2A, and maintain epithelial phenotype by inhibiting the role of E2A in E-
cadherin suppression. Conversely, TGF- β-mediated inhibition of Id proteins can 
lead to activation of E2A (a transcription factor), maintaining the mesenchymal 
phenotype during EMT (Zavadil & Bottinger, 2005). 
Another basic helix-loop-helix transcription factor that appears to be centrally 
associated with EMT is Twist, which is an important trigger factor involved in 
embryogenesis and carcinogenesis (Pozharskaya et al., 2009; Zavadil & Bottinger, 
2005). Twist can be induced during EMT by the expression of EGFR, TGF-β and the 
transcription factor nuclear factor κB (NF-κB). Pozharskaya et al reported in a recent 
study that Twist contributes to EMT in the model of virus-induced lung fibrosis 
(Pozharskaya et al., 2009).  Yang and colleagues reported that Twist suppression in 
mammary carcinoma cells specifically inhibits their ability to metastasize from the 
mammary gland to the lung; they also reported that ectopic expression of Twist in 
MDCK cells leads to loss of E-cadherin with subsequent expression of mesenchymal 
markers (e.g. vimentin, α-SMA and N-cadherins) and an increase in migratory 
potential, thus playing a very important role in tumour metastasis (type-3 EMT) (J. 
Yang et al., 2004; Zavadil & Bottinger, 2005). In another study, Kida et al reported 
that Twist was associated with renal tubular EMT leading to proliferation of 
myofibroblasts and subsequent renal fibrosis in an obstructed kidney model (Kida, 
Asahina, Teraoka, Gitelman, & Sato, 2007), but there are very few studies reporting 
role in EMT associated with chronic inflammation (Mironchik et al., 2005).  
2.10 The EMT proteome  
The EMT proteome is defined as the essential changes in proteins gained, maintained 
or attenuated during the EMT process (Figure 2.20). This involves a wide range of 
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proteins and most of the studies reported in the literature have been able to focus on a 
few specific markers and are far from complete. The majority of studies suggest that 
transcriptional factors, especially from the Snail family are the main players in the 
events leading to the loss of epithelial markers (e.g. E-cadherin, muc-1, cytokeratin 
and desmosomes) and gain of mesenchymal markers (e.g. FSP-1, or S100A4, 
vimentin, fibronectin and N-cadherin) with increased mobility (Raghu Kalluri & 
Neilson, 2003), but actually very little attention has been given to clearly identifying 
EMT in vivo and in vitro, and the best/most specific markers to use are still a matter 
of debate. Michael Zeisberg and colleagues have made an attempt to define the in 
vivo and in vitro criteria to identify EMT in this way (Figure 2.21) (Zeisberg & 
Neilson, 2009).  
 
EMT has been widely studied in different cell culture systems and most of the 
attention has been given to the process of identifying cells undergoing transition to a 
fibroblast like phenotype. One of the benefits associated with an in vitro system is 
the ability to detect the phenotype and movement of the cells in the culture medium, 
but on the other hand it is much more difficult in an in vivo system because many of 
the tissue sites are disrupted by inflammation and cicatrisation (Zeisberg & Neilson, 
2009). Unfortunately, because something can be demonstrated in a manipulated in 
vitro system and environment, does not necessarily mean that those change(s) are 
operative in vivo. 
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Figure 2.20: The EMT proteome, showing proteins gained or maintained and lost 
during EMT (Raghu Kalluri & Neilson, 2003).  
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Figure 2.21:  in vivo and in vitro criteria from EMT (Zeisberg & Neilson, 2009).  
Thus, an ideal way to identify EMT associated with chronic inflammation is to use 
reporter genes in cultured epithelial cells that can be tracked to fibroblasts on 
transition. However, marking studies are very difficult to perform with human tissue, 
and in this setting the ideal approach is to identify epithelial cells positive for 
S100A4, a fibroblast specific protein-1 (also known as FSP-1) associated with partial 
or complete loss of cytokeratins or E-cadherins, lying adjacent to the typically 
disrupted and fragmented basement membrane or Rbm (Zeisberg & Neilson, 2009), 
evidence of the effects of the proteolytic activity of matrix metalloproteinases 
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(MMPs) (Ward et al., 2005) which are an inherit part of this process. This basement 
membrane or Rbm change has been suggested as the best “hallmark” of EMT in vivo 
(R. Kalluri & Weinberg, 2009). Alpha-smooth muscle actin has also been observed 
in mature fibroblasts, but is non-specific and is not present in newly transitioning 
epithelial cells, whereas S100A4 is mainly confined to transitioning epithelial cells 
and is a more reliable and specific marker than alpha-SMA (Zeisberg & Neilson, 
2009). Elizabeth Hay et al (Hay, 2005) argued that mesenchymal cells and 
fibroblasts shouldn’t be defined on the basis of alpha-SMA stress fibres, as 
myofibroblast phenotypes are not thought to migrate actively. Another marker of 
EMT widely reported is an intermediate filament protein called vimentin, which has 
the potential to induce changes in cell shape, motility, and adhesion during EMT 
(Mendez, Kojima, & Goldman). Vimentin has also been suggested to play a major 
role in breast cancer progression, an observation made both in vitro and in vivo 
(Kokkinos et al., 2007).  
2.10.1 S100A4 (or FSP-1)  
S100A4 belongs to a large family of Ca2+-binding proteins collectively designated as 
S100. There are at least 21 described members in the S100 family which includes 
two newly discovered members, namely S100A14 and S100Z. Usually S100 proteins 
are low molecular weight proteins ranging between 9 to 13 kDa, sharing a common 
feature of two Ca2+-binding EF-hand motives (helix-loop-helix), and most of the 
members exist as dimmers, including S100A4. S100 proteins do not have any 
enzymatic activity (Rosario, 2003; Schneider, Hansen, & Sheikh, 2008).  
The most widely reported protein in EMT from the S100 family is S100A4, and it is 
considered as a potential mediator of EMT and organ fibrosis in diseases. S100A4 
has both intracellular and extracellular effects leading to a wide range of biological 
actions including increasing contractility, motility, differentiation and cellular growth 
(Rosario, 2003; Schneider et al., 2008).  
Raghu Kalluri et al suggested that S100A4 in the cytoplasm dimerizes and binds to 
the c-terminal of p53 (it is a tumour suppressor protein encoded by TP53 gene in 
humans), in the presence of calcium and this process may guard p53 from the APC-
mediated destruction pathway and may raise levels of free β-catenin (Figure 2.19), 
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thus facilitating and maintaining the process of EMT. Therefore, the exact role of 
S100A4 is not clear but it also has the potential for angiogenesis (Raghu Kalluri & 
Neilson, 2003), and seems well fitted to be a core mediator of the changes associated 
with chronic inflammation as well as metastatic tumours. Indeed, it may be a link 
between the two processes in diseases such as COPD or IPF.    
S100A4 has been suggested as a prototypical and very reliable cytoskeletal marker 
for detecting EMT in various pulmonary disorders and cancer (Lawson et al., 2005; 
Ward et al., 2005; Zeisberg & Neilson, 2009). Preliminary findings in idiopathic 
pulmonary fibrosis showed strong staining for S100A4 in fibroblasts (Schneider et 
al., 2008), Chris Ward et al showed that S100A4 localises to bronchial epithelial 
cells in human transplanted lungs indicative of EMT in the airways which may 
further lead to remodelling and fibrosis as part of chronic rejection (Ward et al., 
2005). This was further confirmed by a study by Hodge and colleagues (Hodge et al., 
2009).  
There is emerging evidence that S100A4 can also activate expression and release of 
MMPs which in turn may lead to tissue remodelling and assisting in the migration of 
cells by degrading the basement membrane and Rbm and components of the 
extracellular matrix (Raghu Kalluri & Neilson, 2003; Schneider et al., 2008).  
In a very interesting study (in prostrate cancer), Saleem and colleagues observed that 
S100A4 gene repression significantly decreased the expression of MMP-9, while the 
over expression of the S100A4 gene considerably increased MMP-9 expression. 
These expression changes were mirrored in changes in proteolytic activity of MMP-
9. They also suggested that transcriptional activation of MMP-9 is regulated by the 
S100A4 gene, as knock down of the S100A4 gene decreased MMP-9 activity, while 
over expression lead to an increase in MMP-9 promoter activity (Saleem et al., 
2006). Increased expressions of S100A4 and MMP-9 are also observed in human 
non-small cell lung cancer and have significant correlations with clinical and 
biological behaviour of these cancer cells (Chen, Wang, Zhang, Chen, & Sun, 2008).  
Put together all these data suggests that S100A4 could be involved both in 
inflammation-related fibrosis and in cancer progression. Tissue fibrosis and cancer 
share common signalling pathways, molecular and biological programs, and 
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especially EMT. This raises a possibility that S100A4 could be a common mediator 
of both fibrosis and cancer by directing EMT (Hodge et al., 2009; Okada, Danoff, 
Kalluri, & Neilson, 1997; Saleem et al., 2006; Schneider et al., 2008; Ward et al., 
2005; Zeisberg & Neilson, 2009). “Simply stated, S100A4 is central to EMT in 
diseases” (Schneider et al., 2008).  
 
2.10.2 Matrix metalloproteinases-9 (MMP-9)  
MMP-9 or matrix metalloproteinases-9 (MMP-9) is a proteolytic enzyme from a 
family of more than twenty zinc dependent proteases, they all share some structural 
similarities but differ from each other in their expression profile and substrate 
specificity (Chakrabarti & Patel, 2005; Elkington & Friedland, 2006). Since MMPs 
have a broad range of substrate specificity they have the potential to cause significant 
damage to the host tissue, so their expression is tightly regulated at transcriptional 
level. MMPs are secreted as proenzymes which further require proteolytic cleavage 
to become active, but in the tissue they are tightly regulated by tissue inhibitors of 
metalloproteinases (TIMPs). TIMPs block the enzymatic activity of the MMPs and 
equilibrium between these two determines matrix turnover (Chakrabarti & Patel, 
2005; Elkington & Friedland, 2006). Another physiological inhibitor reported for 
MMPs is α-2 macroglobulin (Lagente et al., 2005). 
 
MMP-9 is also known as gelatinase B, as gelatin is one of its major enzymatic 
substrate; it also has the potential to degrade other components of the ECM such as 
type IV collagen, aggrecan, elastin and vitronectin. Human MMP-9 is highly 
glycosylated with a molecular mass of 92 kDa as a pro-enzyme and 83 kDa when 
active (Atkinson & Senior, 2003; Chakrabarti & Patel, 2005). MMP-9 is secreted by 
a variety of cells in the lungs including bronchial epithelial cells, macrophages, 
eosinophils, mast cells, natural-killer cells, dendritic cells, neutrophils, fibroblasts, 
smooth muscle cells, alveolar type II cells and endothelial cells (Atkinson & Senior, 
2003).  
 
Increased MMP-9 expression has been reported in various respiratory disorders 
including asthma, COPD and IPF (Atkinson & Senior, 2003), although there are 
relatively few studies reporting MMP-9 levels in airways of COPD patients. 
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However, substantial evidence exists in smoking related emphysema leading to the 
protease/anti-protease imbalance theory of its aetiology (Atkinson & Senior, 2003; 
Elkington & Friedland, 2006). Juanita et al reported an increase in MMP-9 activity in 
induced sputum from mild-to-moderate COPD patients; in addition they also 
suggested an aetiological protease-antiprotease imbalance in COPD (Vernooy, 
Lindeman, Jacobs, Hanemaaijer, & Wouters, 2004). Mercer and colleagues reported 
increase in both MMP-9 and TIMP-1 levels in sputum of COPD patients during 
acute exacerbations (Mercer et al., 2005).  
In EMT, MMP-9 expression is up-regulated in epithelial cells (Atkinson & Senior, 
2003) and can act as a marker of epithelial and basement membrane damage (Figure 
20) (Ward et al., 2005). Type IV collagen is the major component of the “true” 
basement membrane (BM) and MMP-9 has the potential to digest the BM collagen 
and hence can assist the migration of cells through the BM into the lamina propria  
(Atkinson & Senior, 2003; Raghu Kalluri & Neilson, 2003; Ward et al., 2005). 
MMP-9 is one of the major MMPs secreted during the process of EMT (Raghu 
Kalluri & Neilson, 2003). Chris Ward et al reported an increased expression of 
MMP-9 during EMT in clinically stable lung transplant recipients (Ward et al., 
2005). Tan and colleagues reported that MMP-9 mediates EMT in vitro in murine 
renal tubular cells (Tan et al.). Another study suggested that MMP-9 can mediate 
EMT by disrupting the E-cadherin complex in renal tubular cells hence promoting 
migration (Zheng et al., 2009). MMP-9 also stimulates EMT during tumor 
development (Orlichenko & Radisky, 2008). MMP-9 expression has also been 
reported in IPF and may be involved in cell migration and activation of TGF-β, 
hence facilitating the process of EMT in that disease (Atkinson & Senior, 2003). 
MMP-9 expression has also been observed in human non-small cell lung cancer and 
was significantly associated with its biological behaviour (Chen et al., 2008). These 
studies suggest that MMP-9 can play an important role in the process of EMT.    
2.10.3 Vimentin 
Vimentin is a 57 kDa type III intermediate filament protein normally expressed in 
cells of mesenchymal origin, cells undergoing EMT (Raghu Kalluri & Neilson, 
2003) and also in tumour invasion (Fuchs & Weber, 1994).Vimentin increases in 
abundance in epithelial cells undergoing EMT suggesting a paticular role in 
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epithelial cell migration (J. M. Lee et al., 2006). Gilles et al reported that vimentin 
could be functionally involved with migration of mammary epithelial cells during 
EMT (Gilles et al., 1999). In breast cancer, observations made both in vitro and in 
vivo by Kokkinos et al suggested that during cancer-associated EMT, cell 
intermediate filament status changes from a  keratin rich network to a vimentin rich 
network favouring migration and increased invasion (Kokkinos et al., 2007). In 
another study, co-expression of vimentin and keratin intermediate filaments was 
associated with increased motility in human melanoma cells (Chu, Seftor, Romer, & 
Hendrix, 1996). Increased vimentin expression was also reported during EMT in 
human kidney transplant patients (Vongwiwatana, Tasanarong, Rayner, Melk, & 
Halloran, 2005).  
Data on vimentin in lungs is very sparse. However, Borthwick et al demonstrated an 
increase in vimentin with subsequent decreases in airway epithelial markers like E-
cadherins during the process of EMT and airway remodelling in lung transplant 
recipients (Borthwick et al., 2009). In a recent study, Hackett et al found increased 
levels of vimentin in TGF-β-induced EMT in primary airway epithelial cell cultures 
from patients with asthma (T. L. Hackett et al., 2009). Increased levels of anti-
vimentin antibody were also observed in sera of patients with IPF (Y. Yang et al., 
2002) suggesting abnormal expression of this protein in this disease.  
2.10.4 (Cyto) keratins  
Cytokeratins are keratin-containing intermediate filaments found in epithelial cells 
and are vital for regular tissue function and structure. The term “cytokeratin” was 
used in 1970 when keratins were first identified inside cells and then later in 2006 
was technically replaced by the term “keratins” but is still widely used (Franke, 
Schmid, Osborn, & Weber, 1979; Schweizer et al., 2006).  
Keratins are the biggest and most complex family of intermediate filaments 
comprising three different types (type I, type II and type III). Types I and type II are 
the main members, whereas type III involves vimentin, desmin, peripherin and glial 
fibrillary acidic protein (GFAP). Type I keratins include acidic keratin with 11 
epithelial proteins (K9-K20), and also four hair keratins (Ha1-Ha4). Type II keratins 
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on the other hand are more basic with 8 epithelial keratins (K1-K8) identified so far 
(Fuchs & Weber, 1994; Schweizer et al., 2006).   
Data on (cyto) keratins are widely reported in the literature on EMT. They are one 
group of epithelial proteins which generally decrease in abundance during EMT, but 
with substantial increase in mesenchymal markers (vimentin) (Kokkinos et al., 2007; 
J. M. Lee et al., 2006). Cytokeratins are very tightly regulated during the process of 
EMT and these protein changes in the cell reflect specific transcriptional activity 
during EMT (Savagner, 2001).  
Borthwick and colleagues reported decreased expression of cytokeratin-19 with 
subsequent increase in the mesenchymal markers (vimentin) in epithelial cells from 
lung transplant recipients during TGF-β1-induced EMT (Borthwick et al., 2009). 
Furthermore, in IPF a decrease in cytokeratin levels was also observed in alveolar 
epithelial cells during TGF-β1-induced EMT (Brigham C. Willis et al., 2005).  
2.11 EMT in the lungs 
The exact role of EMT in the respiratory tract’s response to injury and development 
of fibrosis is not clearly understood (B. C. Willis & Borok, 2007). Myofibroblasts 
have been implicated as key mediators of fibrosis in idiopathic pulmonary fibrosis 
(IPF) but the precise origin of these primary effector cells of fibrosis in the lungs is 
not yet established. However, there are several potential sources of fibrogenic cells 
within the respiratory tract: first, there may be expansion of a local fibroblast pool by 
in-situ proliferation in response to injury which may lead to pathological fibrosis; 
second, recruitment of circulating bone-marrow derived fibrocyte progenitors may 
occur; and third, transition of respiratory epithelial cells into a mesenchymal 
phenotype via EMT (Brigham C. Willis et al., 2006).  
 
In pulmonary fibrosis it was recently reported that circulating bone-marrow derived 
mesenchymal progenitor cells (fibrocytes) can play an important role in the 
progression of pulmonary fibrosis (Strieter, Keeley, Hughes, Burdick, & Mehrad, 
2009). Phillip et al demonstrated in a murine model of bleomycin-induced 
pulmonary fibrosis that CD45 (+) Col I (+) CXCR4 (+) fibrocytes contribute to the 
pathogenesis of pulmonary fibrosis (Phillips et al., 2004). Hashimoto et al 
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demonstrated using a chimeric mice model in which they transplanted of GFP+ 
(green fluorescent protein) bone marrow into a wild-type mice and then that bone 
marrow-derived GFP+ Col1+ cells were found in the lungs of mice exposed to 
bleomycin, suggesting that circulating fibrocytes may contribute to pathogenesis of 
pulmonary fibrosis  (Hashimoto, Jin, Liu, Chensue, & Phan, 2004).  
 
EMT has only recently been recognised in the human lung and airway, (T. L. Hackett 
et al., 2009; Hodge et al., 2009; Ward et al., 2005; Brigham C. Willis et al., 2006) but 
it is well described in lung embryogenesis, (J. M. Lee et al., 2006) metastatic 
malignant disease (Bjornland et al., 1999) and as part of the repair process in renal 
disease following tissue injury (Yanez-Mo et al., 2003). There are no reported studies 
in COPD associated with EMT, although Araya and colleagues suggested a key role 
for integrin-mediated TGF-β activation in amplifying squamous metaplasia and 
driving IL-1β-dependent profibrotic mesenchymal response in smokers with COPD 
(Araya et al., 2007).  
 
2.12 Histone acetylation and deacetylation in COPD 
Chronic inflammatory diseases like COPD, asthma, cystic fibrosis, interstitial lung 
disease, inflammatory bowel disease and rheumatoid arthritis are associated with a 
specific pattern of inflammation, which requires a coordinate expression of a wide 
range of different pro-inflammatory genes coding for various inflammatory 
mediators leading to infiltration and activation of a panoply of inflammatory cells 
(Barnes, 2006a, 2006b; Barnes et al., 2005). In COPD, the specific pattern of 
inflammation is mainly characterized by increased numbers of luminal, sputum and 
BAL (bronchial alveolar lavage) neutrophils and airway wall macrophages and T-
lymphocytes, predominantly cytotoxic (CD8+) cells (Barnes et al., 2005). The 
increased expression of these inflammatory genes is at least partly regulated by 
acetylation of core histones around which DNA is wound, and on the other hand 
these activated genes can be switched off by deacetylation of these histones (Barnes 
et al., 2005). Transcription of various proinflammtory genes in chronic inflammatory 
diseases including COPD, is regulated by transcpriton factors, such as nuclear factor-
Kappa B (NF-κB), activator protein-1 (AP-1) and glucocorticoid receptors  as well 
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(which act as transcription factors when activated by glucocorticoids) (Barnes, 
2006d).  
Compared to asthma, COPD responds relatively poorly to the anti-inflammatory 
corticosteroids. The potential molecular mechanism behind this relative 
corticosteroids resistance in COPD is now being revealed, as the details of the anti-
inflammatory mechanisms of steroids are becoming better understood (Barnes, 
2006b; Barnes & Stockley, 2005). It has been suggested that corticosteroids 
resistance in COPD is due to a decrease in the key nuclear enzyme histone 
deacetylase -2 or HDAC-2 (Barnes, 2006c; Ito et al., 2001). The exact reason behind 
HDAC-2 reduction in COPD is not clear, but it is suggested that increased oxidative 
and nitrative stress in the airways due to cigarette smoking might lead to inactivation 
or destruction of the enzyme (Barnes et al., 2005). Since 1960 it has been known that 
acetylation of DNA-associated histone proteins and remodelling of the tightly packed 
chromatin structure is associated with induction of a variety of genes (Littau, 
Burdick, Allfrey, & Mirsky, 1965). Indeed, it is now understood that histone and 
chromatin remodelling is central to gene expression and regulation through the 
process of acetylation, deacetylation and also methylation (Barnes et al., 2005; Rice 
& Allis, 2001).  
2.12.1 Chromatin remodelling  
In each human eukaryotic cell of average size (say 50-100µ in diameter), there are 46 
chromosomes giving a total length of DNA per cell of 1-2 meters, packed into a 
nucleus millions of times smaller in diameter. A very convoluted, precise and 
sophisticated packing method indeed is needed to achieve this amazing phenomenon. 
DNA in cells exists as chromatin, a DNA-protein complex (Elliott; Peterson & 
Laniel, 2004). Chromatin is made up of a basic unit called a nucleosome, which 
further consists of 146 base pairs of genomic DNA wrapped around an octamer (8) 
of core histone proteins. The histone octamer consists of a central subunit of histones 
H3 and H4 tetramer, and two histones H2A and H2B dimers. Nucleosome are 
separated from each other by 10-60 base pairs of linker DNA, and the resulting 
nucleosomal array comprises a chromatin fibre 10 nm in diameter (Figure 2.22) 
(Barnes et al., 2005; Rahman, 2003).  
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In a resting cell, chromatin is a tight compact structure with DNA tightly wound 
around the core histones, which makes DNA inaccessible to various transcription 
factors and RNA polymerase II, which has the potential to induce messenger RNA 
formation. This architecture or conformation of the chromatin is described as 
“closed” and is associated with gene suppression. Gene transcription can only occur 
if the chromatin structure becomes loose and is “opened” by unwinding of the DNA 
wrapped around the histone proteins, so that the DNA becomes accessible to the 
various transcription factors and RNA polymerase II enzyme to initiate the process 
of transcription of respective genes (Barnes et al., 2005; Rahman, 2003).  
This alteration in the chromatin architecture is known as “chromatin remodelling”, 
which means the effective removal of nucleosomes from the promoter site of the 
gene to be activated. However, it is not well understood whether a nucleosome is 
physically dissociated from the DNA during the whole process or just changes its 
attachment or is completely lost, so as to permit the transcription machinery to 
assemble on the promoter site of the gene to be activated. The term remodelling 
avoids implications of what exactly is happening in molecular terms. It is not known 
how many nucleosomes need to be remodelled during this gene activating procedure 
(Elliott; Rahman, 2003). However, it is understood that the chromatin structure is 
strongly controlled by post-translational modification of histones, which may involve 
methylation and/or phosphorylation, but the two best studied modifications are 
histone acetylation and histone deacetylation which involves opposing  types of 
enzymes, respectively (de Ruijter, van Gennip, Caron, Kemp, & van Kuilenburg, 
2003).  
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Figure 2.22: Diagrammatic representation of a chromatin fibre and a nucleosome, 
taken from (bricker.tcnj.edu/Amb/le8/nucleosome.jpg) and 
(employees.csbsju.edu/.../DNA/oldnastructure.html) 
 
2.12.2 Histone acetylation  
Acetylation is the best understood histone modifications. Transcriptionally active 
genes are regulated by acetylation of lysine residues on N-terminal histone tails. All 
core histones become acetylated, but modifications to H3 and H4 are more 
characterised then H2A and H2B. Hypoacetylated histones are associated with gene 
suppression (de Ruijter et al., 2003). Acetylation leads to the opening of the 
chromatin structure, allowing recruitment and activation of proinflammatory 
transcription factors (P. J. Barnes, 2008).   
When these transcription factors are themselves activated in response to extracellular 
stimuli, they bind to specific sites on DNA and start interacting with various 
coactivator molecules (Figure 2.23) such as CREB-binding protein (cyclic AMP 
response element binding protein), p300, p300/CBP-associated factor (PCAF) and 
signal transduction activated transcription factors (STATs). These act as molecular 
86 
 
switches to control gene transcription. All these coactivator molecules also have 
intrinsic complementary histone acetyltransferase (HAT) activity (P. J. Barnes, 2008; 
Ogryzko, Schiltz, Russanova, Howard, & Nakatani, 1996; S. Y. Roth, Denu, & Allis, 
2001). Histone acetyltransferases or HATs are the enzymes responsible for 
acetylation of the lysine residues on histone tails and therefore the resulting opening 
up of the structure of chromatin, so that acetylation, opening of chromatin and DNA-
RNA transcription are complementarily regulated events (S. Y. Roth et al., 2001). In 
COPD, expression of pro-inflammatory genes is predominantly regulated by 
increased acetylation of H4 which is induced by the binding of NF-κB and AP-1 
transcription factors, which also go on sequentially to activate inflammatory 
mediator genes (P. J. Barnes, 2008).  
In a resting cell, basic histone proteins (positively charged) are tightly associated 
with an acidic DNA backbone (negatively charged) thus reducing the accessibility of 
the DNA to transcriptional activators.  Each histone protein has a long terminal rich 
in lysine residues, acetylation of which leads to decrease in overall positive charge of 
the tail, which further leads to reduced association between histone tails and DNA. It 
may also change the conformational state of the nucleosomes, further enhancing the 
accessibility to DNA of transcription factors (Rice & Allis, 2001). This further 
allows the binding of the TATA box-binding protein (TBP), TBP-associated factors 
and finally binding of RNA polymerase II enzyme leading to gene transcription. Ito 
and colleagues reported that there is an increase in acetylation of histones associated 
with the promoter region of inflammatory genes, such as IL-8 which are regulated by 
NF-κB. In COPD specimens of peripheral lung; airway biopsies and alveolar 
macrophages the rate of acetylation increases with diseases severity (Ito et al., 2005).  
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Figure 2.23: Histone acetylation leading to gene activation and deacetylation leading 
to gene suppression (Barnes et al., 2005).  
 
2.12.3 Histone deacetylation  
In the process of histone dacetylation, histone deacetylase enzymes (HDACs) reverse 
the process of acetylation by removing the acetyl groups, and are hence associated 
with closed conformation of the chromatin leading to gene suppression (Barnes et al., 
2005). Interplay between HATs and HDACs is central to control of chromatin 
structure and function (Peterson, 2002). HDACs induce gene suppression by 
recruitment of co-repressor proteins as such nuclear receptor co-repressor (NCoR) 
and silencing mediator of retinoid and thyroid hormone receptors (SMRT).  This 
leads to formation of a co-repressor complex associated with gene suppression 
(Figure 2.23) (Barnes, 2006b).  
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There are 11 HDAC isoenzymes that deacetylase histones within the nucleus and 
specific HDACs appear to be differentially regulated to control different set of genes. 
They are divided into two major classes. Class I comprises HDAC1, 2, 3, 8 and 11 
whereas class II includes HDAC4, 5, 6, 7, 9 and 10. Marked reduction in HDACs has 
been observed in a variety of chronic inflammatory diseases (Barnes et al., 2005; de 
Ruijter et al., 2003; Ficner, 2009). In COPD a marked reduction in HDAC2 
expression and activity has been observed, with rather less reduction in HDAC5 and 
HDAC8 expression, and normal expression of other HDACs. It appears that for the 
regulation of inflammatory genes HDAC2 appears to be of critical importance 
(Barnes, 2009; Ito et al., 2005).   
2.12.4 HDAC2 in COPD  
Ito and colleagues showed (by using an HDAC fluorescence activity assay) that there 
was progressive reduction in total HDAC “activity”, HDAC2 mRNA and protein 
expression (measured by using quantitative reverse-transcriptase–polymerase-chain-
reaction (qRT-PCR) and Western blotting) in samples of peripheral lung tissue, 
alveolar macrophages and bronchial biopsy specimens from patients with COPD in 
comparison to healthy non-smokers. They also reported an increase in IL-8 mRNA 
expression and H4 acetylation in COPD patients (by using a chromatin 
immunoprecipitation assay) and interestingly there was a positive correlation 
between H4 acetylation and HDAC activity indicating that the balance between the 
two had shifted toward the hyperacetylation of the histones in the peripheral lung of 
patients with COPD, but no change was observed with HDAC activity in patients 
with pneumonia or cystic fibrosis, or patients with mild asthma, which further shows 
that change in HDAC activity might be specifically related to COPD. They also 
reported that there was a marked decrease in HDAC2 activity with lesser reduction in 
HDAC5 and HDAC8 in COPD (Ito et al., 2005).   
In a prominent study it was reported that the decrease in HDAC activity is associated 
with the intensity of inflammation, as measured by IL-8 expression and the number 
of inflammatory cells in peripheral airways of COPD patients and also accounted for 
resistance to anti-inflammatory effects of corticosteroids, a typical feature associated 
with COPD (Barnes et al., 2005). Cigarette smoking has been considered as an main 
etiological factor associated to COPD, and Ito et al reported that cigarette smoking 
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reduced HDAC2 expression in alveolar macrophages and biopsies and enhanced the 
expression of inflammatory mediators (TNF-α and IL-8) and also reduced 
glucocorticoid responsiveness in alveolar macrophages (Barnes et al., 2005; Ito et al., 
2001).Their immunohistochemical analysis suggested that HDAC2 expression is not 
different between non-smokers and normal lung function smokers in bronchial 
biopsies, and although localized to all airway cells, most intense staining was within 
the epithelium. However, this analysis was limited by lack of any analysis of the 
cellular profile of the biopsy sections. Looking now at the images they published in 
the paper it is quite clear that total cellularity of the lamina propria in normal lung 
function smokers was substantially less than in normal controls (Figure 2.24). This 
could lead to potential bias associated with results produced from molecular 
techniques and protein analysis (Ito et al., 2001). Using Western blotting they 
showed reduced HDAC2 protein content in bronchial biopsies from normal lung 
function smokers compared to normal controls (Ito et al., 2001), but as stated above, 
this did not take into account the overall decrease in cellularity and therefore total 
protein available.  
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Figure 2.24: Showing decreased cellularity in lamina propria (black arrows) in a 
normal lung function smoker compared to a normal control, stained for HDAC2 (Ito 
et al., 2001).  
 
Marwick et al reported that HAT activity is increased and HDAC2 activity is 
decreased in lungs of rats exposed to cigarette smoke, with increased NF-κB 
activation and inflammatory gene expression (Marwick et al., 2004), but again it is 
difficult to know if any cell density changes were taken into account. In another 
study Ito and colleagues reported that inducing HDAC2 over-expression in 
glucocorticoid-insensitive alveolar macrophages from COPD patients restored 
glucocorticoid sensitivity (Ito et al., 2006). Tomita et al reported that oxidative stress 
has the potential to acetylate H4 in epithelial cell lines and lead to elevated levels of 
inflammatory cytokines such as IL-8 (Tomita, Barnes, & Adcock, 2003).  
2.12.5 Mechanism of HDAC2 reduction in COPD 
The reason for the decrease in total HDAC activity in COPD, especially HDAC-2 is 
not well understood, but evidence is emerging gradually that this may be due to 
increase in oxidative and nitrative stress in the lungs with COPD (Barnes et al., 
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2005). Peter Barnes indicated (Figure 2.25) that cigarette smoke and inflammatory 
cells produce superoxide anions (O2-) and nitric oxide (NO), and this leads to the 
formation of peroxynitrite. Inducible nitric oxide synthase (iNOS) induces NO 
production from inflammatory cells during the process. Peroxynitrite nitrates 
HDAC2, possibly at tyrosine residues within the catalytic site of the enzyme, which 
may then obstruct enzymatic activity and may also mark the enzyme protein for 
ubiquitination, and so degradation proteasome which leads to a decrease in HDAC2 
expression and intensification of the inflammatory response and increased resistance 
to corticosteroids in COPD.  
 
HDAC activity may be restored using antioxidants, iNOS inhibitors, or by using 
peroxynitrite scavengers that potentially decrease tyrosine nitration. Theophylline 
may also act as an HDAC activator and has the potential to restore HDAC, but the 
mechanism behind it is not well understood (Barnes, 2006d; Barnes et al., 2005; 
Rahman, 2003). The oxidative pathway also has the potential to activate the 
phosphoinositide-3-kinase (PI3K) pathway leading to phosphorylation of serine 
residues, also resulting in inactivation of HDAC2 (Barnes, 2009). 
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Figure 2.25: Possible mechanism of HDAC2 impairment in COPD (Barnes, 2006a).  
 
2.13 Role of inhaled corticosteroids (ICS) in COPD 
Corticosteroids or more fully glucocorticosteroids (though commonly used clinically 
in asthma and COPD simply as “steroids”) are considered as the most effective 
therapy for the treatment of non-infectious chronic inflammatory airway disorders, 
especially asthma. They are thought of as relatively less effective in other 
inflammatory disorders such as COPD, although are very widely used in this 
condition. Mechanistically, the main effect of steroids at the cellular level is to 
inhibit the expression of multiple inflammatory genes encoding for chemokines, 
cytokines and growth factors, activated as part of the inflammatory process (Barnes, 
2006a).  
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As stated above, it is perhaps paradoxical that steroids are extensively used for the 
treatment of COPD even though their efficacy is still a matter of debate (Telenga, 
Kerstjens, Postma, Ten Hacken, & van den Berge). However, several studies have 
shown that short term use of ICS improves lung function and frequency of 
exacerbation in long term users (Chanez et al., 2004; Telenga et al.).  
 
Pauwels et al in a double-blind, placebo-controlled study in 1277 subjects with 
moderate COPD who continued smoking, investigated the effects of budesonide 
400µg, and reported that during the first six months of the study, FEV1 improved at 
the rate of 17 ml per year in the treatment arm, as compared with a placebo group (81 
ml decline). However, from nine months of treatment to the end of treatment which 
was at 3 years there was no significant difference between the groups, suggesting 
that ICS is associated only with a short term improvement in lung function but does 
not appreciably affect the long-term progressive decline in lung function in patients 
with COPD (Pauwels et al., 1999).  
 
A multicenter TORCH study (Toward a Revolution in COPD Health) performed 
with 5343 patients with COPD in 2004 evaluated the effects of fluticasone 
propionate combined with salmeterol (LABA, long acting β agonist) for 3 years. In 
the treatment arm a reduced rate of lung function decline was observed compared to 
the placebo group (Vestbo, 2004).  
 
As explained above, it can be concluded that steroids do improve lung function but 
still today the type of inflammation and structural changes effected by ICS in COPD 
are not well understood, and there are very few studies reporting the effects of ICS 
on airway inflammation and even fewer on structural changes (airway remodelling) 
in COPD. Overall our knowledge is limited (Chanez et al., 2004).  
 
Hattotuwa and colleagues reported a significant reduction in CD4/CD8 cell ratios in 
the epithelium, and in subepithelial mast cells in bronchial biopsies obtained from 
COPD patients in the active ICS arm treated with fluticasone propionate compared to 
placebo (Hattotuwa, Gizycki, Ansari, Jeffery, & Barnes, 2002). Reid and et al 
reported from observations made in bronchial biopsies and BAL from COPD 
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patients, that fluticasone propionate reduced  BAL neutrophils and epithelial cell 
numbers  and CD68+ macrophages, CD8+ lymphocytes and mast cells in bronchial 
biopsies, but interestingly noted increased neutrophils in bronchial biopsies (D. W. 
Reid et al., 2008). In another study, it was reported that three month treatment with 
fluticasone propionate significantly decreased mucosal mast cells and increased 
neutrophils in biopsies from COPD patients (Gizycki, Hattotuwa, Barnes, & Jeffery, 
2002).  
 
Recently, in a very interesting study, Lapperre et al reported the effects of fluticasone 
propionate on inflammation in airway biopsies and sputum from COPD patients, and 
found that fluticasone significantly decreased the number of mucosal CD3+ cells, 
CD4+ cells, CD8+ cells and mast cells after 3 months, with effects maintained to 30 
months. They also reported that treatment with fluticasone for 30 months reduced the 
number of mast cells, increased number of eosinophil and increased the percentage 
of intact epithelium (This is the only study to my knowledge reporting effects of ICS 
on epithelium). There was also a decrease in sputum neutrophils, macrophages, and 
lymphocyte accompanied by improvements in FEV1 decline, dyspnea, and quality of 
life. The decrease in inflammatory cells correlated with clinical improvements. 
Discontinuing fluticasone for 6 months on the other hand increased CD3+ cells, mast 
cells, and plasma cells and thus was accompanied by deterioration in clinical 
outcomes (Lapperre et al., 2009). 
 
The baseline Rbm thickness in COPD is also debatable, with some studies reporting 
abnormally thick Rbm and others not (Chanez et al., 2004; Liesker et al., 2009; 
Postma & Timens, 2006). The effects of ICS on the Rbm have not been specifically 
studied in COPD. Zanini and et al, (Zanini et al., 2009), however reported in a cross-
sectional study that bronchial vascular remodelling may have potential for change 
with ICS, but we need further longitudinal studies to confirm that.  
 
So, careful review of the literature is fairly convincing that COPD is not strictly 
steroid resistant as frequently stated. However, It is not clear exactly how steroids 
work in COPD, but in general (this is not just COPD) it is suggested that they can 
work in two different ways; at higher concentration they are associated with the 
activation of anti-inflammatory genes and at low doses they are associated with gene 
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suppression by recruiting HDACs to the sites of pro-inflammatory transcription, 
details are given below (Barnes, 2006b).   
 
2.13.1 Gene activation by corticosteroids 
At high dose the activation of anti-inflammatory genes (Figure 2.26) (Barnes, 2006b) 
is mainly through binding to glucocorticoid receptors (GRs) localized in the 
cytoplasm of the target cell; the complex acts as a transcription factor to control the 
transcription of several steroid responsive genes. In the cytoplasm of the cells GRs 
are usually attached to proteins recognized as molecular chaperons, which include 
heat shock-proteins-90 (hsp-90) and FK binding protein (FK or also called as FK506 
is a family of proteins that have prolyl isomerise activity which suggests that they 
have the capacity of interconverting the cis and trans isomers of peptide bonds) 
(Wikipedia). These proteins when bound to the receptor prevent its nuclear 
localisation by covering the sites of the receptor that are essential for transportation 
into the nucleus (Wu et al., 2004).  
 
Binding of corticosteroids to GR leads to changes in the receptor structure which 
further leads to dissociation of these inhibitory molecular chaperons proteins, by 
exposing the sites essential for nuclear localisation. This results in rapid transport of 
active GR-complex into the nucleus, where it binds to glucocorticoid response 
elements (GRE) in the promoter region of steroid responsive genes, including several 
types of anti-inflammatory genes and thus leading to increase in synthesis of anti-
inflammatory proteins such as annexin-1 (lipocortin-1), secretory leuko-protease  
inhibitor (SLPI), IL-10, the inhibitor of NF-κB, IκB-α, glucocorticoid-induced 
leucine zipper protein, which inhibits both NF-κB and AP-1 and mitogen-activated 
protein (MAP) kinase phosphatase-1, which inhibits p38 MAP kinase (Barnes, 
2006b; Barnes et al., 2005).  
 
Activation of anti-inflammatory genes by high dose of corticosteroids is associated 
with a selective acetylation of lysine residues 5 and 16 on H4, resulting in increased 
gene transcription, whereas in response to inflammatory stimuli differential 
acetylation of residues 8 and 12 is involved. However, the relevance of this 
mechanism is in doubt. It seems hard to explain the anti-inflammatory actions of 
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corticosteroids by inducing the transcription of a small number of anti-inflammatory 
genes, as high doses of corticosteroids are generally required for these types of 
responses, whereas on the other hand in clinical practice, corticosteroids are able to 
suppress inflammation at low doses (Barnes, 1998a, 2006b, 2006d, 2009; Barnes et 
al., 2005).   
 
 
 
 
Figure 2.26: Gene activation by corticosteroids at high dose (Barnes, 2006b). 
 
2.13.2 Gene suppression by corticosteroids  
Corticosteroid at lower doses leads to suppression of inflammatory genes by 
recruiting HDAC2 to activated pro-inflammatory transcriptional complexes (Figure 
2.27). Initially it was believed that gene suppression by corticosteroids is generally 
induced by binding of GR to negative GRE sites in their promoter region, but later it 
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was confirmed that this process is applicable to only a small number of genes, and 
this mechanism does not include genes encoding most inflammatory proteins (Ismaili 
& Garabedian, 2004). It was observed in asthma that most of the genes which are 
activated during the inflammatory process do not have GRE sites, but are still 
effectively repressed by corticosteroids (Barnes et al., 2005). There is convincing 
evidence now that anti-inflammatory actions of corticosteroids are due to inhibition 
of transcription factors such as AP-1 and NF-κB (by inhibition of histone acetylation 
and stimulation of histone deacetylation), which are transcription factors actively 
involved in regulation of many genes coding for a host of pro-inflammatory proteins 
(Barnes, 2006d; Barnes & Karin, 1997). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.27: Gene suppression by corticosteroids at low dose (Barnes et al., 2005). 
 
Inflammatory genes get activated in response to inflammatory stimuli (Figure 2.28) 
which may then be potentially reinforced by production of interleukin (IL)-1β and/or 
tumour necrosis factor (TNF)-α which lead to activation of I-κB kinase (IKK)2 
which further activates NF-κB, a hetrodimer made up of proteins p50 and p65 
(Barnes, 2006d). NF-κB proteins move to the nucleus and bind to the specific κB 
recognition sites and also bind to co-activator proteins like CBP or PCAF. All of 
these factors have intrinsic HAT activity, which leads to acetylation of lysine 
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residues in H4, and thereby augmented expression of genes encoding for 
inflammatory proteins, for e.g. GM-CSF, cyclo-oxygenase-2 (COX-2), and 
numerous cytokines, chemokines and receptors.  
 
 
Figure 2.28: Role of transcription factors and gene suppression by corticosteroids at 
low dose, for details please see text (Barnes, 2006d).  
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Thus, this whole integrated process leads to activation of numerous inflammatory 
genes. As already described, corticosteroids at low concentrations activate GRs 
which rapidly move to the nucleus and bind to co-activators such as CBP or PCAF to 
directly inhibit intrinsic HAT activity, so that HDACs are recruited leading to histone 
deacetylation and suppression of inflammatory genes. So in very general terms, 
corticosteroids at low concentrations recruit HDACs to the transcription complex and 
convert the process of acetylation to deacetylation to suppress the transcription of 
inflammatory genes (Barnes, 2006a, 2006b, 2006c, 2006d; P. J. Barnes, 2008; 
Barnes, 2009; Barnes et al., 2005; Barnes & Karin, 1997).  
 
2.13.3 Proposed mechanism of relative CS resistance in COPD  
Even though corticosteroids have been highly effective in asthma, the inflammatory 
process in COPD has been at least partly and relatively resistant to the anti-
inflammatory effects of corticosteroids, regardless of the fact that active airway and 
lung inflammation is present. Although this resistance has perhaps been over stated 
by some, it is true that the inflammation in COPD is not fully suppressed nor to the 
same extent as in asthma, by corticosteroids. (Culpitt et al., 1999; Culpitt et al., 2003; 
Keatings, Jatakanon, Worsdell, & Barnes, 1997; Loppow et al., 2001). Furthermore, 
Hogg and colleagues reported in a histological analysis of peripheral airways of 
patients with COPD that despite treatment with high dose steroids intense 
inflammatory responses still existed (James C. Hogg et al., 2004), and evidence is 
available that COPD has active steroid resistance mechanisms (Culpitt et al., 1999; 
Culpitt et al., 2003; Keatings et al., 1997; Loppow et al., 2001). Corticosteroid 
resistance in COPD may be explained on the basis of increased oxidative and 
nitrative stress due to cigarette smoking leading to impaired HDAC2 function in 
COPD (Figure 2.25) and resistance to corticosteroids as explained before in previous 
sections(Barnes, Ito, & Adcock, 2004).  
The oxidative pathway also has the potential to activate the phosphoinositide-3-
kinase (PI3K) pathway leading to phosphorylation of serine residues, which results 
in inactivation of HDAC2 (Barnes, 2009). PI3K are a family of enzymes involved in 
cellular functions such as cell growth and migration, inflammatory cell function, 
proliferation and differentiation, motility, survival and intracellular trafficking. They 
are divided into three different classes: the primary class reported to be associated 
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with impairment of steroid responsiveness in COPD is class I PI3K, including the 
isoforms PI3Kγ and PI3Kδ, and especially PI3Kδ (Ito, Caramori, & Adcock, 2007).  
Marwick et al investigated this system in a study designed to evaluate the role of 
PI3K in the development of cigarette smoke-induced steroid insensitivity in a model 
of wild type, PI3Kγ knock out and (dead) PI3Kδ kinase knock-in transgenic mice. 
They showed that cigarette smoke reduced HDAC2 activity and impaired steroid 
function in mice, which was blocked by elimination of PI3Kδ kinase as shown in 
(dead) PI3Kδ kinase knock-in transgenic mice. The overall data suggested that 
activation of the PI3Kδ isoform might be playing an important role in the 
development of impaired steroid function in an oxidative environment (Marwick et 
al., 2009).  
In another study, using peripheral lung tissue and blood monocytes obtained from 
patients with COPD, smokers with normal lung function and healthy never smokers, 
the same group reported that PI3Kδ and Akt (protein kinase) phosphorylation was 
increased in macrophages from patients with COPD and smokers compared to 
controls in vivo. Their in vitro data revealed that oxidative stress-induced 
phosphorylation disappeared by selective inhbition of PI3Kδ but not of PI3Kγ. 
However, the study was limited by the fact that COPD subjects were also       
suffering from lung cancer (Marwick et al.) and material was obtained from cancer-
containing lung resections. However, these studies taken together suggest that PI3K 
might be playing an important role in steroid unresponsiveness in COPD and PI3Kδ 
might be a future therapeutic target.  
Perhaps the important question that the Barnes group, from which these data have 
mainly emerged, have not asked, is how/why ICS do (undoubtedly) have some 
positive effects both clinically and also on inflammation in COPD airways, at least 
over 6-9 months, and what important elements of inflammation, and indeed 
remodelling could be made more responsive if the PI3K system was suppressed? In 
other words, if COPD really is a corticosteroid-resistant disease, what are the 
strategically important resistant elements of its pathology?   
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Chapter 3 
Materials and Methods 
 
3.1 Introduction  
In preliminary observations we found that the Rbm in smokers is extensively 
fragmented, which can be a hallmark of EMT, as explained in previous chapters. 
Following our preliminary observation (Chapter 1), I designed a comprehensive 
cross-sectional study to test the hypotheses. I investigated current smokers with 
established COPD (COPD-CS) and also current smokers with normal lung function 
(NS), comparing them to ex-smokers with COPD (COPD-ES) and normal healthy, 
never-smoking controls (NC) by immuno-staining airway biopsies for different 
markers of EMT (S100A4, MMP-9, vimentin, cytokeratin and EGFR). To address 
the potential for our data to be confounded by infiltrating inflammatory cells, 
representative sections from the same tissue blocks were stained for neutrophil 
elastase (neutrophil marker), CD68 (macrophage and mature fibroblast marker) 
(Beranek, 2005; Inoue, Plieth, Venkov, Xu, & Neilson, 2005), CD4+/CD8+, CD19 
as a B-cell marker (Bertrand et al., 1997) and CD11c for potential dendritic cells (K. 
F. Chung & Adcock, 2008). To confirm the extent of suppressed HDAC2 expression, 
airway biopsies were immuno-stained for HDAC2. In a longitudinal analysis, I used 
the material collected in a double blind randomised controlled trial comparing 
fluticasone propionate (0.5 mg/twice daily) with placebo for 6 months (D. W. Reid et 
al., 2008), and assessed the effects of ICS on Rbm fragmentation and HDAC2. 
Materials and methods for these studies are detailed in this chapter.  
 
3.2 Subject recruitment  
The study was approved by the Alfred and Royal Hobart Hospital Ethic Committees. 
All subjects (Table 3) gave written, informed consent prior to participation.  
Seventeen current smokers with established COPD (COPD-CS), 16 current smokers 
with normal lung function (NS), 15 ex-smokers with COPD (COPD-ES) and 15 
normal healthy, never-smoking controls (NC) were recruited by advertisement in 
local newspapers and placement of posters in clinic waiting areas in the hospital, as 
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well as on the notice boards of social and Veterans clubs. Potential participants were 
interviewed and examined by a respiratory physician clinically, physiologically and 
ultimately pathologically. 
 
Table 3: Demographic and lung function data for subjects.    
Groups 
(numbers) 
COPD-CS 
(n=17) 
COPD-ES 
(n=15) 
NS 
(n=16) 
NC 
(n=15) 
 
GOLD I/GOLD II 10/7 8/7 N/A N/A 
Male/female 9/8 9/6 12/4 7/8 
Age (years) 61 (46-78) 
(p=0.001)† 
62 (53-69) 
(p=0.001)† 
50 (30-66) 
(p=0.31) 
44 (20-68) 
Smoking (pack 
years) 
45 (18-78) 51 (18-150) 32 (10-57) 0 
FEV1% predicted 
(Post BD)* 
83 (66-102) 
(p<0.001)† 
83 (54-104) 
(p<0.001)† 
99 (78-125) 
(p=0.01)† 
113 (86-140) 
FEV1/FVC % 
(Post BD)* 
59 (46-68) 
(p<0.001)† 
  57 (38-68)  
  p<0.001)† 
   77 (70-96) 
   (p=0.22) 
   82 (71-88) 
 
Data expressed as median and range  
†Significance difference from NC  
* Post BD values after 400µg of salbutamol  
 Diagnosis of COPD was made according to GOLD guidelines (GOLD, 2007) 
 
3.2.1 Exclusion criteria  
 
1. Subjects with a history suggestive of asthma, which includes symptoms in 
childhood, related atopic disorders, eczema or hay fever, substantial day-to-
day variability or prominent nocturnal symptoms, or a history of wheeze 
rather than progressive breathlessness and any who had previously used ICS 
(oral or inhaled) were excluded.  
 
2. Significant uncontrolled comorbidities such as diabetes, angina or cardiac 
failure, and other coexisting respiratory disorders including pulmonary 
fibrosis, lung cancer and bronchiectasis. 
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3. Subjects with inability to give written informed consent were also excluded. 
  
3.2.2 Inclusion criteria  
 
1. Current-smokers with COPD aged at least 40 years with smoking history 
equal to or more than 15 pack-years and subsequently obtained BAL fluid 
had to be free of bacterial colonisation; FEV1 40% to 80% predicted, with 
FER (ratio of FEV1to FVC) ≤ 70% post bronchodilator with definite 
scalloping out of the descending limb of flow-volume loop on spirometry. 
COPD ex-smokers with atleast six months of smoking cessation were 
included.   
 
2. Normal healthy never smoking controls and current smokers with normal 
lung function recruited also underwent bronchoscopic examination and 
physiological evaluation. They were at least 18 years old and FEV1/FVC 
ratio of 70% or higher and FEV1% predicted of 80% or higher.  
 
3. None of the never-smoking controls individuals had any history of respiratory 
illness or smoking.  For normal lung function current smokers the inclusion 
criteria were; a minimum 10 pack-year history of cigarette smoking with 
spirometry within normal limits (FEV1 (forced expiratory volume) >80% of 
predicted, and FEV1/FVC (forced vital capacity) >70%) and no scalloping 
out of the expiratory descending limb of the flow-volume curve, suggesting 
small airway dysfunction. 
 
3.3 Bronchoscopy 
Fiberoptic bronchoscopy was performed, subjects were pre-medicated with nebulized 
salbutamol (5 mg) approximately 15–30 min before the bronchoscopic examination 
and sedation was achieved with intravenous administration of midazolam (3–10 mg) 
and fentanyl (25–100 µg) to COPD current smokers and ex-smokers and normal 
healthy non-smokers and smokers with normal lung function. Lignocaine (4%) was 
applied topically to the nose, pharynx and larynx, and 2 % lignocaine was 
administered below the cords in 2 ml aliquots as required up to a maximum dose of 
6ml. Subjects were monitored by pulse oximetry and administered oxygen during the 
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procedure. Endobronchial biopsies were taken from subsegmental carinae of the right 
lower pulmonary lobe of each patient, using alligator forceps (FB-15C; Olympus, 
Tokyo, Japan). At each fiberoptic bronchoscopy performed, up to eight good biopsy 
specimens were obtained.  
 
3.4 Processing of biopsies  
Two biopsies were immersed with ornithine carbamyl transferase (OCT) and snap 
frozen in liquid nitrogen-chilled isopentane slurry, and stored at -80°C for 
immunohistochemistry and two more were snap frozen in liquid nitrogen for 
molecular studies (not presented here). The other four were fixed in 10% neutral 
buffered formalin for two hours, and then transferred into 50% ethanol until they 
were processed using a Leica ASP 200 tissue processor. Fixed tissue blocks were 
progressively dehydrated in graded ethanol followed by clearing in xylene before 
being infiltrated with wax under vacuum pressure. Two 3 µm paraffin embedded 
sections, separated by at least 50 microns, were cut for staining and mounted on a 
slide (Figure 3.1). 
 
3.5 Immunostaining with staining antibodies used 
Sections were stained with the following monoclonal antibodies: anti-MMP-9 (R&D 
systems, cat no. MAB911, Gymea, NSW, Australia), anti-EGFR (Chemicon, cat no. 
CBL417, Billerica, United States), anti-S100A4 polyclonal antibody (Dako, cat no. 
A5114, Glostrup, Denmark), anti-Cd11c monoclonal antibody (Abcam, cat no. 
ab52632, Waterloo, NSW, Australia), anti-CD4/CD8 monoclonal antibodies 
(Novocastra, cat no. NCL-CD4-IF6 / cat no. NCL-CD8-4B11, Newcastle Upon 
Tyne, UK) were used for CD4/CD8 T lymphocytes, anti-CD68 monoclonal antibody 
for macrophages (Dako, cat no. M0814, Glostrup, Denmark) and mature fibroblasts, 
anti-CD19 monoclonal antibody for B-cells (Abcam, cat no. Ab31947, Waterloo, 
NSW, Australia), neutrophil elastase, a monoclonal antibody for neutrophils (Dako, 
cat no. Ab31947, Glostrup, Denmark) and for HDAC2, sections were stained with 
monoclonal antibody: anti-HDAC2 (Abcam cat no.ab12169, Waterloo, NSW, 
Australia), together with a horseradish peroxidase (HRP) conjugated DAKO 
Envision plus reagent for secondary antibody binding and colour resolution using 
diaminobenzidine (DAB). Double staining with vimentin and cytokertain was 
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elaborated using an anti-vimentin monoclonal antibody (Dakocytomation, cat no. M 
7020 clone 3B4 at 1:1000 for two hours, Glostrup, Denmark) and a pan-cytokeratin 
monoclonal antibody for cytokeratin (cytokeratin AE1/AE3 at 1/40 in diluent Abcam 
ab 27988, Waterloo, NSW, Australia) and then secondarily bound using 
Dakocytomation “Real” (cat no K5005) alkaline phosphatase reagents and visualised 
using Dakocytomation liquid permanent red (Cat no. K0640, Glostrup, Denmark).  
The primary antibody was replaced using a species appropriate IgG1 at equivalent 
dilutions and conditions on a sequential section as negative controls. Details of 
general immunostaining procedure for different tissue markers used are given below. 
All tissues were stained with Haematoxylin before immunostaining. All monoclonal 
and polyclonal antibodies were titrated to maximal sensitivity and to minimise non-
specific staining using standard methods (Immunocytometry solutions and Histo-
techniques)  
.  
3.5.1 Measurements and biopsy analysis  
Computer-assisted image analysis was performed with a Leica DM 2500 microscope 
(Leica Microsystems, Germany), Spot insight 12 digital camera and Image Pro V5.1 
(Media Cybernetics, USA) software (Figure 3.2). On each slide two biopsy sections 
were fixed (Figure 3.1). Firstly, as many pictures as possible were taken of the tissue 
from the area of interest (for this study it was mainly epithelium, Rbm and lamina 
propria) avoiding overlapping of tissue. All image analyses were done using the 
above described image analyser. Five randomly selected images from the total 
number taken were used for desired measurements. Cellular and other changes, e.g. 
clefts/cracks in the Rbm, (Figure 3.3) were normalised for purposes of comparisons 
in terms of the total length of basement membrane assessed. The length of the 
individual “clefts” was measured, summed and results expressed as percentage of the 
total Rbm length to give a comparable measure of the degree of Rbm fragmentation 
for each individual. EGFR was measured as percentage of epithelium stained for 
EGFR over total basement membrane length. Using the image analyser HDAC2 
positive and total number of cells were counted up to 50µ deep into the lamina 
propria and results presented as cells per sqmm of lamina propria and in the 
epithelium HDAC2 was measured as percentage of epithelium stained for HDAC2 
over total basement membrane length. All slides were coded and randomised by an 
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independent person and then counted in a single batch by me blinded to subject and 
diagnosis, with quality assurance on randomly selected slides provided by a 
professional academic pathologist (Professor H.K. Muller).   
 
3.5.2 Statistical analyses  
Results are presented as medians and ranges. A non-parametric ANOVA (Kruskal 
Wallis Test) was undertaken, and specific group differences then explored using the 
Mann Whitney U test. Associations between variables were assessed using 
Spearman's rank test. Statistical analyses were performed using SPSS 15.0 for 
Windows, 2003, with a two-tailed P-value ≤ 0.05 being considered statistically 
significant. Wilcoxon two related-samples test was used to test the effect of ICS and 
placebo in the longitudinal study. Associations between variables were assessed 
using Spearman's rank test. Linear regression analysis for potential confounders was 
undertaken and differences between groups in gender balance, age, and atopy were 
found to be non-contributory.  
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Figure 3.1: Showing two biopsy sections fixed on a slide with black circles around 
them.   
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Figure 3.2: Computer-assisted image analyser (Leica DM 2500 LB microscope, 
Leica Microsystems, Germany; Dage-MTI DC200 one-chip video camera;  Image 
Pro V4.5, media Cybernetics, USA software) 
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Figure 3.3: Bronchial biopsy specimen from a COPD current smoker, black arrows 
showing Rbm fragmentation with many “clefts” evident which frequently contain 
cells. Stain: haematoxylin and eosin (H & E). Original magnification, x630  
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3.5.3 MMP-9 immunostaining procedure 
 
1. Paraffin blocks were sectioned at 3 microns after cooling in a -20 freezer or 
on ice blocks for 5-10 minutes.  
2. Two sections separated by 40-50 microns (approximately 10 sections) were 
placed on each slide on 3 Aminopropyl triethoxy-silane APTS (Sigma A-
3648) coated slides (in milli Q water bath with one drop of Tween 20 (ICN 
103168) in water bath at approx 50 degrees centigrade). 
3. The slides were dried for 2 hours in slide drying oven. 
4. Slides were sorted out and had positive tissue control and a negative reagent 
control for each section being stained.  
5. Circles were made at the back of the slide around the sections with xylene 
resistant pen and labelled with date of staining. 
6. Sections were dewaxed in “xylene” 2 x 5 mins each in fume hood. 
7. Then hydrated to water using 100% ethanol followed by 95% then 70%, 3 
minutes each change. 
8. Sections were rinsed well in running tap water (2 minutes). 
9. Then placed in 3% H2O2 in distilled water for 15 minutes.  
10. Washed in running water for 2 minutes. 
11. Placed in 500ml of dist water in bottom of pressure cooker. 
12. Added 500ml of Dako S1700 solution from the fridge, in plastic incubation 
vessel (or diluted to concentration 1 in 10 and reused). 
13. Slides were placed in S1700 solution and then heated in pressure cooker for 6 
minutes on high then 14 minutes on about 6.5 to maintain steam.  
14. Allowed pressure cooker to cool and then removed the lid and placed vessel 
in the running water until the solution had reached 35 degrees C. Then placed 
sections in running water for 1 minute.  
15. Covered slides with PBS pH 7.4.    
16. Applied primary antibody to sections for appropriate time at appropriate 
concentration and temperature (1:50 for 2 hours). Also applied negative 
control sera (normal sera from same species as primary antibody, mouse 
IgG1) to control section and if possible used reagent control antibody that is 
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well demonstrated in the tissue under investigation. Made primary antibody 
using Dako diluent. 
17. Washed sections well using PBS 3 x changes 5 mins each change. 
18. Appled DAKO Envision + (Dako k4001) reagent to sections for 30 mins. 
19. Washed sections well using PBS 3 x changes 5 mins each change. 
20. Made DAKO DAB plus solution (K3468) using 20 micro litres of DAB to 1 
ml of substrate buffer. 
21. Appled DAB to sections for 10 mins. 
22. Washed sections well using PBS 5 mins. 
23. Sections were rinsed in running water. 
24. Sections were placed in Mayer’s haematoxylin to elaborate nuclei for1 min.  
25. Then rinsed in running water.  
26. Placed in approx 400ml of water with 6-8 drops of ammonia 30 seconds. 
27. Rinsed well in running water.  
28. Then Dehydrated sections in clean fresh 95% ethanol, and then changed 
twice with 100% ethanol (2 minutes each change) (made sure that 95% is not 
pink, if so, it was changed). 
29. Cleared in three changes of xylene (2 minutes each change) and mounted 
sections in Depex (or similar). 
30. Then finally coversliped using machine with 54 mm coverslips. 
31. Dried on hotplate overnight. 
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3.5.4 EGFR immunostaining procedure 
 
1. Paraffin blocks were sectioned at 3 microns after cooling in a -20 freezer or 
on ice blocks for 5-10 minutes.  
2. Two sections separated by 40-50 microns (approximately 10 sections) were 
placed on each slide on 3 Aminopropyl triethoxy-silane APTS (Sigma A-
3648) coated slides (in milli Q water bath with one drop of Tween 20 (ICN 
103168) in water bath at approx 50 degrees centigrade). 
3. The slides were dried for 2 hours in slide drying oven. 
4. Sections were dewaxed in “xylene” 2 x 5 mins each in fume hood. 
5. Then hydrated to water using 100% ethanol followed by 95% then 70%, 3 
minutes each change. 
6. Sections were rinsed well in running tap water (2 minutes). 
7. Then placed in 3% H2O2 in distilled water for 15 minutes.  
8. Washed in running water 2 minutes. 
9. Rinsed in working phosphate buffered saline (diluted from Tubbs stock 
buffer 1 in 25) 2 mins. 
10. Applied primary antibody to sections (chemicon CBL417 clone F4) 1/40 
1hrrt made up using diluent with 3% BSA. Also applied negative control sera 
(normal sera from same species as primary antibody) to control section and if 
possible used reagent control antibody which was well demonstrated in the 
tissue under investigation. 
11. Washed sections well using PBS 3 x changes 5 mins each change. 
12. Applied DAKO Envision + (Dakok4001) reagent to sections for 30 mins. 
13. Washed sections well using PBS 3 x changes 5 mins each change. 
14. Made DAKO DAB plus solution (K3468) using 20 micro litres of DAB to 1 
ml of substrate buffer. 
15. Applied DAB to sections for 10 mins.  
16. Washed sections well using PBS 5 mins. 
17. Rinsed sections in running water. 
18. Sections were placed in Mayers haematoxylin to elaborate nuclei, 2 mins (or 
in Harris’s 2 mins then differentiated with three dips in 1% acid alcohol).  
19. Rinsed in running water again. 
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20. Placed in approx 400ml of water with 6-8 drops of ammonia 30 secs. 
21. Rinsed well in running water. 
22. Dehydrated in 95% ethanol then changed twice in 100% ethanol (2 minutes 
each change). 
23. Cleared in three changes of xylene (2 minutes each change) and sections were 
mounted in Depex (or similar). 
24. Then finally coversliped using machine with 54 mm coverslips. 
25. Dried on hotplate overnight. 
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3.5.5 S100A4 immunostaining procedure 
 
1. Paraffin blocks were sectioned at 3 microns after cooling in a -20 freezer or 
on ice blocks for 5-10 minutes.  
2. Two sections separated by 40-50 microns (approximately 10 sections) were 
placed on each slide on 3 Aminopropyl triethoxy-silane APTS (Sigma A-
3648) coated slides (in milli Q water bath with one drop of Tween 20 (ICN 
103168) in water bath at approx 50 degrees centigrade). 
3. The slides were dried for 2 hours in slide drying oven. 
4. Sections were dewaxed in “xylene” 2 x 5 mins each in fume hood. 
5. Then hydrated to water using 100% ethanol followed by 95% then 70%, 3 
minutes each change. 
6. Sections were rinsed well in running tap water (2 minutes). 
7. Then placed in 3% H2O2 in distilled water for 15 minutes.  
8. Washed in running water 2 minutes. 
9. Slides were placed in pressure cooker 1 for 6 minutes on high then 15 
minutes at about 6.5 on dial till just expelling steam using: 500ml of s1700 
dako buffer solution with 500mls of distilled water in pressure cooker.  
10. Washed in running tap water for 2 minutes. 
11. Covered slides with PBS pH 7.4 for 1 minute. 
12. Applied primary antibody to sections for appropriate time (90 mins rt) at 
appropriate concentration and temperature. Also applied negative control sera 
(normal sera from same species as primary antibody) to control section and if 
possible used reagent controlled antibody that was well demonstrated in the 
tissue under investigation, (S100 A4 (Dako polyclonal antibody code A 5114 
protein concentration 0.72g/l) at dilution of 1/2500 (2.88x10-4  g/l)  made 
from stock of 1 in 100 diluted in dako diluent and normal rabbit 
immunoglobulin as negative control at dilution of 1/70000(2.85 x 10-4 g/l) 
(from stock Dako X0903 protein concentration 20g/l).  
13. Washed sections well using PBS 3 x changes 5 mins each change. 
14. Applied DAKO Envision + (rabbit polyclonal) (Dako K4003) reagent to 
sections for 30 mins. 
15. Washed sections well using PBS 3 x changes 5 mins each change. 
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16. Made DAKO DAB plus solution (K3468) using 20 micro litres of DAB to 1 
ml of substrate buffer.  
17. Applied DAB to sections for 10 mins. 
18. Washed sections well using PBS 5 mins. 
19. Rinsed sections in running water. 
20. Sections were placed in Mayer’s haematoxylin to elaborate nuclei, 2 mins (or 
in Harris’s 2 mins then differentiated with three dips in 1% acid alcohol).  
21. Rinsed in running water. 
22. Placed in approx 400ml of water with 6-8 drops of ammonia 30 secs. 
23. Rinsed well in running water. 
24. Dehydrated in 95% ethanol then changed twice in 100% ethanol (2 minutes 
each change). 
25. Cleared in three changes of xylene (2 minutes each change) and mount 
sections in Depex (or similar). 
26. Then finally coversliped using machine with 54 mm coverslips. 
27. Dried on hotplate overnight. 
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3.5.6 Vimentin immunostaining procedure 
 
1. Paraffin blocks were sectioned at 3 microns after cooling in a -20 freezer or 
on ice blocks for 5-10 minutes.  
2. Two sections separated by 40-50 microns (approximately 10 sections) were 
placed on each slide on 3 Aminopropyl triethoxy-silane APTS (Sigma A-
3648) coated slides (in milli Q water bath with one drop of Tween 20 (ICN 
103168) in water bath at approx 50 degrees centigrade). 
3. The slides were dried for 2 hours in slide drying oven. 
4. Sections were dewaxed in “xylene” 2 x 5 mins each in fume hood. 
5. Then hydrated to water using 100% ethanol followed by 95% then 70%, 3 
minutes each change. 
6. Sections were rinsed well in running tap water (2 minutes). 
7. Slides were placed in pressure cooker1, for 6 minutes on high then 15 
minutes at about 6.5 on dial till just expelling steam using: 500ml of Citrate 
Buffer pH6 solution with 500mls of distilled water in pressure cooker. 
8. Washed in running tap water for 2 minutes. 
9. Applied Dako monoclonal anti-vimentin antibody at 1/1000 for 2 hours at 
room temp (diluted in Dako diluent). 
10. Washed three times with tris buffer for three minutes each. 
11. Covered all sections in link reagent (Dako REAL K5355 or K5005), for 
20mins at room temperature (RT). 
12. Washed three times with tris buffer for three minutes each. 
13. Incubated in REAL streptavidin (also known as AP enzyme enhancer) (Dako 
K5355) with ALK phos conjugate for twenty minutes at RT. 
14. Washed three times with tris buffer for three minutes each change. 
15. Made up chromogen by adding 20 microlitres of chromogen to each ml of 
substrate and then incubate sections for ten minutes. 
16. Washed in running tap water for 2 minutes. 
17. Sections were placed in Mayers haematoxylin to elaborate nuclei, 2 mins (or 
in Harris’s 2 mins then differentiated with three dips in 1% acid alcohol).  
18. Rinsed in running water. 
19. Placed in approx 400ml of water with 6-8 drops of ammonia for 30 secs. 
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20. Rinsed well in running water. 
21. Dehydrated on hotplate. 
22. Cleared in three changes of xylene (2 minutes each change) and mounted 
sections in Depex (or similar).  
23. Then finally coversliped using machine with 54 mm coverslips. 
24. Dried on hotplate overnight. 
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3.5.7 S100A4 and vimentin double- immunostaining procedure 
 
1. Paraffin blocks were sectioned at 3 microns after cooling in a -20 freezer or 
on ice blocks for 5-10 minutes.  
2. Two sections separated by 40-50 microns (approximately 10 sections) were 
placed on each slide on 3 Aminopropyl triethoxy-silane APTS (Sigma A-
3648) coated slides (in milli Q water bath with one drop of Tween 20 (ICN 
103168) in water bath at approx 50 degrees centigrade). 
3. The slides were dried for 2 hours in slide drying oven. 
4. Sections were dewaxed in “xylene” 2 x 5 mins each in fume hood. 
5. Then hydrated to water using 100% ethanol followed by 95% then 70%, 3 
minutes each change. 
6. Sections were rinsed well in running tap water (2 minutes). 
7. Slides were placed in pressure cooker1, for 6 minutes on high then 15 
minutes at about 6.5 on dial till just expelling steam using: 500ml of citrate 
buffer pH6 solution with 500mls of distilled water in pressure cooker. 
8. Washed in running tap water for 2 minutes. 
9. Applied Dako monoclonal anti-vimentin M7020 clone 3B4 antibody at 
1/1000 for 2 hours at room temp (diluted in Dako diluent). 
10. Washed three times with tris buffer for three minutes each. 
11. Covered all sections in link reagent (Dako REAL K5355 or K5005), for 20 
minutes RT.  
12. Washed three times with tris buffer for three minutes each. 
13. Incubated in REAL streptavidin (also know as AP enzyme enhancer) (Dako 
K5355) with ALK phos conjugate twenty minutes room temperature. 
14. Washed three times with tris buffer for three minutes each change. 
15. Made chromogen by adding 20 microlitres of chromogen to each ml of 
substrate and then incubated sections for ten minutes. 
16. Washed in running tap water for 2 minutes. 
17. Placed in 3% H2O2 in distilled water for 15 minutes.  
18. Washed in running tap water 2 minutes. 
19. Applied primary antibody to sections for appropriate time (60 mins RT) at 
appropriate concentration and temperature. Also applied negative control sera 
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(normal sera from same species as primary antibody) to control section and if 
possible used reagent control antibody which was well demonstrated in the 
tissue under investigation. Use S100 A4 (Dako polyclonal antibody code A 
5114 protein concentration 0.72g/l) at dilution of 1/3000 (2.4x10 -4  g/l)  
made from stock of 1 in 100 diluted in dako diluent  Used normal rabbit 
immunoglobulin as negative control at dilution of 1/70000( 2.9. x 10 -4  g/l) 
(from stock Dako X0903 protein concentration 20g/l). 
20. Washed sections well using PBS pH 7.4 3 x changes 5 mins each change. 
21. Applied DAKO Envision + (rabbit polyclonal) (Dako K4003) reagent to 
sections for 30 mins. 
22. Washed sections well using PBS 3 x changes 5 mins each change. 
23. Made up DAKO DAB plus solution (K3468) using 20 micro litres of DAB to 
1 ml of substrate buffer. 
24. Applied DAB to sections for 10 mins. 
25. Rinsed sections in running water. 
26. Placed sections in Mayers haematoxylin to elaborate nuclei, 2 mins (or in 
Harris’s 2 mins then differentiate with three dips in 1% acid alcohol).  
27. Rinsed in running water. 
28. Placed in approx 400ml of water with 6-8 drops of ammonia 30 secs. 
29. Rinsed well in running water. 
30. Dehydrated on hotplate. 
31. Cleared in three changes of xylene (2 minutes each change) and mounted 
sections in Depex (or similar). 
32. Then finally coversliped using machine with 54 mm coverslips. 
33. Dried on hotplate overnight. 
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3.5.8 Vimentin and cytokeratin double-immunostaining procedure 
 
1. Paraffin blocks were sectioned at 3 microns after cooling in a -20 freezer or 
on ice blocks for 5-10 minutes.  
2. Two sections separated by 40-50 microns (approximately 10 sections) were 
placed on each slide on 3 Aminopropyl triethoxy-silane APTS (Sigma A-
3648) coated slides (in milli Q water bath with one drop of Tween 20 (ICN 
103168) in water bath at approx 50 degrees centigrade). 
3. The slides were dried for 2 hours in slide drying oven. 
4. Sections were dewaxed in “xylene” 2 x 5 mins each in fume hood. 
5. Then hydrated to water using 100% ethanol followed by 95% then 70%, 3 
minutes each change. 
6. Sections were rinsed well in running tap water (2 minutes). 
7. Placed in 3% H2O2 in distilled water for 15 minutes. 
8. Washed in running tap water 2 minutes. 
9. Slides were placed in pressure cooker1, for 6 minutes on high then 6 minutes 
at about 6.5 on dial till just expelling steam using: 500ml of citrate buffer 
pH6 solution with 500mls of distilled water in pressure cooker. 
10. Allowed to cool to below 35 degrees C before washing in running tap water 2 
minutes. 
11. Washed sections well using PBS pH 7.4. 
12. Applied Dako monoclonal anti-vimentin M7020 clone 3B4 antibody at 1/500 
for 2 hours 20 mins at room temp (diluted in Dako diluent). 
13. Washed sections well using PBS pH 7.4 3x 3mins each change. 
14. Applied Dako Envision + (monoclonal) (Dako K4001) reagent to sections for 
30 mins. 
15. Washed sections well using PBS 3 x changes 5 mins each change. 
16. Made Dako DAB plus solution (K3468) using 20 micro litres of DAB to 1 ml 
of substrate buffer. 
17. Applied DAB to sections for 10 mins. 
18. Rinsed sections in running water. 
19. Placed sections in Harris’s haematoxylin to elaborate nuclei, 5 mins then 
differentiated with three dips in 1% acid alcohol. 
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20. Rinsed in running water. 
21. Placed in approx 400ml of water with 6-8 drops of ammonia 30 secs. 
22. Rinsed well in running water and check nuclei (adjusted further if necessary). 
23. Washed with tris buffer for three minutes. 
24. Applied primary antibody (cytokeratin AE1/AE3 at 1/40in diluent Abcam ab 
27988) to sections for appropriate time (2hrs RT) at appropriate concentration 
and temperature. Also applied negative control sera (normal sera from same 
species as primary antibody) to control sections and if possible used reagent 
control antibody which was well demonstrated in the tissue under 
investigation.  
25. Washed three times with tris buffer for three minutes each. 
26. Covered all sections in link reagent (Dako REAL K5355 or K5005), for 
20mins RT. 
27. Washed three times with tris buffer for three minutes each change. 
28. Incubated in REAL streptavidin (also know as AP enzyme enhancer) (Dako 
K5355) with ALK phos conjugate twenty minutes at RT. 
29. Washed three times with tris buffer for three minutes each change. 
30. Made up Chromogen by adding 20 microlitres of chromogen to each ml of 
substrate and then incubated sections for ten minutes. 
31. Washed in running tap water 2 minutes. 
32. Rinsed in distilled water. 
33. Dehydrated on hotplate. 
34. Cleared in three changes of xylene (2 minutes each change) and mounted 
sections in Depex (or similar). 
35. Then finally coversliped using machine with 54 mm coverslips. 
36. Dried on hotplate overnight. 
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3.5.9 CD11c immunostaining procedure 
 
1. Paraffin blocks were sectioned at 3 microns after cooling in a -20 freezer or 
on ice blocks for 5-10 minutes.  
2. Two sections separated by 40-50 microns (approximately 10 sections) were 
placed on each slide on 3 Aminopropyl triethoxy-silane APTS (Sigma A-
3648) coated slides (in milli Q water bath with one drop of Tween 20 (ICN 
103168) in water bath at approx 50 degrees centigrade). 
3. The slides were dried for 2 hours in slide drying oven. 
4. Sections were dewaxed in “xylene” 2 x 5 mins each in fume hood. 
5. Then hydrated to water using 100% ethanol followed by 95% then 70%, 3 
minutes each change. 
6. Sections were rinsed well in running tap water (2 minutes). 
7. Placed in 3% H2O2 in distilled water for 15 minutes. 
8. Washed in running tap water 2 minutes. 
9. Slides were placed in pressure cooker1, for 6 minutes on high then 6 minutes 
at about 6.5 on dial till just expelling steam using: 500ml of citrate buffer 
pH6 solution with 500mls of distilled water in pressure cooker. 
10. Allowed to cool to below 35 degrees C before washing in running tap water 2 
minutes. 
11. Washed sections well using PBS pH 7.4. 
12. Applied CD11c Abcam ab52632 clone ep1347Y for 2 hours mins at room 
temp (dilute in dako diluent) and rabbit IgG1 at 1/20,000 for two hours at RT 
on serial sections. 
13. Washed sections well using  PBS pH 7.4 3x 3mins each change 
14. Applied Dako Envision + (anti rabbit) (Dako K4003) reagent to sections for 
30 mins. 
15. Washed sections well using PBS 3 x changes 5 mins each change 
16. Made up Invitrogen DAB plus solution using 20 micro litres of DAB to 1 ml 
of substrate buffer. 
17. Apply DAB to sections for 10 mins. 
18. Rinsed sections in running water 
19. Placed sections in mayers haematoxylin to elaborate nuclei, 2 mins.   
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20. Rinsed in running water.  
21. Placed in approx 400ml of water with 6-8 drops of ammonia 30 secs. 
22. Rinsed well in running water and check nuclei (adjusted further if necessary). 
23. Washed in running tap water 2 minutes.  
24. Rinsed in distilled water. 
25. Dehydrated in 95% then 2 x 100% ethanol for 1 minute each change.  
26. Cleared in three changes of xylene (2 minutes each change) and mounted 
sections in Depex (or similar).  
27. Then finally coversliped using machine with 54 mm coverslips. 
28. Dried on hotplate overnight. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
124 
 
3.5.10 CD4/CD8 immunostaining procedure 
 
1. Paraffin blocks were sectioned at 3 microns after cooling in a -20 freezer or 
on ice blocks for 5-10 minutes.  
2. Two sections separated by 40-50 microns (approximately 10 sections) were 
placed on each slide on 3 Aminopropyl triethoxy-silane APTS (Sigma A-
3648) coated slides (in milli Q water bath with one drop of Tween 20 (ICN 
103168) in water bath at approx 50 degrees centigrade). 
3. Dried overnight at 37 degrees. 
4. Dried on hotplate for a further hour at 56 degrees just prior to sectioning.  
5. Dewaxed sections in “xylene” 2 x 5 mins each  in fume hood.  
6. Hydrated to water using 100% ethanol followed by 95% then 70%, 3 mins 
each change. 
7. Rinsed sections well in running tap water (2 mins). 
8. Placed in 0.5% H2O2 in water for 15 minutes. (5 ml of 30% H2O2 in 295ml 
of Water).  
9. This was an important step since the antigens are destroyed if harsh 
peroxidase treatment was used. Use only 0.5% in water. 
10. Washed in running water 2 minutes. 
11. Added 500ml 1mm EDTA pH 8.00 in round plastic medium staining jar and 
placed in plastic autoclave container that has 250ml of distilled water in it  
(0.186g of EDTA in 400ml of distilled water, adjust pH to 8 with 1 molar 
sodium hydroxide and then make up to 500ml with distilled water).   
12. Heated solutions without slides in microwave in autoclave (with lid in open 
position but rubber bung in place) for 10minutes on high. 
13. Heated for 3 minutes on high in microwave with autoclave in closed position 
and yellow button pressed down.  
14. Removed autoclave from microwave and cool rapidly in running water until 
yellow button drops (5 mins, care was required here, gloves or cloth was used 
to remove autoclave and do not open until temperature returns to RT). 
15. Removed plastic staining jar from autoclave and further cool sections in 
water bath until temperature reached about 35 degrees C. 
16. Placed slides in PBS pH 7.4, 2 minutes.   
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17. Applied primary antibody to sections for 2hr RT diluted to appropriate 
dilution in Dako antibody Diluent. (1:15) Also applied negative control sera 
(normal sera from same species as primary antibody) to control sections and 
if possible used reagent control antibody that is well demonstrated in the 
tissue under investigation. 
18. Washed sections well using PBS 3 x changes 5 mins each change. 
19. Applied Dako Envision + (Dako 003355) reagent to sections for 30 mins. 
20. Washed sections well using PBS 3 x changes 5 mins each change. 
21. Made up Dako DAB plus solution (K3468) using 20 micro litres of DAB to 1 
ml of substrate buffer. 
22. Applied DAB to sections for 10 mins. 
23. Washed sections well using PBS 5 mins.  
24. Rinsed sections in running water.  
25. Placed sections in Mayers haematoxylin to elaborate nuclei, 1 min (or in 
Harris’s 2 mins then differentiate with three dips in 1% acid alcohol).  
26. Rinsed in running water.  
27. Placed in approx 400ml of water with 6-8 drops of ammonia 30 secs. 
28. Rinsed well in running water. 
29. Dehydrated in 95% ethanol, then twice in 100% ethanol (2 minutes each 
change) 
30. Cleared in three changes of xylene (2 minutes each change) and mounted 
sections in Depex (or similar). 
31. Dried on hotplate overnight. 
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3.5.11 Neutrophil elastase immunostaining procedure 
 
1. Paraffin blocks were sectioned at 3 microns after cooling in a -20 freezer or 
on ice blocks for 5-10 minutes.  
2. Two sections separated by 40-50 microns (approximately 10 sections) were 
placed on each slide on 3 Aminopropyl triethoxy-silane APTS (Sigma A-
3648) coated slides (in milli Q water bath with one drop of Tween 20 (ICN 
103168) in water bath at approx 50 degrees centigrade). 
3. The slides were dried for 2 hours in slide drying oven. 
4. Sections were dewaxed in “xylene” 2 x 5 mins each in fume hood. 
5. Then hydrated to water using 100% ethanol followed by 95% then 70%, 3 
minutes each change. 
6. Rinsed sections well in running tap water (2 mins). 
7. Placed in 3% H2O2 in distilled water for 15 minutes.  
8. Washed in running water 2 minutes. 
9. Rinsed in working phosphate buffered saline (diluted from Tubbs stock 
buffer 1 in 25) 2 mins. 
10.  Applied Neutrophil elastase (Dako M 0752) 1/500 1hr RT (no protease). 
Also applied negative control sera (normal sera from same species as primary 
antibody) to control section at similar concentration.  
11. Washed sections well using PBS 3 x changes 5 mins each change. 
12. Applied Dako Envision + (Dako k4001) reagent to sections for 30 mins. 
13. Washed sections well using PBS 3 x changes 5 mins each change. 
14. Made up Dako DAB plus solution (K3468) using 20 micro litres of DAB to 1 
ml of substrate buffer. 
15. Applied DAB to sections for 10 mins. 
16. Washed sections well using PBS 5 mins.  
17. Rinsed sections in running water.  
18. Placed sections in Mayers haematoxylin to elaborate nuclei, 2 mins (or in 
Harris’s 2 mins then differentiate with three dips in 1% acid alcohol).  
19. Rinsed in running water.  
20. Placed in approx 400ml of water with 6-8 drops of ammonia 30 secs. 
21. Rinsed well in running water. 
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22. Dehydrated in 95% ethanol then changed twice with 100% ethanol (2 minutes 
each change). 
23. Cleared in three changes of xylene (2 minutes each change) and mounted 
sections in Depex (or similar).  
24. Dried on hotplate overnight. 
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3.5.12 CD19 immunostaining procedure 
 
1. Paraffin blocks were sectioned at 3 microns after cooling in a -20 freezer or 
on ice blocks for 5-10 minutes.  
2. Two sections separated by 40-50 microns (approximately 10 sections) were 
placed on each slide on 3 Aminopropyl triethoxy-silane APTS (Sigma A-
3648) coated slides (in milli Q water bath with one drop of Tween 20 (ICN 
103168) in water bath at approx 50 degrees centigrade). 
3. The slides were dried for 2 hours in slide drying oven. 
4. Sections were dewaxed in “xylene” 2 x 5 mins each in fume hood. 
5. Then hydrated to water using 100% ethanol followed by 95% then 70%, 3 
minutes each change. 
6. Rinsed sections well in running tap water (2 mins). 
7. Placed in 3% H2O2 in distilled water for 15 minutes.  
8. Washed in running water 2 minutes. 
9. Rinsed in working phosphate buffered saline (diluted from Tubbs stock 
buffer 1 in 25) 2 mins. 
10. Applied primary antibody to sections for 2hours at 1/8000 dilution at room 
temperature. Also applied negative control sera (normal mouse sera at 
1/5000) to control section and if possible used reagent control antibody which 
was well demonstrated in the tissue under investigation. 
11. Washed sections well using PBS 3 x changes 5 mins each change. 
12. Applied Dako Envision + (Dako k4001 or k4003) reagent to sections for 30 
minutes. 
13. Washed sections well using PBS 3 x changes 5 minutes each change.  
14.  Made up Invitrogen DAB solution (cat no 882014) using 20 micro litres of 
DAB to 1 ml of substrate buffer.  
15. Applied DAB to sections for 10 minutes. 
16. Washed sections well using PBS 5 minutes.  
17. Rinsed sections in running water.  
18. Placed sections in Mayers haematoxylin to elaborate nuclei, 2 minutes  
19. Rinsed in running water.  
20. Placed in approx 400ml of water with 6-8 drops of ammonia 30 seconds.  
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21. Rinsed well in running water.  
22. Dehydrated in 95% ethanol, then two changes of 100% ethanol (2 minutes 
each change).  
23. Cleared in three changes of xylene (2 minutes each change) and mounted 
sections in Depex (or similar). 
24. Dried on hotplate overnight. 
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3.5.13 CD68 immunostaining procedure 
 
1. Paraffin blocks were sectioned at 3 microns after cooling in a -20 freezer or 
on ice blocks for 5-10 minutes.  
2. Two sections separated by 40-50 microns (approximately 10 sections) were 
placed on each slide on 3 Aminopropyl triethoxy-silane APTS (Sigma A-
3648) coated slides (in milli Q water bath with one drop of Tween 20 (ICN 
103168) in water bath at approx 50 degrees centigrade). 
3. Dried on hotplate at 56 degrees one hour and overnight at 37 degrees. 
4. Dewaxed sections in “xylene” 2 x 5 mins each in fume hood.  
5. Hydrated to water using 100% ethanol followed by 95% then 70%, 3 mins 
each change. 
6. Rinsed sections well in running tap water (2 mins). 
7. Placed in 3% H2O2 in distilled water for 15 minutes.  
8. Washed in running water 2 minutes. 
9. Rinsed in working phosphate buffered saline (diluted from Tubbs stock 
buffer 1 in 25) 2 mins. 
10. Pre-incubated them in PBS at 37 degrees in water bath for 5 mins. 
11. Incubated in 0.025% protease type VIII (Sigma P5380) in PBS for three 
minutes at 37 degrees in water bath. 
12. Washed in running tap water 5 minutes.  
13. Covered slides with PBS pH 7.4.   
14. Applied primary antibody to sections for 30 mins at room temp diluted to 
1/500 in Dako antibody diluent. Also applied negative control sera (normal 
sera from same species as primary antibody) to control sections and if 
possible used reagent control antibody which was well demonstrated in the 
tissue under investigation. 
15. Washed sections well using PBS 3 x changes 5 mins each change. 
16. Applied DAKO Envision + (Dako k4001) reagent to sections for 30 mins. 
17. Washed sections well using PBS 3 x changes 5 mins each change. 
18. Made up Dako DAB plus solution (K3468) using 20 micro litres of DAB to 1 
ml of substrate buffer. 
19. Applied DAB to sections for 10 mins. 
20. Washed sections well using PBS 5 mins. 
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21. Rinsed sections in running water.  
22. Placed sections in Mayers haematoxylin to elaborate nuclei, 2 mins (or in 
Harris’s 2 mins then differentiate with three dips in 1% acid alcohol).  
23. Rinsed in running water. 
24. Placed in approx 400ml of water with 6-8 drops of ammonia 30 secs. 
25. Rinsed well in running water.  
26. Dehydrated in 95% ethanol then changed twice in 100% ethanol (2 minutes 
each change). 
27. Cleared in three changes of xylene (2 minutes each change) and mount 
sections in Depex (or similar). 
28. Dried on hotplate overnight. 
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3.5.14 General procedure for Haematoxylin and Eosin (H&E) stain 
 
1. Paraffin blocks were sectioned at 5 microns and were picked on APTS coated 
slides. 
2. Dried overnight at 37 degrees or on hotplate at 56 degrees two hours. 
3. Dewaxed sections in fresh “xylene substitute (Shandon- kept in flame 
cupboard)” 2 x 5 mins each in fume hood.  
4. Hydrated to water using 100% ethanol followed by 95% then 70%, 2 mins 
each change. 
5. Rinsed sections well in running tap water (2 minutes). 
6. Placed sections in Mayer’s haematoxylin to elaborate nuclei, 5 minutes. 
7. Rinsed in running water.  
8. Placed in approx 400ml of water with 8 drops of ammonia 30 seconds. 
9. Rinsed well in running water. 
10. Checked nuclei, if they are sufficiently stained using microscope.  
11. Placed in eosin solution 2 minutes.  
12. Rinsed quickly in running water to remove excess eosin and place into 95% 
ethanol 30 seconds with agitation. 
13. Further dehydrated with 3 changes of 100% ethanol 1 min each change.  
14. Cleared sections using 3 changes of fresh substitute xylene 2 minutes each 
change.  
15. Placed sections in Xylene for 1 min prior to coverslipping with xylene based 
mountant (Depex or similar). 
16. Dried on hotplate overnight. 
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Chapter 4 
 
Rbm fragmentation and potential EMT 
in the airways of smokers is exaggerated 
in COPD 
4.1 Introduction  
Chronic obstructive pulmonary disease (COPD) is characterized by progressive fixed 
airflow limitation and associated chronic airway inflammation; usually due to 
tobacco smoke inhalation (Barnes, 2003; Barnes et al., 2003).One of the features of 
chronic airway diseases, including COPD, is airway remodelling (Churg et al., 2006; 
J. C. Hogg et al., 1968; Nakano et al., 2002; Saetta et al., 2000). In COPD the 
mechanism and structural changes of remodelling are poorly described. 
 
A new explanation for remodelling in inflammatory respiratory diseases, which may 
be applicable to COPD, is transition of airway epithelial cells to a mesenchymal 
phenotype and then migration through the Rbm to the sub epithelial lamina propria, a 
process termed epithelial mesenchymal transition (EMT) (Peter K. Jeffery, 2004; 
Brigham C. Willis et al., 2006). However, to our knowledge, there have been no 
reported studies undertaken examining markers of EMT in human airway biopsy 
tissues from subjects with COPD, although EMT was recently demonstrated in the 
similar bronchiolitis obliterans syndrome (BOS) that occurs as a manifestation of 
chronic rejection post lung transplant. (Ward et al., 2005) 
 
In preliminary observations (Chapter 1) I found that the Rbm in smokers was 
significantly fragmented, which can be a hallmark of EMT (Acloque et al., 2009; R. 
Kalluri, 2009; Raghu Kalluri & Neilson, 2003; R. Kalluri & Weinberg, 2009; 
Zeisberg & Neilson, 2009). This encouraged me to test the hypothesis that the airway 
epithelium is activated in smokers, promoting EMT, but that this will be especially 
active in COPD. As the first such study that I am aware of in COPD, I examined 
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airway biopsies for expression of markers generally accepted to represent EMT 
proteome, including matrix metalloproteinase-9 (MMP-9), which can digest type IV 
collagen, (Ward et al., 2005) S100A4 (also known as fibroblast specific protein 1, 
Fsp1) and epidermal growth factor receptor (EGFR) as a marker of epithelial 
activation, and vimentin to further strengthen the possibility of EMT (R. Kalluri & 
Weinberg, 2009).  
 
I have investigated current smokers with established COPD (CS) and also current 
smokers with normal lung function (NS), comparing them to ex-smokers with COPD 
(ES) and normal healthy, never-smoking controls (NC) using airway biopsies.  This 
is a detailed study of Rbm fragmentation and a preliminary study of EMT in COPD, 
and provides novel data and potentially important new insights into the pathogenesis 
of airway disease in smokers and COPD.  
 
4.2 Methods and materials  
 
4.2.1 Subjects 
The study was approved by institutional Ethics Committees (details given in Chapter 
3). Subjects were recruited by advertisement. All subjects signed informed consent. 
Subjects with a history of other respiratory disorders were excluded. The diagnosis of 
COPD was made according to GOLD guidelines (GOLD, 2007). None were 
receiving corticosteroids (oral or inhaled).  
 
4.2.2 Bronchoscopy 
Details of bronchoscopic procedures are given in Chapter 3. 
 
4.2.3 Immunostaining  
Sections were stained with these monoclonal antibodies: anti-MMP-9, anti-EGFR 
and anti-S100A4 polyclonal together with a horseradish peroxidase (HRP) 
conjugated DAKO Envision plus reagent for secondary antibody binding and colour 
resolution using diaminobenzidine (DAB). Double staining with vimentin was 
elaborated using an anti-vimentin monoclonal antibody and then secondarily bound 
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using Dakocytomation “Real” alkaline phosphatase reagents and visualised using 
Dakocytomation liquid permanent red (details given Chapter 3).  
 
4.2.4 Biopsy analysis  
Computer-assisted image analysis was performed with a Leica DM 2500 microscope 
(Leica Microsystems, Germany), Spot insight 12 digital camera and Image Pro V5.1 
(Media Cybernetics, USA) software.  Cellular and other changes, e.g. in the Rbm, 
were normalised for purposes of comparisons in terms of the total length of basement 
membrane assessed. EGFR was measured as percentage of epithelium stained for 
EGFR over total basement membrane length (details given in Chapter 3).   
 
4.2.5 Statistical analysis  
Results are presented as medians and ranges. A non-parametric ANOVA was 
undertaken, and specific group differences then explored using the Mann Whitney U 
test. Associations between variables were assessed using Spearman's rank test. 
Statistical analyses were performed using SPSS 15.0 for Windows, 2003, with a two-
tailed P-value ≤ 0.05 being considered statistically significant. Linear regression 
analysis for potential confounders was undertaken, and differences between groups 
in gender balance, age, and atopy were found to be non-contributory. 
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4.3 Results 
The group demographics of subjects who participated in the study are presented in 
the table given below: 
 
 
Table 4: Demographic and lung function data for subjects.    
Groups 
(numbers) 
COPD-CS 
(n=17) 
COPD-ES 
(n=15) 
NS 
(n=16) 
NC 
(n=15) 
 
GOLD I/GOLD II 10/7 8/7 N/A N/A 
Male/female 9/8 9/6 12/4 7/8 
Age (years) 61 (46-78) 
(p=0.001)† 
62 (53-69) 
(p=0.001)† 
50 (30-66) 
(p=0.31) 
44 (20-68) 
Smoking (pack 
years) 
45 (18-78) 51 (18-150) 32 (10-57) 0 
FEV1% predicted 
(Post BD)* 
83 (66-102) 
(p<0.001)† 
83 (54-104) 
(p<0.001)† 
99 (78-125) 
(p=0.01)† 
113 (86-140) 
FEV1/FVC % 
(Post BD)* 
59 (46-68) 
(p<0.001)† 
  57 (38-68)  
  p<0.001)† 
   77 (70-96) 
   (p=0.22) 
   82 (71-88) 
 
Data expressed as median and range  
†Significance difference from NC  
* Post BD values after 400µg of salbutamol  
 Diagnosis of COPD was made according to GOLD guidelines (GOLD, 2007) 
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4.3.1 Fragmentation and presence of “clefts” within the Rbm  
Following our preliminary observation of linear “clefts” or elongated spaces/cracks 
in the Rbm, we have pragmatically used this for quantifying the degree of 
fragmentation. However, there were also commonly fragments of Rbm “hanging off” 
and similar pieces seemingly separated from it, albeit in the largely two-dimensional 
sections (Figure 4.1). This fragmentation was very rarely present in normal controls. 
The length of the individual “clefts” was measured, summed and results expressed as 
percentage of the total Rbm length to give a comparable measure of the degree of 
Rbm fragmentation for each individual.  The number of clefts was significantly 
(p<0.001) higher in CS, NS and ES compared to NC (Figure 4.2 and 4.3). The 
finding was more pronounced in current smoking COPD subjects. There was a 
significant positive correlation (R=0.41, p=0.02) between smoking (pack years) and 
percentage of clefts in Rbm in both COPD current smokers and ex-smokers (Figure 
4.4) but not in NS. However, no association was found with lung function 
measurements.   
 
4.3.2 MMP 9 positive cells associated with Rbm 
There were significantly more cells that stained positively for MMP-9 (Figure 4.2) in 
the Rbm per mm in CS, NS and ES compared to NC (p<0.002) (Figure 4.5). These 
cells were located predominantly within the “clefts”, but were also present 
immediately below and just adjacent to the Rbm (Figure 4.2) and were included on a 
single count. There was some minor degree of MMP-9 staining of cells within the 
airway epithelium, counted separately, with no difference between the groups. No 
association was found with lung function measurements.  
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Figure 4.1 : Bronchial biopsy section from (A) COPD current smoker; (B) COPD 
ex-smokers; (C) normal lung function smoker; compared to a (D) normal control: 
black arrows indicating Rbm fragmentation with many “clefts” evident with cells 
within them. Original magnifications, x 400. Stain: haematoxylin and eosin (H & E).  
 
 
139 
 
 
 
 
 
Figure 4.2: Immunohistochemical staining of bronchial biopsy sections for MMP-9 
from: (A) COPD-CS (B) COPD-ES (C) NS compared to (D) NC, with black arrows 
indicating clefts with cells positive for MMP-9. Original magnifications, x 630.  
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Figure 4.3: Percentage of “clefts” (percentage of the total Rbm length examined); 
†significant difference from NC (p<0.001). Values for clefts represent total length of 
clefts as percentage of total length of Rbm.  
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Figure 4.4: Correlation between percentage of clefts in Rbm length examined and 
smoking (pack years) in COPD current smokers and ex-smokers.  
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Figure 4.5: Number of MMP-9 positive cells in clefts per mm of Rbm; †significant 
difference from NC (p<0.002).  
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4.3.3 S100A4 positive cells in basal epithelium  
There were marked increases in cells staining for S100A4 within the basal layers 
(Figure 4.6) of the airway epithelium compared to NC in CS, NS and ES (p<0.004; 
Figure 4.7). There was a significant negative correlation (R = - 0.49, p = 0.04) 
between basal cell S100A4 staining and FEV1/FVC % in COPD current smokers 
(Figure 4.8), i.e. with airflow obstruction.    
 
4.3.4 S100A4 positive cells in Rbm  
The Rbm showed cells positively staining for S100A4 cells (Figure 4.6), but not 
exclusively within the clefts. This was significantly higher in CS, NS and ES than in 
NC per mm of Rbm (p<0.001). In addition, there was also a significant difference 
between CS compared to ES and NS (p<0.007) for S100A4 positive cells in Rbm per 
mm (Figure 4.9). No association was found with lung function measurements. 
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Figure 4.6: Immunohistochemical staining of bronchial biopsy sections for S100A4 
from: (A) COPD-CS (B) COPD-ES (C) NS compared to (D) NC, with black arrows 
indicating clefts, cells positive for S100A4 in the Rbm and in the basal epithelium. 
Original magnifications, x 630. 
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Figure 4.7: Number of basal epithelial cells positive for S100A4, per mm of Rbm; 
†significant difference from NC (p<0.004). 
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Figure 4.8: Correlation between basal S100A4 positive cells per mm of Rbm and 
FEV1/FVC (FER) % as index of airflow obstruction, in COPD current smokers.  
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Figure 4.9: Number of S100A4 positive cells within the Rbm, per mm of Rbm; 
†significant difference from NC (p<0.001); ! significant difference from COPD-ES 
(p=0.006);*significant difference from NS (p<0.001). 
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4.3.5 Double immunostaining of sections for S100A4 and vimentin  
To further strengthen the evidence for EMT, we double stained and assessed multiple 
representative sections for COPD-CS subjects for S100A4 and the mesenchymal 
marker vimentin simultaneously from the same tissue block (Figure 4.10). In the 
basal epithelium nearly the same percentage of cells were stained for S100A4 (15.6 
%) and vimentin (13.2 %) separately, and 13.4 % were double positive. In Rbm a 
very similar percentage of cells stained for S100A4 (19.6 %) and vimentin (23.0 %) 
separately, while 22.4 % cells were double positive.   
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Figure 4.10: Bronchial biopsy section form a COPD current smoker, with black 
arrows indicating  staining of cells positive for: (A) S100A4 (brown), stained with 
anti-S100A4 polyclonal antibody (B) vimentin (red), stained with anti-vimentin 
monoclonal antibody and (C) double stained for both S100A4 and vimentin (brown 
and red) in the basal epithelium and Rbm from the same tissue block . Original 
magnifications, x 630 (D) area high-magnification (100 x /1.30 oil PH 3) picture of 
the boxed area shown in (C).  
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4.3.6 EGFR expression in the airway epithelium  
A greater proportion of the airway epithelium stained positive for EGFR (Figure 
4.11) in the CS, NS and ES subjects compared to NC (p<0.001; Figure 4.12). Once 
again, no association was found with lung function measurements.    
 
 
 
Figure 4.11: Immunohistochemical staining of bronchial biopsy sections for EGFR 
from: (A) COPD-CS (B) COPD-ES (C) NS compared to (D) NC, intense brown 
staining for EGFR in the epithelium. Original magnifications, x 630.  
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Figure 4.12: Percentage of epithelium stained for EGFR; †significant difference 
from NC (p<0.001). Horizontal bars represent the median for each group.  
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4.4 Discussion 
This is the first description of marked Rbm “remodelling” with fragmentation 
represented by quantifiable clefts, in airway wall biopsies from smokers and COPD 
patients, especially in current smokers. “Clefts” within the disrupted Rbm contained 
cells expressing the proteolytic enzyme MMP-9 and the early fibroblast-transition 
marker S100A4. Superficial to the Rbm, the airway epithelium stained strongly for 
cells expressing the activation marker EGFR. There was also marked staining with 
S100A4 in cells within the deeper basal layer of the airway epithelium, situated in 
close proximity to the Rbm, in smokers and COPD. Dual immunostaining for 
S100A4 and vimentin in the basal epithelium and Rbm further strengthened the 
likelihood that these cells are undergoing transition to a mesenchymal phenotype. 
We suggest that these findings indicate active migration of cells from the epithelium 
into and presumably through the Rbm, with these cells possessing proteolytic 
capacity and a fibroblast phenotype. 
 
In general, current smokers with COPD had greater differences in these novel 
changes compared to normal controls than did physiologically normal smokers, 
although the differences overall were not statistically significant. Given the relatively 
small numbers of subjects, this probably reflects a Type-2 statistical error. The ex-
smoker COPD group was more variable but mostly quite similar to COPD. For 
S100A4 cells in the Rbm, there were significant differences between current 
smoking COPD and both other comparator groups (COPD-ES and NS). The only 
significant relationship with degree of physiological fixed airflow obstruction was 
with S100A4 cells in the basal layer of the epithelium in the current smoking COPD 
group.  These data taken together suggest that the remodelling changes are more 
exaggerated in established COPD as might be expected, especially in active current 
smokers, and that the changes we describe and attribute to likely EMT, may be of 
pathophysiological relevance. 
 
Epithelial EGFR expression suggests that these cells are possibly primed for 
migration. (de Boer et al., 2006; Raghu Kalluri & Neilson, 2003) The positive 
findings in smokers with normal lung function, compared to normal non-smokers, 
suggests that smoking itself has the potential to initiate EMT. Furthermore, our data 
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in the ex-smoker COPD group suggest that once these changes are initiated they may 
be irreversible, though longitudinal smoking cessation studies will be needed to fully 
clarify that. However, the difference between COPD current smokers versus COPD 
ex-smokers for expression of S100A4 in Rbm with no difference in basal epithelial 
cell S100A4 staining may suggest that migration from the epithelium across the Rbm 
decreases following smoking cessation. 
 
One of the common features of chronic inflammatory airway diseases, including 
COPD, is thought to be airway remodelling, although this has been predominantly 
studied in asthma. As a simile to the epithelium-mesenchymal transition suggested in 
BOS (Ward et al., 2005) it is likely that in COPD, the epithelium gets damaged 
and/or activated by irritants such as cigarette smoke constituents, and this stimulates 
deposition of collagen from myofibroblasts in the lamina propria. The precise origin 
of these primary effector cells of fibrosis in the human airway is not yet established, 
but there are several potential sources of fibrogenic cells within the airway wall: first,  
there may be expansion of a fibroblast pool by in-situ proliferation in response to 
injury which may lead to pathological fibrosis; (Phan, 2002) second, recruitment of 
circulating fibrocyte progenitors  into the airway wall; (Hashimoto et al., 2004) and 
third, transition of airway epithelial cells via EMT (Peter K. Jeffery, 2004; Brigham 
C. Willis et al., 2006). Our current study provides, for the first time that we are aware 
of, preliminary evidence suggesting that EMT may well be active in the airway wall 
in smokers and COPD. EMT has only recently been recognised in the human 
lung/airway, (Ward et al., 2005; Brigham C. Willis et al., 2006) but it is well 
described in lung embryogenesis, (J. M. Lee et al., 2006) metastatic malignant 
disease (Bjornland et al., 1999) and as part of the repair process in renal disease 
following tissue injury (Yanez-Mo et al., 2003). Active EMT is indicated by the 
degradation of underlying basement membrane and development of a mesenchymal 
cell with migratory potential that moves away from the epithelium in which it 
originated (R. Kalluri & Weinberg, 2009; Zeisberg & Neilson, 2009). 
 
Our finding in smokers and COPD subjects of Rbm fragmentation is quite consistent 
with other studies that suggest basement membrane fragmentation as a key indicator 
of EMT in-vivo (Acloque et al., 2009; R. Kalluri, 2009; Raghu Kalluri & Neilson, 
2003; R. Kalluri & Weinberg, 2009; Zeisberg & Neilson, 2009). In retrospect, and 
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with our new insights, we have noted Rbm fragmentation in work published by other 
investigators, (for e.g. de Boer et al., 2006) but this has not previously been 
commented on. Within the “clefts” in the Rbm, we observed cells expressing MMP-9 
and S100A4 and vimentin, and we suggest that these cells have originated from the 
surface airway epithelial layer. It is also possible that the cells in the clefts have 
migrated from the lamina propria, but against this explanation was the presence of 
S100A4 and vimentin staining cells in the basal layer of the epithelium in smokers 
and COPD, and the accompanying increase in expression of EGFR in the epithelium. 
These observations strongly suggest that the most likely origin of the S100A4 
positive cells apparent within the Rbm is airway epithelial cells (Raghu Kalluri & 
Neilson, 2003). 
 
A potential criticism of our findings is our attribution of mechanistic interpretation to 
``static`` immunohistochemical observations and that the Rbm fragmentation 
presented may be an “artefact” of tissue processing. Against this is that clefts 
contained cells (and to some extent vessels, data not shown) and also that tissues 
from normal healthy controls and asthmatics (data not shown) were processed in 
exactly the same way, but rarely showed Rbm fragmentation. In COPD the Rbm is 
variably thickened, but not significantly so as in asthma (data not shown). The 
simultaneous occurrence of Rbm fragmentation and presence of MMP-9 and SI00A4 
cell staining and EGFR expression in the epithelium within the “remodelled” airways 
of subject with established COPD offers a biologically plausible hypothesis of cause 
and effect, which fits with current ideas on EMT is chronic inflammatory disease 
pathogenesis (Acloque et al., 2009; R. Kalluri, 2009; Raghu Kalluri & Neilson, 2003; 
R. Kalluri & Weinberg, 2009; Zeisberg & Neilson, 2009). Our observations indicate 
the potential for EMT due to smoking and especially evident in smoking COPD, but 
are obviously limited by the fact that they are invasive human studies. Further studies 
may require further EMT signals and molecular markers to confirm and extend these 
prelimnary but novel and exciting findings.  
 
In summary, I have demonstrated that smoking is likely to initiate EMT and resulting 
Rbm fragmentation and cleft formation, which is associated with cells expressing the 
proteolytic enzyme MMP-9. Increased epithelial expression of EGFR suggests that 
epithelial cells are activated and therefore primed for migration. Increased cellular 
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co-expression of the early EMT fibroblast-transition marker S100A4 and vimentin 
also suggests phenotypic transition. All of these changes seem to be especially 
amplified in COPD, suggesting that EMT may be initiated by smoking, and also may 
be a particular feature of COPD pathophysiology.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
156 
 
Chapter 5 
Confirming EMT-Excluding potential 
confounding by inflammatory cell 
infiltrate  
 
5.1 Introduction  
In the previous Chapters I have described and detailed a comprehensive cross-
sectional study looking at the potential for active EMT in COPD and I found that this 
was indeed very likely on the basis of “classic” published criteria. I have shown that 
Rbm in COPD is highly fragmented, with elongated spaces or cracks, termed 
“clefts”. This I believe is the primary hallmark of EMT, strongly supported in the 
literature (Acloque et al., 2009; R. Kalluri, 2009; Raghu Kalluri & Neilson, 2003; R. 
Kalluri & Weinberg, 2009; Zeisberg & Neilson, 2009). These elongated spaces and 
cracks or clefts in the Rbm were not empty; they frequently contained cells, and 
these cells I found were positive for mesenchymal markers (S100A4 and vimentin) 
and also for a proteolytic enzyme MMP-9 which increases in abundance during the 
process of EMT. MMPs are thought to assist cell migration by dismantling 
underlying basement membrane as explained in Chapter 4.  
 
Even though I have shown that these cells in the Rbm and basal epithelium are 
positive for mesenchymal markers, these data in themselves do not confirm that these 
cells are of epithelial origin. Therefore to confirm the epithelial origin of these cells 
in the Rbm, I needed to undertake double immunostaining with epithelial and 
mesenchymal markers.  
 
The second major issue with the study presented in Chapter 4 was that I needed to 
address whether our data was confounded by infiltrating inflammatory cells that may 
carry epitopes for MMP-9 and S100A4. To refute this I needed to immunostain 
biopsies from COPD patients for neutrophils, macrophages, fibroblasts, CD4+ and 
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CD8+ lymphocytes, B cells and perhaps most importantly dendritic cells, as S100A4 
is also expressed by dendritic cells (Boomershine et al., 2009).    
 
Therefore, to confirm the epithelial origin of the S100A4 stained cells in the Rbm I 
double-stained biopsies from COPD patients for the epithelial marker cytokeratin 
and the mesenchymal marker vimentin. To address the potential for our S100A4 
staining data to be confounded by infiltrating inflammatory cells we stained 
representative sections from the same tissue blocks for neutrophil elastase 
(neutrophil marker), CD68 (macrophage and mature fibroblast marker) (Beranek, 
2005; Inoue et al., 2005), CD4+/CD8+, CD19 as a B-cell marker (Bertrand et al., 
1997) and CD11c for potential dendritic cells (K. F. Chung & Adcock, 2008), and 
compared the number of cells staining for these markers versus the number staining 
for the S100A4 epitope. 
 
5.2 Material and methods  
Details are given in Chapter 3.  
 
5.2.1 Biopsy analysis and measurements  
This comparison involved bronchial biopsy sections from 10 COPD current smokers 
only. This analysis was an empirical semi-quantative analysis, as cellular changes in 
the Rbm were confirmed in the previous Chapters. For this analysis I had one best 
representative biopsy section from 10 different sections from COPD current smokers 
having maximum cellularity and assessed for different markers (as explained above) 
and results are presented as percentage of cells stained for different markers 
compared to S100A4, details are given below. 
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5.3 Results 
Details of the subjects involved in this study are given in Chapter 4. 
 
5.3.1 Confirming epithelial origin of cells stained for S100A4 in the 
Rbm 
To confirm the epithelial origin of cells in the Rbm I double stained bronchial biopsy 
sections from COPD current smokers for cytokeratins (epithelial marker) and 
vimentin (another mesenchymal marker). This analysis demonstrated that 87 % of 
total cells double-stained for both cytokeratin and vimentin in the Rbm, while the 
rest of the cells were positive for vimentin but not for cytokeratin, presumably 
because these cells had lost epithelial markers during development of EMT (Figure 
5.1). 
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Figure 5.1: Bronchial biopsy specimen from a COPD current smoker, black arrows 
showing cells in the Rbm stained for both cytokeratin (pink or red; epithelial marker) 
and vimentin (brown; mesenchymal marker). Original magnification, x400 
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5.3.2 Comparative analysis of S100A4 staining with that for 
CD4+/CD8+ T lymphocytes and CD19 for B-cells in Rbm 
To address the potential for our data to be confounded by infiltrating CD4+/CD8+ T 
lymphocytes and/or B-cells in the Rbm, I stained and assessed representative biopsy 
sections from COPD current smokers for CD4+ /CD8+ T lymphocytes and CD19 (B-
cell marker) in the Rbm and basal epithelium.  
 
This comparison demonstrated that in the epithelium no cells stained for CD4 or 
CD19, while approximately 4 % cells stained positive for CD8 whereas 68 % of total 
cells stained for S100A4 in the basal epithelium. 
 
 In Rbm no cells stained for CD4 or CD19 and approximately 3 % cells stained 
positive for CD8 whereas 97 % of total cells stained for S100A4. This analysis 
suggested that there are very few T or B lymphocytes within the Rbm or airway 
epithelium (Figure 5.2).  
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Figure 5.2: Bronchial biopsy specimen from a COPD current smoker, black arrows 
showing cells positive for: (A) CD4, mainly in the lamina propria (B) CD8, mainly 
in the lamina propria with very few cells +ve in the basal epithelium or Rbm (C) CD 
19 (B-cell marker), mainly in the lamina propria (D) S100A4 stained cells, in the 
basal epithelium and Rbm, but also in the lamina propria, E (epithelium), LP (lamina 
propria). Original magnification, x630 
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5.3.3 Comparative analysis of S100A4 staining with that for 
dendritic cells 
To address this question I stained and assessed matched representative biopsy section 
from COPD current smokers for CD11c (human dendritic cell marker) (Takano et 
al., 2005) and S100A4. This comparative analysis revealed that in the Rbm only 3.3 
% of the total number of cells were stained for CD11c whereas 96.6 % were stained 
for S100A4, while in the basal epithelium only 1.5 % of the total number of cells 
stained for CD11c while 65 % of total cells stained for S100A4 (Figure 5.3). This 
analysis demonstrated that there were very few dendritic cells in the Rbm and 
epithelium compared to S100A4 positive cells.  
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Figure 5.3: Bronchial biopsy specimen from a COPD current smoker, black arrows 
showing cells in the Rbm stained for: (A) CD11c (dendritic cell marker) and (B) 
S100A4 (mesenchymal marker). Original magnification, x400 
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5.3.4 Comparative analysis of MMP-9 and S100A4 staining with that 
for polymorphonuclear neutrophils (PMNs) and macrophages  
To address the potential for our data to be confounded by infiltrating inflammatory 
cells that may carry epitopes for MMP-9 and S100A4, I stained and assessed, 
representative sections  from the same tissue blocks (as above) for neutrophil elastase 
(neutrophil marker) and CD68 (macrophage and mature fibroblast marker) (Beranek, 
2005; Inoue et al., 2005; Kunz-Schughart et al., 2003). This comparison 
demonstrated that no cells stained for neutrophil elastase or CD68 whereas again 
67.6 % (same data as above) of total cells stained for S100A4 in the basal epithelium. 
In the Rbm no cells stained for neutrophil elastase or CD68 whereas 96.9 % (as 
given above) of total cells stained for S100A4 (Figure 5.4).  
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Figure 5.4: Bronchial biopsy specimen from a COPD current smoker, black arrows 
showing cells positive for: (A) neutrophil elastase (neutrophil marker) mainly in the 
lamina propria; and (B) CD68 (macrophage and mature fibroblast marker) also 
mainly in the lamina propria; (C) S100A4, where there are frequent S100A4 +ve 
cells in the basal epithelium and Rbm, E (epithelium), LP (lamina propria). Original 
magnification, x630 
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5.4 Discussion  
In the previous Chapter, I demonstrated that EMT could well be an active process in 
COPD airways. I showed that the Rbm in COPD is highly fragmented with cells 
staining for S100A4 and MMP-9. In this Chapter, I have followed this up by 
demonstrating that these cells in the Rbm are of epithelial origin, they are not 
infiltrating macrophages or fibroblasts, nor CD4+/CD8+ T lymphocytes or B-cells or 
dendritic cells. Thus, my data has not been confounded by infiltration by 
inflammatory or immune cells. This has been a criticism of my work when it was 
presented at international meetings and from journal reviewers.  
 
To address the epithelial origin of cells in the Rbm I double stained biopsy sections 
from COPD current smokers for the epithelial marker cytokeratin, as well as the 
mesenchymal marker vimentin. This analysis confirmed that the cells in the Rbm are 
of epithelial origin as well as demonstrating a co-staining mesenchymal epitope. Had 
these cells been negative for cytokeratin, this would have been difficult to interpret 
as during development of EMT epithelial cells loose epithelial markers as they gain 
mesenchymal markers. Therefore, a cell which has gone through a complete 
transition will not express epithelial markers. I find the presence of cells staining 
with cytokeratin and still in the epithelium staining for vimentin especially 
suggestive of EMT, but it is not surprising that there are more cells staining for 
vimentin than cytokeratin. Indeed, this is likely to be another signal that EMT is 
active in this epithelium ie that epithelial cells are loosing epithelial markers.  
 
I found that there were very few CD8+ T lymphocytes and no CD4+ T cells or CD19 
B-cell cells in the Rbm and basal epithelium. There were some cells positive for CD4 
and CD19, but these were mainly in the lamina propria region and not in the basal 
epithelium or Rbm as such. I also confirmed that my data was not confounded by 
infiltrating dendritic cells for which I stained sections for CD11c and found that there 
were very few such cells in the basal epithelium and Rbm compared to S100A4. I 
also confirmed that they are not infiltrating neutrophils, macrophages or fibroblasts, 
and most of the cells positive for these markers were observed in the lamina propria 
below the Rbm, and not in the Rbm itself, nor in the basal epithelium in contrast to 
S100A4 positive cells which were very frequent in the Rbm. 
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In summary I have demonstrated that the cells in the Rbm are of epithelial origin, 
and they are not infiltrating macrophages, fibroblasts, CD4+/CD8+ T lymphocytes, 
B-cells nor dendritic cells. These data confirm that EMT is indeed likely to be an 
active process in the airways in smokers and COPD patients, and that my data 
presented in Chapter 4 was not confounded by infiltrating inflammatory or immune 
cells.  
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Chapter 6 
Effect of Inhaled Corticosteroids on Rbm 
Fragmentation: potential for the 
amelioration of EMT 
 
6.1 Introduction  
Inhaled corticosteroids (ICS) are widely used for treatment of COPD even though 
their efficacy is still a matter of debate (Telenga et al.). However, several studies 
have shown that with short term use of ICS lung function is improved in COPD, long 
term use reduces the frequency of exacerbation in those with severe disease. Even so 
it is still likely that some aspects of airway and lung parenchymal inflammation and 
structural changes involved in COPD are less responsive to ICS than in asthma 
(Chanez et al., 2004; Telenga et al.). Bronchial biopsies have been suggested as a 
useful tool to investigate the anti-inflammatory effects of ICS in both asthma and 
COPD, but there are very few studies reporting the effects of ICS on airway 
inflammation and even fewer on structural changes or airway remodelling in COPD 
using bronchial biopsies. The reality is that we really don’t know much about these 
processes and drug efficacy on them, especially in COPD (Chanez et al., 2004).  
 
Hattotuwa and colleagues reported a significant reduction in CD4/CD8 cell ratios in 
the epithelium, and in sub-epithelial mast cells in bronchial biopsies obtained from 
COPD patients in the active ICS arm treated with fluticasone propionate (Hattotuwa 
et al., 2002). Reid and et al reported from observations made in bronchial biopsies 
and BAL from COPD patients, that fluticasone propionate reduced BAL neutrophils 
and epithelial cell numbers and CD68+ macrophages, CD8+ lymphocytes and mast 
cells in bronchial biopsies, but interestingly increased neutrophils in bronchial 
biopsies (D. W. Reid & et al., 2008). In another study it was reported that three 
month treatment with fluticasone propionate significantly decreased mucosal mast 
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cells and increased neutrophils in biopsies from COPD patients (Gizycki et al., 
2002).  
 
The data on effects of ICS on structural changes in COPD is very sparse, and there 
are no studies examining effects of ICS on epithelium. Even the baseline Rbm 
thickness in COPD is in doubt, with some studies reporting abnormally thick Rbm 
and some not (Chanez et al., 2004; Liesker et al., 2009; Postma & Timens, 2006). 
The effects of ICS on the Rbm have not been specifically studied in COPD. Zanini 
and et al, however reported that bronchial vascular remodelling may have potential 
for change with ICS but need further longitudinal studies to confirm that (Zanini & et 
al., 2009).  
 
As described in previous chapters, it is likely that in COPD the epithelium may get 
damaged by cigarette smoke and remodelling may occur in response to cigarette 
smoke-induced damage to the airways and related inflammation (Pera & et al 2010; 
Hu & et al 2009), but the precise mechanisms and details structural changes are 
poorly described in the literature. As already discussed at length, new emerging 
explanation for remodelling in chronic lung diseases is epithelial mesenchymal 
transition (EMT) which involves transition of airway epithelial cells to a 
mesenchymal phenotype and movement through the Rbm to the lamina propria, 
causing Rbm fragmentation (for details  please see Chapter 1, 2, 3 and 4) (Peter K. 
Jeffery, 2004; Brigham C. Willis et al., 2006).  
 
In previous Chapters, I have shown that the Rbm in COPD is highly fragmented, 
with elongated spaces or cracks, which I have termed “clefts”. These, I believe, are 
the hallmark of EMT, strongly suggested by previous non-airway models of EMT 
described in detail in the literature (Acloque et al., 2009; R. Kalluri, 2009; Raghu 
Kalluri & Neilson, 2003; R. Kalluri & Weinberg, 2009; Zeisberg & Neilson, 2009). 
In the previous chapters I described a comprehensive cross-sectional study looking at 
the potential for EMT in COPD and I concluded that EMT is likely to be an active 
process in COPD but a key question which still remains unanswered is whether ICS 
have any potential for amelioration or even reversal of EMT in COPD. Therefore, I 
hypothesized that Rbm fragmentation, a hallmark of EMT is normalised by 
aggressive ICS therapy in patients with COPD. To address this question I used 
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material from a longitudinal study (D. W. Reid et al., 2008) in which COPD subjects 
(current smokers and ex-smokers) entered a double blind randomised controlled trial 
comparing fluticasone propionate (0.5 mg inhaled twice daily) with identical placebo 
for 6 months. 
 
6.2 Hypothesis  
I hypothesized that Rbm fragmentation, a hallmark of EMT is normalised by 
aggressive ICS therapy in patients with COPD.  
 
6.2.1 Aim 
To assess the effect of fluticasone propionate on Rbm fragmentation, which I have 
regarded as the hallmark of EMT. 
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6.3 Methods and materials 
The group demographics of subjects who participated in the study are presented in 
the table given below. As the number of samples available for analysis for different 
markers varied slightly due to loss during processing, the number of samples 
included in each comparison is detailed.    
 
Table 5: Demographic and lung function data for subjects.    
 
 
Data expressed as median and range  
* Post BD values after 400µg of salbutamol  
 Diagnosis of COPD was made according to GOLD guidelines 
 
 
 
 
 
 
 
Groups (numbers) FP (22) Placebo (10) 
GOLD I/GOLD II 10/12 4/6 
Male/female 8/14 3/7 
Age (years) 60(46-69) 62(52-69) 
COPD-CS / COPD-ES 12/10 3/7 
Smoking (pack years) 42(18-150) 54(22-147) 
FEV1% predicted  (Post BD)* 77(55-112) 77(54-94) 
FEV1/FVC %  (Post BD)* 58(41-66) 56(38-67) 
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6.3.1 Biopsy analysis  
All slides were coded and randomised by an independent person (lab manager Steven 
Weston), and then counted (as described in Chapter 3 and 4) by me in a single batch 
while fully blinded to subject diagnosis and phase of the study with quality assurance 
on randomly selected slides provided by a professional academic pathologist 
(Professor HK Muller).    
 
6.3.2 Statistical analysis  
Wilcoxon two related-samples test was used to test the effect of ICS and placebo. 
Associations between variables were assessed using Spearman's rank test. Statistical 
analyses were performed using SPSS 15.0 for Windows, 2003, with a two-tailed P-
value ≤ 0.05 being considered statistically significant. I also performed power and 
sample size calculations for this analysis. This test showed that number of subjects 
smaller than 15 were adequate to find differences for Rbm fragmentation before and 
after treatment with alpha error 5% and beta error 80%. Richmond et al showed in 
studies done with airway biopsies (cellular quantitative studies) that sample size of 
15 are adequate (Richmond, Booth, Ward, & Walters, 1996).  
 
6.4 Results 
 
6.4.1 Rbm fragmentation  
The length of the individual “clefts” was measured, summed and results expressed as 
percentage of the total Rbm length to give a comparable measure of the degree of 
Rbm fragmentation for each individual. The degree of fragmentation decreased 
significantly (p=0.03) in the treatment arm (fluticasone propionate) (Figure 6.1) and 
when compared to placebo (p=0.4). At the end of treatment, there was no longer any 
difference between normal controls and COPD subjects who had received ICS 
(p=0.7) for Rbm fragmentation, while in the placebo group fragmentation was still 
increased above normal compared (p=0.02). Thus, inhaled steroids normalised Rbm 
fragmentation over 6 months of treatment (Figure 6.2).  
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Figure 6.1: The percentage decrease in clefts (or Rbm fragmentation) in the Rbm per 
mm of Rbm on treatment with (A) fluticasone propionate (p=0.03) and (B) placebo 
(p=0.4), the horizontal bars represent the medium.  
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Figure 6.2: The Rbm fragmentation (given by % of clefts) is normalised on 
treatment with (A) ICS (fluticasone propionate) (p=0.7), but not with (B) placebo 
(p=0.02), compared to normal controls, the horizontal bars represent the medium.  
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6.5 Discussion  
This is the first study reporting the potential of fluticasone propionate for affecting 
Rbm fragmentation and hence EMT. But since I am the first to describe 
fragmentation and potential EMT in COPD airway biopsies this is perhaps not 
surprising! In this study I have shown that Rbm fragmentation, which my reading of 
the literature has brought me to believe is a hallmark of EMT (Acloque et al., 2009; 
R. Kalluri, 2009; Raghu Kalluri & Neilson, 2003; R. Kalluri & Weinberg, 2009; 
Zeisberg & Neilson, 2009) is responsive to ICS, and indeed effectively normalised 
by it, at least on average although there was some variation in response. 
 
ICS are considered to be the most effective therapy for the treatment of chronic 
inflammatory disorders such as asthma, although they may be rather less effective in 
control of inflammation in other inflammatory airway disorders such as COPD and 
cystic fibrosis. However, there are studies showing that ICS have been beneficial in 
controlling inflammation to some extent in COPD, but there are hardly any studies 
reporting effects of ICS on structural changes or airway remodelling in COPD using 
bronchial biopsies apart from one study reporting potential for bronchial vascular 
remodelling (Gizycki et al., 2002; Hattotuwa et al., 2002; D. W. Reid et al., 2008; 
Zanini et al., 2009). In asthma Ward et al from our group have shown that Rbm 
thickness does decrease significantly on 12 months treatment with fluticasone 
propionate, closely related to the slow phase of improvement in BHR (bronchial 
hyper-responsiveness) that occurs, showing potential for ICS in airway remodelling 
more generally (Ward et al., 2002).  
 
EMT is well described in post lung transplant in chronic airway rejection (known as 
BOS, bronchiolitis obliterans syndrome) and it is suggested that EMT may be a 
potential link between inflammatory injury and airway remodelling in this situation 
(Borthwick et al., 2009; Ward et al., 2005). However, there have been no previous 
studies reporting EMT in COPD to the best of my knowledge. Even so I believe that 
I have now provided evidence that EMT is an active process in COPD airways (as 
explained in Chapter 1, 4 and 5), and  have now taken this one step further in 
showing that this is positively affected by ICS. This is a key issue, for although ICS 
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do seem to have positive clinical effects in COPD, the science behind this has been 
somewhat opaque.   
 
On a negative note, I accept that this study is limited by the fact that I haven’t 
undertaken comprehensive longitudinal analysis with direct cellular markers of EMT 
as described in Chapter 4, and this was due to time limits I had with my PhD 
submission. Even so, I have used Rbm fragmentation, generally regarded as a central 
hallmark manifestation of active EMT as the outcome measure in this analysis, and 
will follow it up with future analysis of Rbm cellularity and specific cellular EMT 
markers.  
 
In summary I have shown that fluticasone propionate has potential for normalising 
EMT, using quantitation of Rbm fragmentation as the illustrative manifestation of 
the process in COPD airways. I need now a comprehensive longitudinal follow-up 
study with a wider range of markers of EMT (for e.g. S100A4, vimentin, 
cytokeratins) to confirm and extend these prelimnary findings.  
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Chapter 7 
HDAC2 in COPD 
 
7.1 Introduction 
As already described in detail in Chapter 2, COPD is characterized by progressive 
inflammation of the airways (and destruction of the lung parenchyma) mediated by 
increased expression of inflammatory genes, in response to noxious particles, gases 
and especially tobacco smoke (Barnes, 2003). In COPD a specific pattern of airway 
inflammation is mainly characterized by increased numbers of neutrophils, 
macrophages and T-lymphocytes, predominantly cytotoxic (CD8+) cells (Barnes et 
al., 2005; Saetta et al., 1993; Saetta et al., 1998; Saetta et al., 1997; Saetta, Turato, 
Maestrelli, Mapp, & Fabbri, 2001). The increased expression of these inflammatory 
genes is regulated by acetylation of core histones around which DNA is wound, 
allowing access of pro-inflammatroy transcription factors to transcription-regulatory 
sites. On the other hand these activated genes are switched off by deacetylation of 
these histones (Chapter 2) (Barnes et al., 2005). Examples of the transcription factors 
involved in this regulatory system in airway diseases are nuclear factor-Kappa B 
(NF-κB), activator protein-1 (AP-1) and also the activated glucocorticoid receptors 
(Barnes, 2006d). These are all at least partly controlled by this histone 
acetylation/deacetylation mechanism.  
 
COPD responds relatively poorly to therapeutic corticosteroids, even though steroids 
have been shown to have effects both in the short term and long term use. As 
discussed in Chapter 2 there is emerging evidence that corticosteroids resistance in 
COPD is due to decrease in histone deacetylase -2 (or HDAC-2) (Barnes, 2006c; Ito 
et al., 2001). Though exact mechanisms are still not clearly understood, it is 
suggested that it may involve modulation of HDACs by nitrosylation on distinct 
tyrosine residues in response to tobacco smoke (Barnes et al., 2005).   
 
Since 1960, it has been known that acetylation of DNA-associated histone proteins 
and remodelling of the tightly packed chromatin structure is associated with 
178 
 
induction of genes (Littau et al., 1965).  Histone and chromatin remodelling is central 
to gene expression and regulation through the process of acetylation, deacetylation 
and also methylation, though this is even less understood (Barnes et al., 2005; Rice & 
Allis, 2001). Research regarding the exact role of histone acetylation and 
deacetylation in chronic inflammatory disease is only in its infancy, and even more 
so in COPD, where the picture has probably been made rather over-simplistic, as 
indeed the degree of absolute ICS insensitivity has been exaggerated. However, there 
is significant body of literature (as explained in Chapter 2) suggesting that expression 
and activity of anti-inflammatory HDAC2 are reduced in COPD lungs, airways and 
alveolar macrophages and becomes worse with severity of the disease (Barnes, 
2006c; Ito et al., 2001). 
 
The methodology that has been used was not comprehensive enough to identify the 
changes in total cellularity in the lamina propria and largely dependent on molecular 
RNA quantitation and protein analysis which could not take into account relative 
differences in cellular profiles in airway tissues in different disease and control 
groups, where biases could arise due to differences in total and differential 
cellularity. There has been a serious lack of comprehensive biopsy studies to confirm 
the extent of suppressed HDAC2 levels by immunostaining within the airways of 
COPD; which can take into account cell numbers and type, its reversibility with ICS 
or smoking cessation. Therefore, I designed a detailed cross-sectional study and used 
material collected in a longitudinal study (D. W. Reid et al., 2008), for looking in 
detail at the status of HDAC2 expression in COPD airways.   
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7.2 Hypothesis 
I hypothesized that the current literature is correct in that HDAC2 is down-regulated 
in COPD airways, and that these reduced HDAC2 levels are normalised by 
aggressive ICS therapy and also smoking cessation in patients with COPD.  
 
7.2.1 Aims 
1. To confirm the extent of suppressed HDAC2 by immunostaining airway biopsies 
from COPD current smokers and also from normal lung function smokers to 
understand whether changes in HDAC2 are solely related to COPD or smoking 
or both.  
 
2. To confirm the potential of smoking cessation to raise HDAC2 expression by 
comparing airway biopsies from COPD ex-smokers versus current smokers with 
COPD, and  the potential for HDAC2 expression to be normalised by aggressive 
ICS therapy.  
 
 
7.3 Methods and materials  
 
7.3.1 Subjects and study design  
The studies involved both detailed cross-sectional and longitudinal analyses. In the 
cross-sectional study, 17 current smokers with established COPD (CS), 16 current 
smokers with normal lung function (NS), 17 ex-smokers with COPD (ES) and 15 
normal healthy, never-smoking controls (NC) were recruited for bronchoscopy and 
airway biopsy. In longitudinal analysis the COPD subjects further entered a double 
blind randomised controlled trial comparing fluticasone propionate (0.5 mg inhaled 
twice daily) with placebo for 6 months (details given in Chapter 3).  
 
7.3.2 Bronchoscopy 
Details are given in Chapter 3.  
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7.3.3 Processing of biopsies and immunostaining 
Sections were stained with monoclonal antibodies: anti-HDAC2, together with a 
horseradish peroxidase (HRP) conjugated DAKO Envision + reagent for secondary 
antibody binding and colour resolution using diaminobenzidine (DAB) (details given 
in Chapter 3).  
 
7.3.4 Biopsy analysis  
Details are given in Chapter 3.  
 
7.3.5 Statistical analysis  
As data were not normally distributed (tested by kolmogorov smirnov & Shapiro 
Wilk test), a non-parametric ANOVA (Kruskal Wallis Test) was undertaken, and 
specific group differences then explored using the Mann Whitney U test. Wilcoxon 
two related-samples test was used to test the effect of ICS and placebo in the 
longitudinal study. Associations between variables were assessed using Spearman's 
rank test. Statistical analyses were performed using SPSS 15.0 for Windows, 2003, 
with a two-tailed P-value ≤ 0.05 being considered statistically significant (details are 
given in Chapter 3).  
.  
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7.4 Results (cross-sectional analysis) 
The group demographics of subjects who participated in the study are the same as 
presented Chapter 4.  
 
7.4.1 HDAC2 expression in the airway epithelium 
HDAC2 expression in the airway epithelium (as measured by percentage area of 
epithelium stained for HDAC2) was not different between the groups (p=0.7, Figure 
7.1 and 7.2).     
 
7.4.2 Total cellularity of the lamina propria  
There, was a significant reduction in total number of cells in lamina propria in 
COPD-CS compared to NC (p=0.04) (Figure 7.3 and 7.1). This total cell change 
strongly negatively correlated to smoking history (R = -0.8, p<0.003) (Figure 7.6). 
No association was found with lung function measurements.    
 
7.4.3 HDAC2 positive cells in the lamina propria 
Compared to NC there was a significant reduction in HDAC2 positive cells in the 
lamina propria in COPD-CS (p=0.02). Interestingly, normal lung function smokers 
had significantly more HDAC2 positive cells in the lamina propria compared to 
COPD-CS (p<001), ie smoking actually seems to be stimulating anti-inflammatory 
HDAC2. There were significantly more HDAC2 positive cells in COPD-ES 
compared to COPD-CS (p=0.04) (Figure 7.4 and 7.1); ie COPD-CS smokers were 
essentially normalised. No association was found with lung function measurements.    
 
7.4.4 Percentage cell HDAC2 staining in the lamina propria 
For percentage cell HDAC2 staining (ie taking into account total cell numbers) 
normal lung function smokers were significantly different from all other groups 
(p<0.001, with smoking again apparently stimulating anti-inflammatory HDAC2), 
but COPD-CS, ES and NC were quite similar (p=0.42) (Figure 7.5). No association 
was found with lung function measurements.    
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Figure 7.1: Bronchial biopsy section from (A) normal control; (B) normal lung 
function smoker; (C) COPD current smoker; and (D) COPD ex-smokers: (black 
arrows) brown staining indicates HDAC2 positive cells in the epithelium and in the 
lamina propria, black arrows, also indicating decreased cellularity in the LP in (B) 
and (C). Original magnification, x400.    
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Figure 7.2: Percentage of area of epithelium stained for HDAC2 in COPD current 
smokers and ex-smokers, normal lung function smokers compared to normal controls 
with no significant difference between groups. Horizontal bars represent the median 
for each group.  
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Figure 7.3: Total number of cells in the lamina propria per Sqmm of lamina propria; 
†significant difference from NC (p=0.04).  
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Figure 7.4: Number of HDAC2 positive cells in the lamina propria per Sqmm of 
lamina propria; †significant difference from NC (p=0.02); significant difference 
from COPD-CS (p<0.001); *significant difference from COPD-CS (p=0.04). 
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Figure 7.5: Percentage cell staining for HDAC2 in the lamina propria per Sqmm of 
lamina propria; significant difference from COPD-CS, ES and NC (p<0.001).  
 
 
 
 
 
 
 
187 
 
 
 
 
 
 
Figure 7.6: Correlation between total number of cells per Sqmm of lamina propria in 
COPD-CS and smoking (pack years). 
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7.5 Longitudinal ICS intervention study 
The group demographics of subjects who participated in the study are the same as 
presented Chapter 6.  
 
7.5.1 HDAC2 expression in the airway epithelium 
Six months of treatment with fluticasone propionate (active arm; p=0.2, placebo; 
p=0.5) made no difference on HDAC2 expression in the airway epithelium (Figure 
7.7).  
   
7.5.2 HDAC2 positive cells in the lamina propria 
There was no difference observed before versus after treatment for HDAC2 positive 
cells in the lamina propria (active arm, p=0.5 and placebo; p=0.3, Figure 7.8). I also 
observed that there was no change in the total number of cells in the lamina propria 
before and after treatment (active arm, p=0.5 and placebo; p=0.8, Figure 7.9). Thus, 
percentage cell HDAC staining was also not different before and after treatment 
(active arm, p=0.5 and placebo; p=0.8, Figure 7.10). 
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Figure 7.7: The percentage change in HDAC2 in the epithelium on treatment with 
(A) fluticasone propionate and (B) placebo, the horizontal bars represent the 
medium. There was no significant difference comparing before and after treatments.  
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Figure 7.8: Number of HDAC2 positive cells in the lamina propria per Sqmm of 
lamina propria on treatment with (A) fluticasone propionate and (B) placebo: the 
horizontal bars represent the mediums. There was no significant difference 
comparing before and after treatments.  
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Figure 7.9: The total number of cells in the lamina propria per Sqmm of lamina 
propria on treatment with (A) fluticasone propionate and (B) placebo: the horizontal 
bars represent the mediums. There was no significant difference between before and 
after treatments.  
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Figure 7.10: Percentage cell staining for HDAC2 in the lamina propria per Sqmm of 
lamina propria; (A) with fluticasone propionate and (B) with placebo: the horizontal 
bars represent the mediums. There was no significant difference comparing before 
and after treatments.  
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7.6 Discussion 
To the best of my knowledge, this is the first detailed biopsy immunostaining study 
looking at the status of HDAC2 expression in COPD and its potential reversibility 
with ICS or/and smoking cessation (albeit the latter in a cross-sectional study only at 
this stage).  
 
The airway epithelium showed strong positivity for HDAC2 staining/expression but, 
interestingly this was not different between the groups. Although COPD current 
smokers showed a slight decrease in HDAC2 staining in the epithelium (as 
percentage of HDAC2 area of staining in the epithelial area measured), this was not 
statistically significant when compared to normal controls. However the difference 
between groups, even if real, hardly suggests that this is a major effect and HDAC2 
is more variable between individuals than groups. The fact that HDAC2 expression 
in the epithelium is well preserved in smokers (even if little less in current smokers 
COPD subjects) suggest that ICS may still be effective in this tissue compartment, as 
the CS-GCR complex should be able to access its transcription sites as CS-sensitive 
genes.  
 
In the lamina propria the data were very striking. I found that there was a decrease in 
the total number of cells in the lamina propria in COPD current smokers compared to 
normal controls. This total cell change was strongly related to smoking history and is 
an effect not previously described.  Normal lung function smokers also showed a 
slight decrease in total cellularity whilst the COPD-ES group showed a normalisation 
in total cellularity.  
In the COPD subjects the plot clearly indicates that smoking is affecting the total 
cellularity of the lamina propria.  Notably, if I had used molecular techniques as used 
by the Barnes group, etc I would have come to a false conclusion as I would not be 
aware that there is a dramatic change in total cellularity in the lamina propria, largely 
causing the apparent down regulation of HDAC2 mRNA and decreased protein 
content. For example (as explained in Chapter 2 as well), Ito et al (Ito et al., 2001), 
showed by using western blotting that HDAC2 protein content was reduced in 
bronchial biopsies from normal lung function smokers compared to normal controls, 
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but looking now at the images they actually published in their paper (but which they 
did not comment on), it is quite clear that total cellularity of the lamina propria in 
their normal lung smokers was also substantially less than in their normal controls. 
But, as stated above, their analysis did not take into account the overall decrease in 
cellularity and therefore the consequential total protein available. ICS made no 
difference to the total number of cells in lamina propria.  
Our data for HDAC2 positive cells in the lamina propria was quite interesting as 
well. It suggested that HDAC2 positive cells decrease in the lamina propria of 
current smokers with COPD compared to normal controls and on the other hand 
there was an increase in HDAC2 positive cells in the lamina propria of COPD ex-
smokers compared to COPD current smokers; essentially returning to normal. Data 
on normal lung function smokers was quite remarkable; paradoxically they had 
significantly higher numbers of HDAC2 positive cells in the lamina propria. This 
suggests that smoking is actually stimulating anti-inflammatory HDAC2 levels, 
although ICS made no difference to HDAC2 positive cells in lamina propria.  
 
The data on percentage cell staining for HDAC2 further confirmed the above data on 
normal lung function smokers that the percentage HDAC2 staining was also 
significantly high in normal lung function smokers compared to other groups, but 
COPD-CS, COPD-ES and NC were quite similar to each other. This strongly 
confirms at least the possibility of smoking stimulating anti-inflammatory HDAC2 
expression in chronic smokers. However, the decrease observed in COPD in relation 
to HDAC2 does seem most likely due to changes in cellularity, and not HDAC2 
itself. ICS made no difference to percentage cell HDAC2 staining. 
 
Taken together, these data suggest that smoking itself stimulates the HDAC2 
expression while COPD does not seems to be affecting the HDAC2 status itself, but 
the apparent decrease in HDAC2 observed in COPD current smokers is due to 
confounding by changes in total cellularity, which itself is strongly negatively related 
to smoking history. Quitting does seem to have a potential for upregulating HDAC2 
at a cell level as shown by an increase in number of cells positive for HDAC2 in the 
lamina propria of COPD ex-smokers and further supported by slight increase in 
percentage cells staining in COPD ex-smokers, although this was not statistically 
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significant when compared to COPD current smokers (type 2 error). Most of the 
effect seems related to change in total cell numbers. However, we need long term 
smoking cessation studies with larger cohorts to confirm and tease out these findings.  
 
More precisely, the key finding is the difference in HDAC2 expression in normal 
lung function smokers and decrease in cells in COPD current smokers. It probably 
suggests that smoking stimulates anti-inflammatory HDAC2 in non-COPD smokers, 
but in those who develop COPD then HDAC2 goes down but mainly due to decrease 
in cellularity of lamina propria and not HDAC2 expression itself. Moreover the 
status of HDAC2 is not different in the epithelium in either smokers or COPD. So 
essentially smoking is stimulating HDAC2, but decreasing the total lamina propria 
cellularity in COPD current smokers. It is possible that this difference between 
smokers with and without COPD may be important in the aetiology of COPD ie if in 
an individual smoking decreases cells more than stimulating anti-inflammatory 
HDAC2, then COPD might ensue.  
 
I cannot say at this stage which particular cell type(s) is decreased in the lamina 
propria in smokers. For more information I would need double staining studies for 
different cells in the lamina propria ie HDAC2 plus specific cell type marker. It is 
also suggested that in COPD there is increased apoptosis but this is controversial and 
is not clearly established. However, increased oxidative stress produced by tobacco 
smoke and protease–antiprotease imbalance, and also genetic susceptibility, may 
contribute to increased apoptosis in COPD airways (Park, Ryter, & Choi, 2007; 
Plataki et al., 2006). In another parallel study in our group (Soltani A, 2009 ) we 
found that there is a significant reduction in total number of vessels in the lamina 
propria in smoking/COPD, so decreased vascular supply might be contributing to 
decreased cellularity in COPD airways, but we need further studies to confirm that.  
 
In summary, our data suggest that HDAC2 expression is increased in normal 
smokers but reduced in current smokers with COPD, though the latter seems largely 
due to confounding by changes in cellularity in the lamina propria but not in HDAC2 
itself. Quitting does seem to have a real effect on up-regulating HDAC2 at a cell 
level, but it is not affected by ICS. We need comprehensive immunohistochemical 
studies to fully understand cellular changes in the lamina propria and prospective 
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long term smoking cessation studies with larger cohorts to confirm these findings.  
Molecular methods must take such changes in the cellular environment into account 
and cannot be taken on simple face value; indeed the current published data is likely 
to be misleading because this was not taken into account.  
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Chapter 8 
Summary and General Discussion 
 
8.1 Overview 
COPD is a multifaceted disease, with underlying pathophysiology not clearly 
understood. It is pathologically and physiologically complex with a number of 
overlapping and interacting components. However, physiologically it has been most 
defined by irreversible airway obstruction and pathologically by chronic airway 
inflammation leading to airway wall remodelling and thickening. Symptoms may 
include impaired exercise capacity and dyspnoea and if associated with chronic 
bronchitis, patient will also have chronic productive cough. Tobacco smoking is 
considered as the main aetiological factor associated with the disease at least in 
western countries, but why only a minority of smokers develop COPD is not clearly 
understood (details of this discussion are given in Chapter 2).  
 
My thesis reports very novel findings of Rbm fragmentation which I propose as the 
“hallmark” of EMT in COPD, not described in the literature before. This will add 
significantly to the body of literature on airway remodelling. My finding will also 
add to the corpus of knowledge on the status of anti-inflammatory HDAC2 in COPD. 
The thesis is divided into five main chapters of results. The first chapter involved a 
prelimnary study into EMT in COPD current smokers followed by a more definitive 
cross-sectional study into EMT markers in Chapter 4. In Chapter 5, I further 
confirmed EMT by taking into account potential confounding by inflammatory and 
immune cells. Chapter 6 was a longitudinal analysis into the effects for potentially 
normalising Rbm fragmentation. Chapter 7 involved a cross-sectional and 
longitudinal analysis looking at the status of HDAC2 expression in COPD and its 
potential modulation with ICS and/or smoking cessation. 
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8.1.1 Preliminary observations 
In the preliminary observations described in Chapter 1, I found that the Rbm in 
COPD current smokers has highly fragmented with elongated spaces and cracks 
(termed “clefts”) with cells within them. The literature strongly suggested that this 
could be a hallmark of EMT (Acloque et al., 2009; R. Kalluri, 2009; Raghu Kalluri 
& Neilson, 2003; R. Kalluri & Weinberg, 2009; Zeisberg & Neilson, 2009). 
Following this initial exciting finding I undertook a preliminary study using the 
classic EMT markers most favored in literature (S100A4, MMP-9 and EGFR) 
applied to sections from bronchial biopsies obtained from COPD current smokers, as 
I thought it likely that EMT would be most active in these individuals.  
 
This preliminary study demonstrated that the Rbm in subjects with COPD who are 
current smokers is indeed consistently highly fragmented and that this appeared to be 
associated with cells expressing the proteolytic enzyme MMP-9. Epithelial 
expression of EGFR suggested that epithelial cells may be primed for migration, and 
increased expression of the fibroblast marker S100A4 suggested phenotypic 
transition to a mesenchymal cell type. These preliminary data suggested that EMT 
could be active in COPD pathology. Thus, I designed a comprehensive cross-
sectional study into the potential for active EMT in COPD, asking whether it is 
specific to COPD and/or smoking or both, and used material from a longitudinal 
therapeutic study to see if ICS has any potential for reducing Rbm fragmentation 
(which is a central feature of EMT).  
 
As a part of my thesis, I also decided to study the status of HDAC2 in COPD. It is 
suggested that expression and activity of HDAC2 is decreased in COPD due to 
increased oxidative stress, secondary to airway inflammation, it has also been 
suggested this may induce (relative) resistance to inhaled corticosteroid therapy in 
COPD/smokers but there is little confirmatory data on this, especially outside of the 
Peter Barnes group in London, which is highly committed to this theory. In fact, 
COPD is responsive to ICS though relatively less clinically, compared to asthma, but 
this is largely ignored in this conceptual model.  Moreover, the methodology used by 
the Barnes group is questionable and largely dependent on molecular RNA 
quantitation and protein analysis which could not take into account relative 
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differences in cellular profiles in airway tissues in different disease and control 
groups, where biases could arise due to differences in total and differential 
cellularity. For the protein assays Barnes team attempted to normalise biopsy-
extracted proteins against bovine serum albumin (BSA) and mRNA RT-PCR assays 
with a so called house-keeping gene GAPDH (glyceraldehyde-3-phophate 
dehydrogenase) and beta-actin, but it is not clear to me, if this is an adequate way to 
allow for a change in the cell sub population of interest, for example inflammatory 
cells in the lamina propria. These house-keeping genes can cause confounding 
(Glare, Divjak, Bailey, & Walters, 2002), but they would also reflect the more global 
environment of the airway with all its complexity. Therefore, the second aspect of 
my thesis involved a comprehensive immunohistochemical cross-sectional and 
longitudinal analysis investigating the status of HDAC2 expression in COPD and 
asking whether smoking cessation and/or ICS therapy have any potential to raise 
HDAC2 airway levels in COPD.  
 
8.1.2 Rbm fragmentation and potential EMT in smoking and COPD 
This study as introduced above and described in detail in Chapter 4 and Chapter 5, 
was a comprehensive cross-sectional analysis into the potential for active EMT in 
COPD, whether it is specific to COPD and/or smoking or both. In this study I found 
that Rbm is highly fragmented in both smokers and COPD patients, but especially in 
current smokers with COPD Rbm fragmentation positively correlated with smoking 
history in the smoking COPD subjects.  
 
Markers of EMT were evident in bronchial biopsies from smokers and COPD 
patients. Dual immunostaining for S100A4 and vimentin in the basal epithelium and 
Rbm further strengthened the likelihood that these cells are undergoing transition to a 
mesenchymal phenotype. COPD ex-smokers were more variable but mostly quite 
similar to COPD. For S100A4 cells in the Rbm, there were significant more positive 
cells in current smoking COPD than both other comparator groups (COPD-ES and 
NS).  
 
The only significant relationship with degree of physiological fixed airflow 
obstruction was with S100A4 cells in the basal layer of the epithelium in the current 
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smoking COPD group. These data taken together suggested that the remodelling 
changes are more exaggerated in established COPD as might be expected, especially 
in COPD with active current smoking, and that the changes we describe and attribute 
to likely EMT, may well be of pathophysiological relevance. 
 
The positive findings for EMT markers in smokers with normal lung function, 
compared to normal non-smokers, suggest that smoking itself has the potential to 
initiate EMT. Furthermore, our data in the ex-smoker COPD group suggest that once 
these changes are initiated they may be irreversible. However, the observations that 
there fewer cells expressing S100A4 in ex-smokers in COPD ex-smokers in the Rbm 
but no difference in basal epithelial cell S100A4 staining, may suggest that migration 
from the epithelium across the Rbm decreases following smoking cessation, to 
confirm this I need long term smoking cessation.  
 
In summary, the main message of the study was that smoking has potential to initiate 
EMT, including Rbm fragmentation, but that this is most marked in currently 
smoking COPD. It also suggested that smoking cessation has the potential to reverse 
the process to some extent. 
 
 The potential criticism of the study is that the cells in the Rbm positive for S100A4 
could be infiltrating inflammatory or immune cells rather than epithelial cells 
undergoing transition. So, to confirm the epithelial origin of these cells in the Rbm 
and to address the potential for our data to be confounded by infiltrating 
inflammatory or immune cells, I undertook double immunostaining with epithelial 
and mesenchymal markers and also specific comparative staining for infiltrating 
inflammatory or immune cells in matched slides. 
 
8.1.3 Confirming EMT 
In Chapter 5, I followed on from Chapter 4 and undertook double immunostaining 
with epithelial and mesenchymal markers and also specific comparative staining for 
infiltrating inflammatory or immune cells in matched slides. The comparative 
analysis demonstrated that these cells in the Rbm are of epithelial origin (by double 
staining for cytokeratin) and they stained with a mesenchymal marker (vimentin) 
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suggesting phenotype change; and they are not infiltrating macrophages or 
fibroblasts, nor CD4+/CD8+ T lymphocytes or B-cells or dendritic cells. This further 
confirmed EMT and also demonstrated that my data is not confounded by infiltrating 
inflammatory or immune cells.  
 
8.1.4 Effect of ICS on Rbm fragmentation: potential for the 
amelioration of EMT 
In the previous chapters (as shown above), I concluded that EMT is likely to be an 
active process in COPD. A key question is whether ICS have any potential for 
amelioration or even reversal of EMT in COPD. To answer this question I performed 
a longitudinal analysis, described in Chapter 6. This analysis revealed that 
fluticasone propionate has potential for normalising EMT in COPD using 
quantitation of Rbm fragmentation as the illustrative and “classic” manifestation of 
the process. The study was limited by the fact that I haven’t yet undertaken 
comprehensive longitudinal analysis with direct cellular markers of EMT as 
described in Chapter 4, but this was due to the time limits I had with my PhD 
submission. However, I need now complement this work with a wider range of 
markers of EMT to confirm and extend these prelimnary findings.  
 
8.1.5 HDAC2 in COPD 
As part of my thesis I also looked at the status of HDAC2 expression in COPD and 
smoking using immunohistochemistry and its potential modulation with ICS and/or 
smoking cessation, described in detail in Chapter 7. This was the first comprehensive 
airway biopsy study looking at the status of HDAC2 in COPD and smoking.  
 
The data regarding HDAC2 was very striking and quite different to what others have 
reported using molecular techniques. Interestingly, HDAC2 expression was not 
different in the epithelium between the groups. The fact that HDAC2 expression in 
the epithelium is well preserved in smokers (even if little less in current smokers 
COPD subjects) suggest that ICS could still be effective in this tissue compartment, 
as the CS-GCR complex should be able to access its transcription sites on CS-
sensitive genes.  
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I found that smoking has the potential to stimulate total HDAC2 expression, 
potentially increasing the anti-inflammatory environment in the airway wall, as 
shown in normal lung function smokers. This does seem to be through a direct action 
on HDAC2 status itself, as the total numbers of cells in lamina propria were lower 
than normal in number while total HDAC2 positive cells were higher in number 
(significantly) and percentage HDAC2 positive cells therefore were also increased 
(significantly). In contrast, a decrease in HDAC2 was observed in COPD current 
smokers (described in terms of reduction in HDAC2 positive cells in the lamina 
propria), but this was largely due to confounding by a decrease in total lamina 
propria cellularity compared to normal, this lowering in cell number was strongly 
negatively related to smoking history. The percentage of HDAC2 positive cells in 
COPD current smokers was down slightly compared to normal but not significantly 
so. There was a significant difference in HDAC2 percentage cell staining between 
smokers with COPD (lower than normal) and physiologically normal smokers 
(higher than normal, as above) 
 
Quitting smoking did seem to have a potential for up-regulating HDAC2 at a cell 
level as shown by an increase in number of cells staining positive for HDAC2 in the 
lamina propria of COPD ex-smokers and also a slight increase in the percentage cells 
staining. However, we need long term smoking cessation studies with a larger 
cohort/size to confirm these findings. 
 
A key finding, I believe, is the difference in HDAC2 expression between normal 
lung function smokers and COPD current smokers. This may reflect a fundamental 
difference between individuals in response to cigarette smoke and through this 
vulnerability to developing COPD ie if in an individual smoker decreases cells more 
than stimulating anti-inflammatory HDAC2, then COPD might ensue.  Moreover the 
status of HDAC2 is not different from normal in the epithelium in either smokers or 
in COPD. ICS made no difference to HDAC2 status in COPD, with little likelihood 
of a type-2 error in this finding. 
 
We now need comprehensive immunohistochemical studies to fully understand 
smoking-related cellular changes in the lamina propria especially in COPD, and 
prospective long term smoking cessation studies with large cohorts to confirm these 
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findings.  Molecular methods must take such changes in the cellular environment 
into account and cannot be taken on simple face value; indeed the current published 
data is likely to be misleading because this may not have been taken adequately into 
account. 
 
8.2 Final Conclusions  
My findings reported in this thesis have confirmed that EMT is an active process in 
COPD and is most likely initiated by smoking, but most exaggerated in active 
smoking COPD. Smoking cessation and ICS both have the potential to reverse the 
process of EMT. This finding of EMT in COPD adds to understand about the 
remodelling process in COPD and to knowledge on pathophysiology of COPD. It 
may also help to understand why lung cancer is so common in smokers with COPD, 
and indeed why it is so aggressive, invasive and fatal in over 80% of cases. 
Observations regarding the status of HDAC2 in COPD reported in this thesis are 
novel and will rebalance the bias currently in the literature. The data confirm that 
HDAC2 expression is stimulated in physiologically normal smokers, but down-
regulated in smoking COPD individuals but the latter effect is due to smoking-
related decrease in lamina propria cellularity.   
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Response to examiners 
 
Response to examiner 1 
 
 
 
List of figures and tables are missing. 
I agree with the examiner’s comment and a list of figures and tables is now provided 
in the thesis.  
 
Chapter 1 
Primary comment 
The link between COPD and lung cancer should be discussed, given the known 
correlation between TGF-induced EMT and cancer metastasis and the 
susceptibility of COPD subjects to lung cancer. Were all of the patients in the 
preliminary study cancer-free? 
All patients were cancer free clinically, radiologically and bronchoscopically at the 
time of the studies, and we are not aware of any subsequent change in status. I 
acknowledge the examiner’s comment that there was little discussion of the potential 
link between COPD and lung cancer, in an attempt to avoid being over-speculative. 
But it is a reasonable point, and I have included some discussion on Chapter 1 page 9 
and 10. 
 
Minor comments  
Re EMT in lung transplantation and investigation of EMT markers on 
epithelial cells: Borthwick is quoted but the previous reports by Ward 2005 and 
Hodge 2009 should also be referenced here. 
In the introduction from Chapter 1, Ward 2005 was quoted as a reference 5 times and 
in the discussion 4 times. I agree with the examiner’s comment that reference from 
Hodge 2009 was not quoted because the study reported by Hodge and et al was 
mainly an in-vitro cell culture study, but was quoted in  Chapter 2 (literature review), 
pages 77 and 78 of the thesis. 
 
Chapter 2  
Primary comments 
Given the important role played by HDAC-I in TGF induced EMT (Lei rnt J 
Biochem Cell BioI 2010) and applicant's focus on EMT in COPD; it is puzzling 
why HDAC-I was not also investigated. 
I agree with the examiner’s comment that HDAC1 may play an important role in 
TGF-induced EMT, but the aim of the study was to first confirm EMT in COPD (as 
this is the first study in the literature reporting active EMT in COPD), which in itself 
was a very comprehensive study. Now that we have confirmed that EMT is active in 
COPD, the next aim of this programme will be to investigate the driving mechanisms 
behind EMT in COPD and HDAC1 would be a very reasonable target. We already 
have NHMRC grants pending to take this work further. I have not added any 
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comment on HDAC1 to the thesis, as it is not immediately relevant to my work 
described in the thesis. 
 
P62, Figure 2.19. This is of very poor quality in my version and should be re-
done. 
I thank the examiner for this and the Figure 2.19 is now re-done as suggested 
(Chapter 1 page 63).  
 
 
 
Minor comments  
Page 17. What are figures in A$. 
Financial figures are now given in A$ on page 18. 
 
Chapter 3 
Primary comments 
3.1 Introduction line 15. Was this really a longitudinal study (that involves 
repeated observations of the same items over long periods of time)? Or a 
double-blind, placebo controlled randomised trial? 
It was indeed a double blind randomised controlled trial comparing fluticasone 
propionate (0.5 mg/twice daily) with placebo for 6 months as explained on page 
number 101. It was also, of course ‘longitudinal’, but I take the point being made and 
have altered the title of the chapter accordingly (page number 177). 
 
I assume that the pharmaceutical company supported this study? Was their 
approval necessary or obtained? 
The original basic clinical and bronchoscopic study was supported by GSK. It 
covered the first phase of analysis which involving clinical and inflammatory 
outcomes. This work has been published (Reid et al., 2008), and formed the core of 
the thesis presented successfully in 2006 by Dr. Yudong Wen titled “smoking-related 
airway inflammation and corticosteroid responsiveness in smoking related COPD”. 
That funding ceased in 2004, but was a completely untied grant. Although it was 
always intended to go on and study airway remodelling in the context of the biopsy 
samples obtained, the details of this only recently emerged with my pilot work and 
were not at all under the direct auspices of GSK. No permission for the analysis was 
needed or sought from them.  
 
2.3 .7 were the Mabs titrated for optimal staining? 
Yes, monoclonal antibodies were titrated for optimal staining. Details are given in 
Chapter 3, pages 104 and 105. 
 
3.3 The use of lignocaine should be discussed given its negative effects on 
epithelial cell viability (Kelsen SO Am J Respir Cell Mol BioI. 1992 (1):66). This 
is potentially increased in COPD where there is fragility of airway surface 
epithelium (Jeffery PK 2001 Novartis Found Symp. 2001; 234). 
This may be a danger for some confounding but really this would only be the case 
with living cells e.g. BAL samples, rather than with fixed tissue. Our group some 
years ago studied this phenomenon in detail (Duddridge, Kelly, Ward, Hendrick, & 
Walters, 1990). It is extremely unlikely that the changes we have seen are related to 
lignocaine, both on the basis of this work, but also because the control subjects were 
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treated in a exactly same way as those with COPD and, as explained in the thesis 
(Chapter 1), we have never found such changes in the Rbm in asthma subjects 
studied over the years, although again treated in the same way. 
 
A demographic table for the subjects used in the main study is required here. In 
the demographic table provided for the PILOT study, there was a large 
difference in median ages for controls vs COPD patients: 47 vs 61. Even more 
concerning were the inclusion of very young subjects in the control group for 
the PILOT study (age 20). Can you be sure that there were no effects of 
increasing age on your findings? 
A demographic table for the subjects is now provided in Chapter 3, page 103 as 
suggested by the examiner. I acknowledge the examiner’s comment that some of the 
controls subjects were of relatively young age for a study of COPD, but as explained 
in the thesis (pages 106 and 135) linear regression analysis was undertaken and age 
was not related to the findings we observed in the COPD or smoking populations.  
 
3.2.2 Do you consider 6 months cessation of smoking to be enough for reversal 
of the Rbm changes? 
The inclusion criteria stipulated that COPD ex-smokers had to have at least six 
months of smoking cessation , but this really was a `theoretical` minimum and as a 
group they had considerably more time from quitting than this ( usually years). In the 
event, we found that S100A4 positive cells in the Rbm were decreased in these 
COPD ex-smokers and there was no indication that this was related to time since 
smoking cessation.  In the near future I/we plan to analyse a specific smoking 
cessation study for which we have serial biopsies from 15 individuals before and 
after they had ceased smoking for 3 months and 12 months .This is supported by our 
current NHMRC grant and should give some indication to the time scale of these 
changes.  
 
3.5 Presentation of the immunostaining techniques pp 109-131 is tedious and 
could be condensed. Details of manufacturers: city/state or city/state/country 
are missing or incomplete. 
Considering the complex nature of the processes being investigated for the first time 
in COPD, details of the stains done seemed to me very important, especially if 
anyone else wishes to replicate the work. I would prefer for this reason to leave the 
section unchanged. As requested, I have updated the manufactures` details and 
sources of the antibodies in the thesis (Chapter 3, pages 104 and 105).  
 
Chapter 4 
Primary comments 
The inclusion criteria states 'over 18' in the controls and '40-70 years' for the 
COPD group (described in 3.2.2) compared to COPD subjects aged '40-70y'. 
However, in 4.3 ' Results', COPD subjects of 78 years of age are included. These 
subjects should be removed and stats redone. 
I thank the examiner for picking up this inconsistency, which reflects a change in 
recruitment policy after the original protocol was designed; and inadvertently it was 
this I was quoting. I should have quoted the operative inclusion criterion for age, 
which was for COPD subjects over  40 years old but with no upper limit as long as 
clinically fit enough for the procedures (page 103). This is now altered in the thesis.  
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Chapter 5 
Primary comments 
Re low numbers of-cells in biopsies. There appears to be surprisingly few T-cells 
in the biopsies. Do you think this could be related to severity of the COPD 
subjects as reported by Di Stefano 2001; 31:893? 
The data referred to are part of a comparison of cells positive for S100A4 in the basal 
epithelium and in the Rbm versus T-cells and other immune cells within these 
structures. This was specifically done to show that cells in the basal epithelium and 
Rbm are of epithelial origin and that the data are not confounded by infiltrating 
inflammatory and immune cells. One would not expect to see many such cells 
normally in these areas. 
 
Chapter 6 
Primary comments 
Page 168 " it is likely that in COPD the epithelium may get damaged by 
cigarette smoke". There have been several studies that have very convincingly 
shown that cigarette smoke does damage the epithelium and/or cause 
remodelling; these should be discussed (e.g., Pera 2010, Zhao 2009). 
The specific reference has been added to the introduction mentioned on page 169; 
further details on epithelial damage and airway remodelling are given in detail in 
Chapter 2.  
 
6.5 Discussion, last para. How exactly will you do a comprehensive longitudinal 
follow up study" Won't the invasive nature of the airway biopsy procedure 
preclude repeated observations over long periods of time? 
As already discussed, in the near future we plan to analyse a specific smoking 
cessation study for which we already have serial biopsies collected.  
 
What are the potential mechanisms for the effects of ICS on Rbm 
fragmentation- direct effect or via effects on inflammatory mediators or injury? 
How will this be assessed in future studies? 
The exact mechanisms for how ICS work in COPD are not very clear, but potential 
molecular mechanisms involved are described in the Chapter 2. It is very hard to say 
anything about the exact mechanisms involved in normalising the Rbm at this stage 
as the findings on Rbm fragmentation are so new. However, we already have plans, 
and a funding grant submitted, to investigate the role of RAGE (Receptor for 
advanced glycation end-products) as a driver of these `amplification` remodelling 
changes in the context of chronic airway inflammation in COPD. We will then be 
able to see if this is the level of control. This itself may be under the influence of 
VEGF or TGF-β, and we wish to dissect these factors out from each other using the 
intervention studies we have done.  
 
Chapter 7. 
Primary comments 
P 177 it is rather harsh to claim that the methodology used in the Barnes study 
were "rather questionable". Rather they were not comprehensive enough to 
identify the changes in total cellularity in the lamina propria. 
The examiner’s phraseology is probably more polite and reasonable, and I have 
changed the use of words in Chapter 7, page 178. 
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Minor comment 
7.3.5 How was normality assessed? 
 
Normality was tested using the Kolmogorov Smirnov & Shapiro Wilk test (Chapter 7 
page 180).  
 
 
Discussion 
Primary comments 
Pl99 Para 2. How do you anticipate doing the “long term smoking cessation" 
study? Would a murine smoking model be appropriate? 
As explained above, we already have serial biopsies from a smoking cessation study 
involving 15 individuals over 12 months. Since we have human tissue available, we 
do not need to revert to animal models.  
 
In future studies, a discussion of potential future studies investigating the 
signaling pathways extensively discussed in pp 64-73 would be appreciated. 
As already mentioned we are now intending to go on and investigate such 
mechanisms. We will focus on RAGE and TGF-β1 systems and their second 
messengers. To assess the drivers of airway inflammation and remodelling, we will 
immunostain airway biopsies for expression of RAGE in epithelium, endothelium 
and inflammatory cells.  We find that TGFβ1 is highly and indiscriminately 
expressed  in airway biopsies from all groups, so for this core mediator we will use 
quantitative PCR (qPCR) on extracted biopsy mRNA for the growth factor itself and 
use both immunostaining and molecular quantitation for its strategic transcription 
factors SMAD-2,-3 and -7.  We will also stain for the downstream major pathogenic 
trigger TWIST and quantitate it by molecular means; and will also perform these 
measures on matched cell pellets (mainly macrophages) from BAL (bronchoalveolar 
lavage; essentially small airway washings) which have been stored for each 
individual. 
However, I feel that these studies are beyond the scope of my thesis as planned and 
written. The work is already rather long, as noted by the examiner, and to do 
adequate justice to these complex issues would require a whole new set of areas to 
discuss at length, and properly reference etc (there is now a substantial literature on 
this) if we were to go down this avenue, which I would prefer to avoid. 
 
Typographical errors 
All the specific typing errors picked up by the examiner have been corrected.  
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Response to examiner 2 
 
Minor points 
Figure 1.1 Assume the asthmatic was a non-smoker 
I acknowledge examiner’s comment. This asthma subject was a non-smoker and the 
figure legend is changed accordingly (Chapter 1, pager 4). 
 
In the study reported in chapter 1.2.1 and associated table, clarity on how the 
asthma phenotype was excluded in the COPD patients and excluded from the 
controls would help ensure no overlapping phenotyping effects. The age was 
different and no discussion about the effects of age on Rbm clefts/fragmentation 
was mentioned. 
As explained in Chapter 3, page 101 & 102, diagnosis were made by a respiratory 
physician clinically, physiologically and ultimately pathologically. Subjects with a 
history suggestive of asthma, which included symptoms in childhood, related atopic 
disorders, eczema or hay fever, substantial day-to-day variability or prominent 
nocturnal symptoms, or a history of wheeze rather than progressive breathlessness 
were excluded. Any previous medical diagnosis of asthma was also an exclusion. 
None of our COPD subjects had an airway histological picture that looked like 
asthma. 
 
I acknowledge the examiner’s comment that some of the control subjects were of 
young age, there was a wide spectrum of age in the control group and in reality the 
differences between smokers/COPD did not depend on the mean age difference. As 
explained in the thesis, linear regression analysis was undertaken within the COPD 
group and age was not related to the findings. 
 
In chapter 3.2.1 exclusion criteria including other co-existing respiratory 
disorders was loosely described ie was CT routinely used to exclude fibrosis and 
bronchiectasis as these are often incidentally found to co-exist in COPD. 
CT scanning was not performed, but clinical and physiological examination was 
done, and subsequently obtained BAL fluid had to be free of bacterial 
growth/colonisation. Thus, there was no clinical (e.g. crackles on auscultation) or 
radiological evidence of fibrosis; and no clinical, radiological or microbiological 
evidence of bronchiectasis. 
 
Discussion in 4.4 should acknowledge that the (a) smoking controls are younger 
and have lower pack years exposure and that adjustment for this does not effect 
the findings which and (b) that changes consistent with EMT was tracking with 
smoking per se and the specific association with COPD and SlOOA4 cells was 
significantly only after correction for Rbm length but not reflected in the cleft 
number. (pg 151). 
The issue of age variations has already been dealt with above. 
 
I agree that the changes I have concluded are related to EMT are related to smoking 
per se, but the data also strongly suggest that the changes are especially marked in 
COPD current smokers. This was extensively discussed in Chapter 4, pages 152-155.  
 
The use of normal controls for comparative purposes in the chapter 6 study is 
problematic as they are younger with less smoking history. I; m sure this 
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researcher would have preferred to have examined changes in biopsies in the 
same patients before and after treatment as a more rigorous means of 
comparing effects of steroid vs. placebo on EMT characteristics in equally 
matched groups. If the placebo group is smaller then any effects may be lost due 
to under-powering. 
The realities of doing intervention studies with bronchoscopic outcome measures 
include the fact that one needs to optimise the material obtained. Our group has made 
the point on many previous occasions that the control data is frequently largely 
wasted; it is there to try and re-assure the reader that no change is spontaneously 
occurring. In the study included in the thesis there is just no suggestion of a 
consistent change in the control group, with no realistic chance of a Type-2 statistic 
error. Further, although the sample size was small in this study, as explained in 
Chapter 6, I did perform power and sample size calculations for this analysis, which 
showed that a number of subjects smaller than 15 was adequate to find differences 
for Rbm fragmentation before and after treatment with an alpha error 5% and beta 
error 80%. This is quite consistent with previous work from our group published 
some years ago by Richmond et al (Richmond, Booth, Ward, & Walters, 1996).   
 
I would have liked to have seen a stronger argument that supported the 
hypothesis that ICS might affect EMT through some mechanism explained in 
chapter 2. 
This issue was dealt with in detail in response to examiner 1. 
 
Typographical errors 
All the typing errors mentioned by the examiner have now been corrected in the 
thesis. I am grateful to the examiner for such a careful and helpful reading of the text. 
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